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Abstract  
 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (CNS) triggered by environmental and genetic factors. There is considerable 
evidence for a significant genetic component to MS susceptibility, such that genome-wide 
association studies (GWASs) have successfully revealed about 100 common genetic 
variants associated with MS. However, at least 60% of the overall heritability of MS has 
not been delineated, so-called “missing heritability”. This thesis describes a series of 
experiments to further elucidate the “missing heritability” of MS. 
 
Chapter 2 describes how to detect rare variants conferring susceptibility to MS using 
identity-by-decent (IBD) mapping, utilising a large GWAS dataset comprising 3,543 
cases and 5,898 controls. We identified a genome-wide significant linkage signal on 
chromosome 19. This linkage region includes a cluster of zinc finger genes that were 
suggested may be involved in very early developmental regulation of the CNS via 
genome wide transcriptome analysis.  
 
Chapter 3 describes how to detect rare or disease-causing variants to MS by employing 
whole genome sequencing on eight samples from one extended pedigree. We identified 
nine candidate variants by both whole genome sequencing analysis and Sanger 
resequencing. Of these, RDBP and PKHD1 are the two most interesting genes, which 
have been demonstrated to be associated with MS and ALS previously. Further research 
on these two genes will be continued after this thesis is submitted.  
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Chapter 4 and Chapter 5 describes how to detect gene-environment interactions 
particularly gene-vitamin D interactions influencing MS clinical course via a well-
validated MS prospective cohort study followed from 2002 to 2005. In Chapter 4 we find 
the relationship between 25(OH)D and hazard of relapse was significantly different for 
different alleles of two intronic SNPs (rs908742 in PRKCZ and rs3783785 in PRKCH) in 
the protein kinase C (PKC) family genes. Additionally, in Chapter 5 we find a number of 
known MS risk-associated SNPs were associated with relapse, or altered the 25(OH)D-
relapse association or modified levels of 25(OH)D. Our findings indicate gene-vitamin D 
interactions may be an important mechanism on MS clinical course, and provide support 
for the role of vitamin D in MS relapse.   
 
In this MS cohort, it was also found that WT1 variants may play a role in altering the 
therapeutic effects of IFN-β in MS, such that two SNPs (rs10767935 and rs5030244) in 
WT1 gene significantly modified the previously demonstrated association between IFN-β 
and 25(OH)D in the patients with MS.  
 
This thesis presents a range of studies which add significantly to the literature on MS 
genetics as well as MS epidemiology. This work will be useful in the scientific 
community; both for hypothesis generation and providing strong evidence in support of 
existing hypothesis, and hopefully be of benefit to people with MS.  
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Chapter 1. Background: multiple sclerosis and its genetics 
 
1.1 Preface 
 
This chapter gives an overview of the disease multiple sclerosis (MS): its clinical features, 
pathogenesis, immunomodulatory treatment, and risk factors, specifically the genetic 
contribution to MS susceptibility. It provides information relevant for the understanding 
of the thesis. The part, “The genetics of multiple sclerosis” has been published in 
Practical Neurology 2012;12:279-288 (Appendix 1A). The grey boxes within this part 
are added and were not part of the original publication. 
 
1.2 Multiple sclerosis  
 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system (CNS) resulting in damage to myelin sheaths and CNS axons, although the 
underlying pathophysiology and precise aetiology remains unknown. MS affects 2.5 
million individuals worldwide of which most are young adults of northern European 
ancestry [1]. The prevalence in southern Australia and New Zealand exceeds 1 per 1000 
and is more common in females than in males, with a sex ratio exceeding 3:1. The median 
age of MS onset is in the fourth decade of life and there is no known cure, with the 
disorder leading to progressive disability in the majority of patients and a large economic 
burden in the community. Improved therapy and prevention depend on a better 
understanding of the causes and mechanisms involved in the onset and progression of MS. 
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1.3 Clinical features of MS 
 
People with MS can suffer from a broad spectrum of signs and symptoms. The most 
common initial symptoms include muscle weakness and spasms, sensory disturbances, 
visual problems and ataxia (difficulties with coordination and balance). Additional 
features that develop with the disease course are bladder and bowel dysfunction, fatigue, 
dysarthria (problems in speech), dysphagia (problems in swallowing) and pain [2]. It has 
been recognised that cognitive impairment, concentration, depression and unstable mood 
are also common during the course of the disease [2]. Several measures have been 
implemented to clinically assess disability progression and symptom severity including 
the Kurtzke Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Score 
(MSSS) and Scripps Neurologic Rating Scale (NRS). The EDSS is the gold standard in 
assessing physical disability in MS, which utilises a ten-point disease severity scale from 
0 (normal) to 10 (death due to MS). Scores of 1-4 usually represent the symptoms and 
physical severity in range from no disability & minimal signs in one Function System to 
moderate disability. Scores of 4-5.5 generally reflect limiting walking 500 meters to 100 
meters without aid or rest. Scores over 6 range from requiring assistance in walking to 
being totally helpless in bed [3]. MSSS is a useful measure of MS severity. It can be 
viewed as a cross-sectional measure of disability progression, as it uses the EDSS and 
takes disease duration into account. It allows a rapid assessment of relative ranks of 
individuals from lowest EDSS to highest EDSS for a given disease duration, and 
expresses this as a decile rank between 0 (least affected) and 10 (most severely affected) 
[4]. NRS score is based on assessment of each component of the neurologic examination 
including 22 parameters of motor, sensory and cognitive function, and accurately reflects 
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overall neurologic function, ranging from 100 (Normal) to 10 (Maximal impairment) [5]. 
 
MS is classified into three subtypes based on the United States National Multiple 
Sclerosis Society standard: relapsing remitting, secondary progressive and primary 
progressive (Figure 1.1) [6]. The relapsing remitting form (RRMS) is characterised by 
unpredictable relapses followed by remission with return to or nearly to pre-existing 
levels of disability, followed by variable periods of disease quiescence. This subtype is 
the predominant form of MS, and accounts for >80% of cases in most case series [2]. The 
average age of onset of RRMS is in the 3th decade of life [2]. Most cases of RRMS will 
convert to secondary progressive MS (SPMS) over time, >50% doing so by 15 years of 
disease duration, this course defined by a gradual worsening of function rather than new 
relapses. The primary progressive MS (PPMS) form is a condition accounting for 10–15% 
of individuals, and is characterised by progression of disability from onset without any 
relapses or remission [7]. The age of onset for the primary progressive subtype is later 
than for the relapsing-remitting, generally around 40 years of age [8]. In some occasions a 
fourth type of MS clinical course is described, of relapsing progressive MS, where 
progression occurs from onset with superimposed relapses. 
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Figure 1.1. Types of MS.  
 
                                                                           Figure modified from Lublin F.D., et al. [9] 
 
1.4 Pathogenesis of MS 
 
MS is a chronic inflammatory disorder of the brain and spinal cord, leading to myelin and 
axonal damage caused by the innate and adaptive inflammatory responses. Myelin is 
synthesised by mature oligodendrocytes, each of which contact axons in white matter 
tracts of the CNS. The disease process starts with increased migration of autoreactive 
lymphocytes: T-cells and B-cells cross into the blood-brain barrier, and their co-
stimulation with other immune cells such as interleukin-17 producing (Th17 cells) [10] 
and soluble factors, including cytokines and antibodies, which in turn leads to 
demyelination, oligodendrocyte death and subsequent axonal loss. Notably, Th17 has 
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been considered the driver of inflammation under Th23 control rather than Th1, due to 
sufficient Th17 cells crossing the blood-brain barrier to kill human neurons and promote 
CNS inflammation through CD4+ lymphocyte recruitment [11]. MS lesions commonly 
involve white matter area whose function is to carry signals between grey matter area. 
Oligodendrocytes are responsible for creating and maintaining the myelin sheath to allow 
saltatory conduction along axons. With disease onset, myelin can be thinned or 
completely lost, such that an axon can display partial or complete conduction block [12]. 
Additionally, as T lymphocytes, B lymphocytes, plasma cells, and macrophages 
accumulate, pro-inflammatory cytokines amplify the immune response through 
recruitment of naive microglia. On activation, these cells increase surface binding for 
myelin basic protein, show greater contact with living oligodendrocytes and produce 
TNF-α, which is capable of killing oligodendrocyte and the activated microglia 
phagocytose myelin breakdown products [13].  
 
Demyelinating lesions, also called plaques, cluster around the lateral ventricles and corpus 
callosum, in the cortex and subcortical white matter, the optic nerves and brainstem, and 
throughout the spinal cord. They are characterized by perivascular CD8+cell infiltrates [2]. 
Acute demyelinating lesions also demonstrate extensive axonal injury, potentially 
mediated by CD8+ cytotoxic T-cell and microglial infiltration [14]. In the secondary 
progressive stage, demyelination coexists with diffuse axonal and neuronal degeneration. 
Cortical demyelination and injury of the normal-appearing white matter are reflected by 
diffuse axonal injury with profound microglia activation, which occur on the background 
of a global inflammatory response in the whole brain and meninges [15]. Pathological 
changes of primary progressive MS are characterised by reduced plaque load, less 
evidence for inflammation, and the absence of lymphoid follicles. Completely 
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remyelinated lesions and partially remyelinated lesions are also called shadow plaques. 
Remyelination is most active during the acute inflammatory process, coinciding with 
phagocytic removal of myelin debris, but also occurs in the progressive phase. In 20% of 
people with MS, plaques are eventually remyelinated [16]. 
 
1.5 Immunomodulatory treatments for MS 
To date, no effective curative agent has been developed since the pathogenesis of MS is 
not adequatly understood. As MS is believed to be the result of a misdirected immune 
response [17], all treatments aimed at treating MS are immunomodulatory in nature, 
either those derived from immunomodulatory cytokines (interferon-β) and immune 
components (antibody therapies), and compounds which modulate the immune system 
(glatiramer acetate, corticosteroids, cladribine, azathioprine, mitoxantrone). In practice, 
treatment varies with the stage reached in the course of the disease, but mainly aim to 
reduce relapse rate and the accumulation of disability. Amongst the available therapeutic 
agents, reducing the relapse rate is best shown by use of the interferon-β (IFN-β), which 
has been in widespread use as first-line disease modifying agents in RRMS since the early 
1990s. These include interferon β-1a (Avonex, Biogen, and Rebif, Ares-Serono) and 
interferon β-1b (Betaferon and Betaseron, Schering). The type-1 interferons generally are 
considered to have an immunomodulatory mechanism of action: IFN-β inhibits the 
proliferation of T lymphocytes and reduces their production of IFN-γ [18] which regulates 
the entry of T-cells into the CNS [19], and it alters the profile of cytokine production 
toward that of the anti-inflammatory Th2 response and reduces T-cell migration by 
inhibiting the activity of T-cell matrix metalloproteinases [19], as well as reducing antigen 
presentation [20].  
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Interferon-βs have been studied in separate placebo-controlled trials with RRMS. It has 
been demonstrated that interferon β-1a treatment can produce a significant delay in time 
to sustain EDSS progression, fewer exacerbations and fewer new lesions over 2 years [21] 
or 4 years [22]. A lower relapse rate and a delay to first relapse by 3 and 5 months has 
been observed, as well as an increased proportion of relapse-free patients [23]. Interferon 
β-1b treatment showed median 80% reduction in Magnetic Resonance Imaging (MRI) 
activity, and a significant reduction in relapse frequency and severity [24]. There was a 
one-third reduction in exacerbation rate in the 8- million international units (MIU) 
treatment arm in those patients with interferon β-1b use, compared with placebo, over 5 
years [25].  
 
Besides interferon-βs, glatiramer acetate is another first-line agent for use in the treatment 
of RRMS. The mechanisms of glatiramer acetate remain incompletely understood. It is 
now thought that glatiramer acetate modifies the immune response in many ways, 
including inducing tolerance of myelin-reactive T-cells, increasing regulatory T-cells, 
inhibiting the activation of myelin basic protein (MBP)-specific T-cells, producing IFN-
gamma and inducing highly cross-reactive Th2-type T-cells [26,27]. From 1996, 
glatiramer acetate has been approved as first line treatment for RRMS in United States 
and currently is approved in Australia and New Zealand as well. It has been demonstrated 
that glatiramer acetate can increase the proportion of patients remaining relapse-free [28], 
reduce relapse rate [29], MRI activity and brain atrophy [30,31], and delay the 
progression from clinically isolated syndrome (CIS) to clinically definite MS [32]. 
However, a side effect was observed in the use of glatiramer acetate, and no effect in 
progressive MS [33].  
 
At present, least contentious is the use of the IFN-β and glatiramer acetate in relapsing-
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remitting disease. Studies showed a modest effect on the accumulation of disability with 
interferon-β  treatment over 5 years [34] or 3 years [35]. These therapies have yet had no 
useful treatment effect on the secondary progressive phase of the disease [36-38]. 
Mitoxantrone, an anthracenedione antineoplastic drug that intercalates with DNA and 
inhibits both DNA and RNA synthesis, is considered probably more efficacious than the 
interferons or glatiramer acetate, but its use is confined to patients with aggressive 
relapsing-remitting MS due to its significant side effect profile with cardiac toxicity and 
increased rates of leukaemia following its use [39]. In particular, it slows the 
accumulation of disability in very active MS cases, but has less or no effect on non-
relapsing progressive disease [40,41]. No agent has been shown to exert effects on 
primary progressive MS [42]. 
 
Other newly developed immunosuppressive therapies include natalizumatb, fignolimod 
and teriflunomide have been reported with superior efficacy in MS in recent years. 
Natalizumab is a humanised monoclonal antibody to α4 integrin (VLA-4), which is 
expressed predominantly on lymphocytes, monocytes, eosinophils, and basophils and is 
critical in mediating Th-1 cell migration in EAE [43-45]. Fingolimod is a derivative of 
myriocin, and has immunosuppressive qualities through modulation of the sphingosine 1 
phosphate (S1P) system [46]. Teriflunomide selectively and reversibly inhibits the 
mitochondrial enzyme dihydroorotate dehydrogenase, which is required for de novo 
pyrimidine synthesis in proliferating lymphocytes [47]. A 68% reduction in relapses and 
42% reduction in the risk of sustained progression of disability has been observed with 
use of natalizumab, compared with placebo in a pivotal clinical trial [48]. In addition, an 
83% reduction in the effects on MRI T2 and gadolinium-enhancing lesions was observed 
over two years [48]. As for fingolimod, two large phase III trials have been reported. Both 
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trials showed the superior efficacy of oral fingolimod in most MRI outcomes, and with 
statistically significant reduction of relapse rate for both doses compared with either IFN-
β [49] or placebo [50]. Similarly, in a phase III clinical trial, teriflunomide has been 
demonstrated to reduce annualised MS relapse rate and the risk of sustained disability 
progression by 31.5-36.3% and approximately 25-30% versus placebo, respectively, 
besides the positive effects on MRI outcomes [51]. Side effects in use of these new 
therapies were reported, including hypersensitivity reactions and the risk of progressive 
multifocal leukoencephalopathy (PML) for natalizumab, cardiac toxicity for fingolimod, 
and nausea, diarrhea, hair thinning and predominantly asymptomatic elevation of alanine 
aminotransferase levels for teriflunomide. 
 
Recently, a number of other agents have emerged and are likely to become part of the MS 
treatment armament within the next few years [52], including BG-12 (dimethyl fumarate), 
alemtuzumab, daclizumab, ocrelizumab and laquinimod. In a phase IIb trial and two 
phase III trials, BG-12 has been shown to produce a reduction in annual relapse rate 
(approximate 50%), and in gadolinium-enhancing lesions (90%) and in new T1 
hypointense lesions (60-70%) [53-55]. The mechanism of BG-12 is thought to act through 
activation of the Nrf-2 pathway, an important protective pathway against oxidative stress 
[56]. Alemtuzumab, a monoclonal antibody to CD-52, has been shown to be highly 
effective in MS trials compared to active therapy (interferon- β-1a) [57-59]. All three 
clinical trials demonstrated significant reductions in relapse rate (49-74%), and two 
showed a significant reduction in sustained accumulation of disability (42-65%) [58,59]. 
As for daclizumab, a monoclonal antibody to CD-25, several small trials (patient numbers 
9 to 19) have shown it is effective in reducing contrast enhancing lesions and relapse rates 
as an add-on therapy [60] or as monotherapy [61] or in overlapping algorithms depending 
on response to therapy [62,63]. A larger phase IIb study with 230 patients also 
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demonstrated that contrast enhancing lesions were reduced by 72% in the higher dose [64]. 
Ocrelizumab, a humanised anti-CD20 monoclonal antibody, has demonstrated a 
significant reduction in new gadolinium-enhancing lesions by 89% and 96% respectively 
at doses of 600mg and 2000mg in a phase II trial, and the relapse rate was reduced by 
between 50-70% at 24 weeks [65]. Although positive outcomes have been demonstrated 
by the use of these emerging therapies, further assessments in large, long-term trials are 
warranted. 
 
 
Treatment guidelines for MS in adults in Australia and New Zealand recommend that 
patients with active relapsing-remitting disease (2 relapses in 2 years) should be offered 
interferon-β, glatiramer acetate, teriflunomide, fingolimod or natalizumab, and clinical or 
MRI relapses should prompt consideration of escalation in therapy to fingolimod or 
natalizumab. When there are poor prognostic indicators in RRMS from the outset, 
fingolimod or natalizumab are recommended as first line medication. However, there is 
no effective therapy in primary progressive MS or established secondary progressive 
disease currently. The issue of whether therapy should be discontinued in those 
converting to progressive disease on a background of relapses is complex. Where there is 
clinical or MRI evidence of active inflammation, any continuous therapy seems to have 
continued effectiveness. While once a state of severe disability has been achieved there is 
probably very little to be gained from continuing therapy, however. 
 
 
1.6 Environmental factors and MS onset 
 
There is considerable evidence that MS is driven by both environmental and genetic 
factors, with the known environmental factors including lower ultraviolet radiation (UVR) 
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exposure and/or lower vitamin D levels, Epstein Barr virus, and smoking now well 
established. 
 
1.6.1 UVR exposure and vitamin D 
Vitamin D deficiency has long been considered as a risk factor for MS. Recently, with the 
immunomodulatory effects of vitamin D [66] along with increasing epidemiological 
evidence, low vitamin D concentrations have achieved substantial strength as having a 
key role on MS risk. It is generally thought that the positive effects of raised vitamin D 
levels may partly be mediated by beneficial increased UVR exposure. In addition, genetic 
factors were considered as influencing circulating vitamin D levels or modifying the 
effect of vitamin D, which will be discussed in the section, “The genetics of MS ” and 
Chapters 3 to 5. 
 
1.6.1.1 Sun exposure and the vitamin D synthesis pathway 
As described in Figure 1.2, the primary form of vitamin D comes from two types of 
sources: skin exposure to ultraviolet radiation (UVR) in sunlight and diet (e.g., fish and 
vitamin D supplementation). Pre-vitamin D3 is formed in skin upon photolysis of 7-
dehydrocholesterol by UVR, which is then converted to vitamin D3 [67]. In the liver, 
vitamin D3 is enzymatically converted by 25-hydroxylase to 25-hydroxyvitamin D 
(25(OH)D), which then undergoes second hydroxylation in the kidney by the enzyme 1α-
hydroxylase converting it to the active form of vitamin D, 1,25-dihydroxyvitamin D 
(1,25(OH)2D3). It is known that most circulating vitamin D in humans comes from sun 
exposure [68], and generally 25(OH)D is used for assessment of an individual’s vitamin 
D status, as 25(OH)D is the major circulating form of vitamin D and is not tightly 
regulated as 1,25(OH)2D3 [69].  1α-hydroxylase is known to exist in many other tissues, 
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including immune system and nervous system cells, allowing extra-renal production of 
the active hormone that is not under the control of the calcium homeostasis system. 
1,25(OH)2D3 binds and activates the vitamin D receptor (VDR), a transcription factor that 
regulates the expression of over 2000 genes [70], which affect calcium and phosphate 
regulation or influence cells proliferation [71].  
 
Figure 1.2. UV radiation and vitamin D synthesis 
 
 
 
 
 
1.6.1.2 UVR and MS risk 
 
It has been demonstrated that the incidence, prevalence and mortality of MS typically 
follows a latitudinal gradient, both in the northern and southern hemispheres [72-76]. In 
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Europe and North America, MS is more common in the northern regions, while it is more 
prevalent in the southern part of Australia [77] and New Zealand [78]. These areas, with 
higher latitude, generally have lower annual sunlight, although genetic effect cannot be 
ruled out. Research has found individuals with higher residential and/or occupational 
solar exposure have a lower MS incidence [79,80], and those born in spring had a higher 
MS risk compared to those born in late autumn and early winter months in both the 
northern and southern hemisphere [81-85].  The underlying mechanisms may be a 
protective effect of UVR-induced immunosuppression in the pregnancy possibly mediated 
directly by maternal UVR or by derived vitamin D [83,86,87]. Experiments conducted 
using experimental autoimmune encephalomyelitis (EAE), an animal model of CNS 
inflammation used to study MS, showed UVR can prevent or delay the clinical symptoms 
of EAE in mice [88]. The association between UVR and MS was initially thought to be 
solely due to UVR’s actions to increase vitamin D levels. However, a potentially 
independent role of UVR on MS onset has been demonstrated. A review pointed out UVR 
suppresses the immune system through mechanisms independent of vitamin D [89], and 
EAE models indicated that UVR suppresses CNS inflammation independent of vitamin D 
production [90].  In addition, study showed sun exposure and vitamin D are independent 
risk factors for CNS demyelination, such that higher levels of past, recent, and 
accumulated leisure-time sun exposure were each associated with a reduced risk of first 
demyelinating events (FDE) [91].  
 
1.6.1.3 25-hydroxyvitamin D and MS risk 
 
Typically, MS patients have lower serum 25(OH)D levels than healthy controls [88], 
especially after MS onset [92,93]. Even prior to the onset of MS, 25(OH)D is also 
considered an important predictor for developing MS in healthy young white adults, 
independently from their place of birth and latitude of residence during childhood [93]. 
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As described in Figure 1.2, 25(OH)D is an integrated measure of vitamin D derived from 
both UVR exposure and diet. It has been noted in Norway that consumption of fatty 
seafood and cod liver oil, both rich sources of vitamin D, protected against the risk of MS 
[94]. In a prospective investigation estimating the association between vitamin D intake 
and MS risk, researchers found those subjects in the top quintile of vitamin D intake had 
higher 25(OH)D concentrations (mean 75 nmol/L vs. 55 nmol/L) and a 33% lower 
incidence of MS, relative to those in the bottom quintile [95]. Interestingly, one study 
found that the relative risk (RR) of MS was 0.95 (95% CI: 0.88–1.02) for a 10 nmol/l 
increase in 25(OH)D even after adjustment for UV dose [91], which indicated that 
25(OH)D alone may predict subsequent MS risk. In general, 25(OH)D concentrations 
above 50 nmol/L have been considered adequate, but evidence suggests that a minimum 
of 75 nmol/L, and perhaps more than 90 nmol/L, is optimum for many health outcomes 
[96,97]. Increasing outdoor activity and dietary consumption of fish or vitamin D 
supplements has been recommended to increase the levels of 25(OH)D concentrations; 
however, genetic factors can also affect 25(OH)D levels.  
 
1.6.1.4 Vitamin D and MS activity and progression 
 
Studies investigating vitamin D for its role in MS clinical course have found levels of 
25(OH)D are lower during relapse relative to remission [98-100]. In the prospective 
Tasmanian MS longitudinal study, an inverse association between seasonal 25(OH)D 
levels and monthly relapse rates was observed [101], and 25(OH)D inversely associated 
with relapse risk was demonstrated too [102].  Also, a number of other cohort studies are 
consistent with their findings of an inverse association between serum 25(OH)D and the 
risk of relapse, including retrospective [103,104] and prospective cohort designs [105]. 
These associations with relapse are likely mediated by the immunomodulatory effects of 
the active metabolite of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D3), acting to up 
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regulate regulatory T-cell function and depress inflammatory immune activity [88]. 
 
In regards to disease severity, most of the studies demonstrated a significant association 
with vitamin D levels. A cross-sectional study showed a negative correlation between 
25(OH)D levels and disease severity [106]. In the study of 193 MS patients, higher 
25(OH)D and 24,25(OH)D were significantly correlated with a decreased MSSS and 
marginally with decreased EDSS [106]. In addition, an inverse association between 
25(OH)D and EDSS were observed in a case-control study [92] and retrospective studies 
[103,107]. This is probably due to reverse causality where an increased EDSS results in 
going less outside and result in lower vitamin D levels, and only prospective longitudinal 
studies can evaluate the causal direction. Interestingly, in the EPIC longitudinal cohort 
study, vitamin D levels were inversely associated with MS activity on brain MRI, and 
each 10ng/ml higher 25(OH)D level was associated with lower subsequent disability (β: -
0.047; 95% CI: -0.091 to -0.003) [108]. However, research into the association between 
the active form vitamin D 1,25(OH)2D3 and MS severity as measured by EDSS, showed 
no association [103]. 
 
Overall, the epidemiological evidence demonstrates a reasonably consistent picture that 
sufficient vitamin D and /or UVR exposure can reduce MS risk, additionally recent 
literature provided evidence for a causal interpretation. Therefore, intervention with 
vitamin D supplementation could have a substantial impact on reducing disease burden. 
Suggesting that over 70% of MS cases in the USA and Europe could be prevented by 
increasing the serum 25(OH)D concentration of adolescents and young adults to above 
100 nmol/L [109,110]. Such high serum 25(OH)D is only common in those with outdoor 
lifestyles in sunny regions, while alternatively can be reached by taking1000–4000 IU 
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vitamin D3 daily for most people [111-113]. However, important questions remain about 
the timing of an intervention, dose-response and the efficacy in slowing progression and 
effects in different ethnic groups. Currently, not many clinical trials have been 
established. A small phase I/II study which compared two groups of MS patients on 
supplementation with either high (up to 40,000 IU/d) or low doses (≤ 4,000 IU/d) of 
vitamin D3 for 52 weeks showed no significantly increase 25(OH)D levels, though high-
dose vitamin D (approximately 10,000 IU/day) in MS is safe [114]. Another small 
randomised trial of high-dose vitamin D2 (targeting 25OHD 130-175 nM) showed no 
significant effect in reducing MRI lesions in patients with RRMS compared to low-dose 
supplementation (1,000 IU/d) [115]. However, a randomised, double blind, placebo 
controlled trial with 66 MS patients showed vitamin D3 as an add on treatment to 
interferon β-1b reduces MRI disease activity in MS, though it showed no significant 
differences in the annual relapse rate compared to placebo add-on group [116]. These 
varying results indicated that developing well-designed large sample-size clinical trials of 
vitamin D supplementation in MS are warranted.  
 
 
1.6.2 Epstein-Barr virus infection 
Epstein-Barr virus (EBV) has been demonstrated with consistent evidence as being 
associated with MS risk. Research into serological exposure to EBV in MS patients found 
nearly 100% of MS cases with exposure to EBV infection [117-123]. Many case-control 
studies have found higher frequencies of detection of EBV [122,124-127] and/or higher 
titres in cases [118-120,125,126,128] relative to controls, although some studies have had 
inconsistent findings [123,129]. Research found those with an undiagnosed EBV infection 
in childhood have 10-times greater risk of MS than those not infected with EBV [130]. A 
systemic review including eight seroepidemiological case-control studies demonstrated an 
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estimated odds ratio of 13.5 (95% CI, 6.3-31.4) for developing MS for those EBV 
seropositive compared to those individuals who are EBV seronegative [131]. In addition, 
consistent findings demonstrated an increase of anti-EBNA antibodies, driven by a 
marked increase of anti- EB nuclear antigen (EBNA) 1 antibodies and a less prominent 
increase in anti-EBNA 2 in MS [132-134]. The increase of titers to EBNA complex and 
EBNA 1 suggests a more severe primary infection or reactivation of infection 
accompanied by a vigorous cellular immune response [135-137]. A prospective cohort 
study and a nested case-control study used samples prior to MS onset also support a role 
of EBV in the aetiology of MS [132,138]. An association between MS and infectious 
mononucleosis (IM), a manifestation of acute EBV infection commonly seen after 
puberty has been demonstrated. A meta-analysis including 14 studies indicated that the 
relative risk of MS after IM was 2.3, such that both in adolescents and young adults, EBV 
is a risk factor for MS [139]. These findings have also been supported by a more recent 
systematic review [140]. 
 
 
The pathogenesis of EBV infection on MS is not completely known. Research found 
T-cells from Cerebrospinal fluid (CSF) and blood of MS patients reacted against EBV-
infected B-cells [141], and in a study comparing CD4-positive T-cells from MS patients 
and controls, EBNA-1-specific memory T-cells had greater frequency, proliferative 
capacity, and interferon  production [142]. These findings suggested that cell-mediated 
immunity is involved in MS, with a special reactivity against EBV antigens. However, as 
the direct aetiologic evidence, EBV virus was detected in the brain in some individual 
studies [143,144], but not all [145,146]. These conflicting studies gave rise to significant 
discussion, but also indicated that the contribution of EBV to the cause of MS is not yet 
established, but a relationship is clearly present [147,148].  
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1.6.3 Smoking  
Smoking has been evaluated as a risk factor for MS for decades. Although some case-
control or cohort studies showed there were no associations with MS between smokers 
and nonsmokers [149,150], most studies, especially the larger studies, have demonstrated 
a consistent association between smoking and MS susceptibility. In the US Nurses’ 
Health Study (121,700 women at baseline in 1976, follow-up to 1994) and Nurses’ Health 
Study II (116,671 women at baseline in 1989, follow-up to 1995), an increased relative 
incidence rate of MS was observed among current smokers (RR=1.6 (95% CI: 1.2–2.1)) 
and past smokers (RR= 1.2(95% CI: 0.9–1.6)) compared to those who never smoked, with 
a clear dose-response effect [151]. Later in 2009, a large, multinational European case–
control study including Sweden, Norway and UK showed a consistent result that cigarette 
smoking was associated with MS risk [152].  
 
Smoking also may exert influence on the course or progression of established MS. It has 
been demonstrated that smoking increased the risk of conversion from relapsing–
remitting to secondary progressive disease, for ever/current smokers compared with never 
smokers [153,154]. Moreover, ever-smokers were more likely to have progressive disease 
compared with never-smokers [155,156]; additionally this effect was stronger in those 
starting smoking early [155] or with heavier cigarette consumption [157]. An increased 
frequency of relapses [155] and number of lesions visible on MRI in MS patients who 
smoked compared to nonsmokers was also observed [157].  
 
The mechanisms by which smoking might influence the risk of MS and its clinical course 
are unclear, since over 4,500 compounds and chemicals are contained in tobacco and the 
resultant smoke from cigarettes, including a number of known carcinogens and other toxic 
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substances [158]. Among these substances, research has indicated nicotine in the cigarette 
has immunological effects in T-cell immunosuppression [159]. However, another form of 
tobacco, snuff use, has not shown an increase in MS risk, which suggested nicotine alone 
may be unlikely to explain the increased MS risk [152,160]. Despite snuff use, cigarette 
smoke have been demonstrated to affect numerous immune functions such as T-cell, B-
cell, and natural killer cell functions [161-163], which is thought important in MS, 
whereas it is also associated with other autoimmune diseases, such as systemic lupus 
erythematosus and rheumatoid arthritis [164,165]. As pointed out by a recent review 
[166], the overall magnitude of effect of smoking on MS susceptibility or disease course 
is small, and detecting small effects are more likely to have inconsistent results [167], 
thus more observational and mechanistic research is needed.  
 
1.7 The genetics of MS 
 
In the 1920s, a worldwide investigation of MS prevalence found that racial and ethnic 
differences might indicate a genetic influence [168]. Later studies found MS aggregates in 
families [169], especially the risk to siblings compared to the general population (OR 16.8 
(95% CI: 14.0–20.3)) [170]. This was further supported by twin studies showing higher 
concordance rates in monozygotic twins (24–30%) than dizygotic twins (3–5%) [171,172], 
and by the observations that there is no increased risk for adoptive relatives [173] and an 
intermediate risk for half-siblings [174] and offspring of conjugal pairs [175]. Although 
these epidemiologic data suggest that genetic variation is important for susceptibility to 
MS, gene discovery has lagged significantly until recently (Figure 1.3).  
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Figure 1.3. The timeline of genetic research in MS. 
 
 
 
1.7.1 Limited success for family-based linkage analysis and candidate-gene studies 
Family-based linkage analysis has been powerful in identifying the genes responsible for 
Mendelian diseases whose traits follow monogenic patterns of inheritance, e.g. cystic 
fibrosis. It has been less helpful in identifying the genes underlying complex traits such as 
MS. In the 1970s [176,177], linkage analysis showed that MS was associated with the 
major histocompatibility complex (MHC) region on chromosome 6 encoding the human 
leukocyte antigen (HLA) genes. Subsequently, several large MS linkage analyses [178-
180] have failed to identify any locus outside the MHC region, even though the largest 
study included 730 multiplex families with 2,692 individuals [181]. The lack of success 
relates to the limitations of classical genetic techniques: for example, microsatellite-based 
screens and low density marker sets, along with disease heterogeneity and the absence of 
large extended families with clear and homogeneous mode of transmission. Candidate-
gene studies are the practical alternative to linkage analysis, and these have successfully 
identified some genes contributing to susceptibility of common diseases, but not MS. 
Generally, candidate-gene studies are based upon biological hypotheses or knowledge of 
the candidate-gene’s location through linkage analysis. When the fundamental 
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physiological basis of a disease is unknown, as in MS, the candidate-gene approach is 
usually unsuccessful. 
 
1.7.2 Success with Genome Wide Association Studies (GWASs) 
The HapMap project [182] defined linkage disequilibrium patterns across the human 
genome, allowing development of GWAS tools that use single nucleotide polymorphisms 
(SNPs) as markers of genetic diversity directly on the basis of linkage disequilibrium. The 
HapMap project defined roughly 11 million common genetic variations (SNPs) in the 
human genome and found that many groups of neighbouring SNPs correlate nearly 
perfectly with each other. This allowed the selection of variants that represent short 
regions of the genome [183]. Many SNPs target a genetic locus and may indicate 
associations with many genes in an area of linkage disequilibrium within the genome. 
Therefore, it is important to take care when assigning a SNP to a specific gene. The 
HapMap data allowed the development of high-density SNP mapping of the genome with 
technologies that simultaneously assess over a million SNPs on a single chip in a highly 
cost-effective manner.  
 
The major problem with GWASs is the statistical burden of multiple testing, such that 
larger and larger studies are needed to detect variants with smaller and smaller odds ratios. 
Despite this, GWASs have been highly successful in finding common variants in many 
complex disorders. Also, newly developed statistical methods have improved the analysis, 
such as the identifying and correcting for population stratification and relatedness 
[184,185], and imputating ungenotyped variants [186]; these approaches increase the 
accuracy and reliability of GWASs outputs.  
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To date, GWASs have detected over 100 loci associated with MS outside the HLA region 
[187], and have confirmed the major role of the HLA-DRB1*15:01 (HLA-DR15) gene 
(OR 3.08, p<10-312) [188]. All the non-HLA associations are common variants with 
modest risk (OR in the region of 1.1–1.3), and many are near genes with key roles in the 
immune system (Table 1.1). A large MS GWAS conducted by the International Multiple 
Sclerosis Genetics Consortium (IMSGC) and Wellcome Trust Case Control Consortium 2 
(WTCCC2) studied 9,772 cases and 17,376 controls and identified a further 29 novel 
suscepbility loci, while replicating almost all of the previously associated loci (Table 1.1). 
It also pointed out that the identified genetic regions were in, or near to, genes with a 
primary role in T-cell-mediated immune mechanisms [188]. 
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Table 1.1. Non-HLA loci identified from GWAS with strong evidence conferring susceptibility for MS 
 
SNP (first reported) Chr Position MAF OR P-value Nearest gene Gene function* Pathway# 
     First reported  Latest reported     
rs3748816 1 2,516,606 0.70 1.16 3.54E-06[187] 
 
1.10E-13[186] 
 
MMEL1 Neuropeptide degradation, degradation of beta-amyloid. Neurological relevance 
rs6680578 1 92,949,466 0.38 1.11 5.0E-04[188] 6.50E-12[186] 
 
EVI5 Cell cycle; cell proliferation; cell division; retroviral 
integration in T-cell lymphomas 
Immune system 
rs6604026 1 93,076,191 0.29 1.14 7.94E-06[188] 2.5E-06 [189] RPL5 For rRNA maturation and formation of the 60S 
ribosomal subunits 
N/A 
rs11581062 1 101,180,107      0.71 1.13  2.50E-10[186]  N/A VCAM1 Mediates leukocyte-endothelial cell adhesion and signal 
transduction 
Immune relevance 
rs12044852 1 116,889,302 0.08 1.24 1.9E-05[188] 2.00E-09[186] 
 
CD58 Cell adhesion, T-cell receptor signaling; T-lymphocyte 
activation 
Immune relevance  
(co-stimulatory) 
rs2760524 1 190,797,171 0.16 0.87 9.77 E-06[190] 8.80E-07[186] 
 
RGS1 Activates G-proteins Immune relevance 
(signal transduction) 
rs12122721 1 199,251,103 0.28 1.22 6.56E-10[191] 4.10E-07[186] KIF21B Neuronal (axonal) transport Neurological relevance 
rs6718520 2 43,179,074 0.48 1.17 3.42E-08[192] N/A THADA Thyroid adenoma-associated  N/A 
rs7595037 2 68,500,599 0.55 1.1 5.10E-11[186] N/A PLEK PLEK protein variant N/A 
rs17174870 2 112,381,672 0.25 1.1 1.30E-08[186] N/A MERTK Cell entry factor N/A 
rs882300 2 136,692,725 0.46 0.84 1.37E-07[190] N/A CXCR4 Acts with the CD4 protein Immune system 
rs10201872 2 230,814,968 0.185 1.13 1.80E-10[186] N/A SP140 Involved in the pathogenesis of acute promyelocytic 
leukaemia and viral infection. 
N/A 
rs11129295 3 27,763,784 0.36 1.11 1.20E-09[186] N/A EOMES Trophoblastic development and gastrulation N/A 
rs170934 3 28,054,089 0.48 1.17 1.57E-08[192] N/A EOMES Trophoblastic development and gastrulation N/A 
rs9657904 
 
3 
 
107,069,404 0.24 1.40 1.6E-10[193] 2.10E-04[186] 
 
CBLB Encodes a negative regulator of adaptive immune 
responses 
I Immune relevance 
(signal transduction) 
rs1132200 3 120,633,526 0.16 1.24 3.09E-9[191] 1.10E-07[186] 
 
TMEM39A N/A N/A 
rs9282641 3 123,279,458 0.09 1.21 1.00E-11[186] N/A CD86 Activation of the T-cell; diminishes the immune 
response 
Immune relevance 
(co-stimulatory) 
rs4680534 3 161,181,639 0.37 1.12 5.58 E-06[190] 3.70E-06[186] 
 
IL12A Acts on T and natural killer cells Immune relevance 
(cytokine pathway) 
rs228614 4 103,797,685 0.45 1.09 1.40E-07[186] N/A NFKB1 A pleiotropic transcription factor, involved in many 
biological processed such as inflammation, immunity, 
differentiation, cell growth, tumourigenesis and 
apoptosis. 
Immune relevance 
rs6897932 5 35,910,332 0.25 1.18 2.94E-07[188] 1.30E-06[186] 
 
IL7R Lymphocyte development; T-cell receptor gamma 
accessibility by STAT5; apoptosis; activation of T 
lymphocytes 
Immune relevance 
(cytokine pathway) 
rs6896969 5 40,460,183 0.38 0.91 2.40 E-07[190] 6.90E-14[186] PTGER4 Activates T-cell factor signaling Immune relevance 
rs2546890 5 158,692,478 0.52 1.1 1.20E-11[186] N/A IL12B As a growth factor for activated T and NK cells, Immune relevance 
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enhance the lytic activity of NK/lymphokine-activated 
killer cells, and stimulate the production of IFN-gamma 
(cytokine pathway) 
rs12212193 6 91,053,490 0.53 1.09 3.80E-08[186] N/A BACH2 Coordinate transcription activation and repression N/A 
rs802734 6 128,320,491 
0.68 
1.1 5.50E-09[186] N/A THEMIS Involves T-cell selection during late thymocyte 
development 
Immune relevance 
rs11154801 6 135,781,048 0.36 1.15 1.00E-13[186] N/A MYB Transcriptional activator; control proliferation and 
differentiation of hematopoietic progenitor cells 
N/A 
rs17066096 6 137,494,601 0.76 1.14 6.00E-13[186] N/A IL22RA2 An IL22 antagonist in the regulation of inflammatory 
responses 
Immune relevance 
(cytokine pathway) 
rs9321619 6 137,916,101 0.47 0.89 1.71 E-05[190] 2.30E-06[186] 
 
OLIG3 Determine the distinct specification program of class A 
neurons in the dorsal part of the spinal cord and 
suppress specification of class B neurons. 
N/A 
rs1738074 6 159,385,965 0.43 1.13 6.80E-15[186] N/A TAGAP A GTPase-activating protein; may play important roles 
during T-cell activation 
Immune relevance 
(signal transduction) 
rs354033 7 148,920,397 0.26 1.1 4.70E-09[186] N/A ZNF767 Zinc finger family member 767 N/A 
rs4410871 8 128,884,211 0.28 1.11 7.70E-09[186] N/A MYC Participates in the regulation of gene transcription N/A 
rs2019960 8 129,261,453 0.77 1.1 5.20E-09[186] N/A PVT1 N/A N/A 
rs2150702 9 5,883,861 0.49 1.16 3.28E-08[192] N/A MLANA Involved in melanosome biogenesis N/A 
rs12722489 10 6,142,018 0.15 1.25 2.96E-08[188] 2.00E-09[186] 
 
IL2RA Elimination of self-reactive T-cells Immune relevance 
(cytokine pathway) 
rs1250540 10 80,706,013 0.35 1.12 1.59 E-06[190] 1.40E-06[186] 
 
ZMIZ1 Increases ligand-dependent transcriptional activity of 
AR and promotes AR sumoylation. 
N/A 
rs7923837 10 94,471,897 
0.38 
1.1 4.90E-09[186] N/A HHEX Transcriptional repressor; may play a role in 
hematopoietic differentiation 
N/A 
rs17824933 11 60,517,188 0.25 1.18 3.79E-09[190] 1.70E-09[186] CD6 Cell adhesion; T-cell activation Immune relevance 
rs630923 11 118,259,563 0.15 1.11 2.80E-07[186] N/A CXCR5 Involves B-cell migration Immune relevance 
 (cytokine pathway) 
rs1800693 12 6,310,270 0.45 1.20 1.59E-11[190] 9.20E-11[186] 
 
TNFRSF1A Apoptosis; cytokine signaling Immune relevance 
(cytokine pathway) 
rs10466829 12 9,767,358 0.50 1.09 1.40E-08[186] N/A CLECL1 May play a role in the interaction of dendritic cells with 
T-cells and the cells of the adaptive immune response. 
Immune relevance 
(co-stimulatory) 
rs703842 12 56,449,006 0.29 0.81 5.4E-11[189]  
 
2.40E-06[186] 
 
CYP27B1 Catalyzes the conversion of 25-hydroxyvitamin D3 
(25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 
(1,25(OH)2D) plays an important role in normal bone 
growth, calcium metabolism, and tissue differentiation 
Vitamin D 
rs1790100 12 122,222,678 0.24 1.11 7.21 E-07[190] 1.50E-04[186] MPHOSPH9 M-phase phosphoprotein 9 N/A 
rs9523762 13 92,129,887 0.35 1.36 7.0E-06[194] N/A GPC5 Cell surface proteoglycan N/A 
rs4902647 14 68,323,944 0.47 1.11 9.30E-12[186] N/A ZFP36L1 Regulates the response to growth factors N/A 
rs2300603 14 75,075,310 0.74 1.11 2.00E-08[186] N/A BATF A negative regulator of AP-1 mediated transcription N/A 
rs2119704 14 87,557,442 0.08 1.26 2.20E-10[186] N/A GALC Hydrolyzes the galactose ester bonds Neurological relevance 
rs2744148 16 1,013,553 0.83 1.12 8.40E-08[186] N/A SOX8 May play a role in CNS, limb and facial development. Neurological relevant 
rs6498169 16 11,156,830 0.37 1.14 3.83E-05[188] 6.30E-14[186] 
 
CLEC16A Glycoprotein uptake for dendritic cell presentation; 
dendritic cell distinguishing between self and non-self 
antigens 
Immune relevance 
rs17445836 16 84,575,164 0.19 1.25 3.73E-09[190] 7.00E-08[186] IRF8 Regulation of immune cells Immune relevance 
(cytokine pathway) 
rs744166 17 37,767,727 0.56 0.87 2.75E-10[195] 3.50E-06[186] STAT3 Transcription factor that binds to the interleukin-6 (IL- Immune relevance 
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 6)-responsive elements (signal transduction) 
rs180515 17 55,379,057 0.65 1.11 8.80E-08[186] N/A RPS6KB1 Phosphorylates specifically ribosomal protein S6 in 
response to insulin or several classes of mitogens. 
N/A 
rs7238078 18 54,535,172 0.77 1.11 2.50E-09[186] N/A MALT1 Enhances BCL10-induced activation of NF-kappa-B Immune relevance 
(signal transduction) 
rs763361 18 150,069,017 0.48 1.13 4.54E-04[196]  
 
N/A CD226 Tumour suppression; T-cell differentiation and 
proliferation; monocyte migration; antigen presentation; 
cell adhesion 
Immune relevance 
rs1077667 19 6,619,972 0.21 1.16 9.40E-14[186] N/A TNFSF14 Activates NFKB, stimulates the proliferation of T-cells. Immune relevance 
(cytokine pathway) 
rs34536443 19 10,324,118 0.047 1.32 2.7E-06[197]  1.50E-06[186] 
 
TYK2 Involved in the initiation of type I IFN signaling Immune relevance 
(signal transduction) 
rs874628 19 18,165,700 0.72 1.12 1.30E-08[186] N/A MPV17L2 N/A N/A 
rs2303759 19 54,560,863 0.75 1.11 5.20E-09[186] N/A DKKL1 Interacts with the Wnt signaling pathway N/A 
rs6074022 20 44,173,603 0.28 1.20 1.3E-07[189] 
 
1.70E-06[186] 
 
CD40 Stimulatory molecule on B-cells, dendritic cells, 
macrophages and microglia. 
Immune relevance  
(co-stimulatory) 
rs2248359 20 52,224,925 0.39 1.12 2.50E-11[186] N/A CYP24A1 Regulates the level of vitamin D3 Vitamin D 
rs6062314 20 61,880,157 0.92 1.17 1.30E-07[186] N/A TNFRSF6B Decoy receptor for the cytotoxic ligands 
TNFS14/LIGHT and TNFSF6/FASL; protects against 
apoptosis. 
N/A 
rs2283792 22 20,461,125 0.48 1.09 4.70E-09[186] N/A MAPK1 Involved in both the initiation and regulation of meiosis, 
mitosis, and post-mitotic functions in differentiated 
cells 
N/A 
rs140522 22 49,318,132 0.33 1.09 1.70E-08[186] N/A SCO2 Acts as a copper chaperone, transporting copper to the 
Cu(A) site on the cytochrome c oxidase subunit II 
(COX2). 
N/A 	  
Chapter 1. Background: multiple sclerosis and its genetics 
	   26	  
Note 1.1 Association between HLA and MS identified from GWASs. 
 
The information about the HLA region that was identified as associated with MS in 
GWASs was not provided in our original published paper. It is necessary to provide the 
relevant data, since HLA region by far is the strongest region identified to be associated 
with MS. Note 1.1 Table A presents the available data reported by Sawcer and colleagues 
[188]. Both class Ι (HLA-A) and class II (HLA-DRB1) in the HLA region have been 
confirmed as protective against or increasing risk of disease onset. Of note, although high 
linkage disequilibrium (LD) across the HLA region, the predominant association with MS 
susceptibility is with the class II DRB1 haplotype (DRB1*15:01, DRB1*13:03, 
DRB1*3:01, DRB1*08:01), and the major role is DRB1*15:01 with an OR of 3.08 (p<10-
312) [188]. 
 
 
Note 1.1 Table A. HLA loci 
identified as associated with MS by 
GWASs 
Locus/allele OR p-value 
DRB*15:01 3.08 <1E-312 
DRB*13:03 2.43 1.30E-11 
DRB*08:01 1.18 1.60E-07 
DRB*03:01 1.26 3.60E-10 
A*02:01 0.73 9.10E-23 
A*02:05 0.76 1.50E-01 
A*02:06 1.23 5.10E-01 
A*68:01 0.97 6.10E-01 
 
 
1.7.3 GWASs explain a small part of the heritability of MS 
Although GWASs have identified over 60 loci associated with MS by 2012, these explain 
only a small fraction of MS heritability. In our own studies, taking account of the 
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identified loci, allele frequencies and sibling relative risk using Risch’s gene effect 
measuring method [200], we found all the identified loci explained only 18–24% of the 
heritability of MS [170]; HLA-DRB1*15:01 explained 11% (Figure 1.4). Hence the 
obvious question: “Where is the missing heritability?”  
 
Figure 1.4.  Genetic contribution to MS risk. In total, 18% of heritability of MS was 
explained by the loci identified in the biggest MS GWAS[188]. 8 HLA-loci explain 
13.2% of heritability of which HLA-DR15 explains 11.1%; 57 non-HLA loci explain 
4.8% of MS heritability with CLEC16A the largest contributor at 0.18% of 
heritability.   
 
 
1.7.4 Where is the missing heritability in MS? 
Several as yet unproven theories may explain the missing heritability:  
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1) Rare variants. GWAS are constrained by their design to the study of common variants 
(minor allele frequencies (MAF) ≥5%); it is hard to detect rare variants (MAF <5%) by 
standard genotyping arrays.  
2) Common variants. There are probably many more undiscovered common variants 
with even smaller effects (1<OR<1.1) waiting to be found by larger and larger GWAS. 
However, one recent modeling exercise in Crohn’s disease suggested that even for an 
infinitely-sized GWAS, common variants explained less than 50% of heritability [201].  
3) Epigenetics. Epigenetic modifications may regulate the expression or activity of genes; 
the effect of a gene may increase by either increasing or decreasing its expression. 
 4) Gene–gene interactions. If two or more genes govern a single phenotype, the genes 
will affect each other’s expression and therefore change their effect.   
5) Pathway involvement, where strongly associated variants cluster with weak ones 
within a known signaling pathway; this may increase the overall effect of the pathway and 
enhance the genetic susceptibility to disease.  
6) Gene–environment interaction, where the environment increases or decreases the 
effect of a gene in determining disease onset. For example, the genetic defect underlying 
phenylketonuria, although completely penetrant when there are two copies of the 
abnormal gene, is phenotypically silent unless the environmental factor—dietary 
phenylalanine—is introduced.   
7) Structural variants refer to regions of DNA from around 1Kb to several Mb, and 
include inversions and balanced translocations or genomic imbalances (insertions and 
deletions), commonly referred to as ‘copy number variants’. Such variation has been 
largely unexplored in relation to complex traits [202]. 
 
1.7.4.1 Rare Variants 
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Recently, rare variants have been receiving increased attention in an attempt to explain 
the ‘missing heritability’ fraction for many complex disorders including MS. Rare 
variants with lower MAF (less than 5%) have not been represented on many of the 
microarrays used for major genetic studies up until very recently and they are often 
difficult to detect in case-control study designs unless the samples are from an isolated 
population or have some other enrichment factor allowing detectable numbers of copies 
for the minor alleles. It is generally thought that rare variants are likely to have larger 
effect sizes (within the pedigrees or populations in which they segregate) and could 
contribute significantly to missing heritability. It is postulated that these variants are also 
likely to have more obvious functional consequences [203]. It is becoming evident that 
rare variants have a large cumulative effect on normal phenotypic variation and are 
extremely important in disease [204]. Recently, studies using exome sequencing in a set 
of multiplex multiple sclerosis families found several rare functional variants in CYP27B1 
underlying the known MS locus on chromosome 12 [205]; this was the first description of 
a rare variant in MS. Interestingly, CYP27B1 encodes the protein that converts 25-
hydroxyvitamin D3 to the active hormone 1,25-dihydroxyvitamin D3. The rare functional 
variants in CYP27B1 are associated with the development of vitamin D-dependent rickets. 
The authors noted that in all proven genetic cases of vitamin D-dependent rickets in 
Norway, there was a 100% concordance with MS. We await further evaluation of this 
finding in other cohorts. This finding also supports the increasing evidence for a role for 
vitamin D deficiency in the onset of MS. 
 
Note 1.2 Evidence in disease aetiology and detecting strategy for rare variants 
 
In Chapter 2 and Chapter 3, we describe how to detect rare variants and/or disease 
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causing variants that confer susceptibility to MS. Thus, we here added here some more 
background of rare variants to better understand the two chapters. 
 
It is known that most SNPs in the human genome are rare SNPs (Figure note 1.1) [206] 
according to the Encyclopedia of DNA Elements (ENCODE) and the International 
HapMap Database (http://hapmap.ncbi.nlm.nih.gov/). Rare variants are likely to have 
larger effect sizes (within the pedigrees or populations in which they segregate) and could 
contribute significantly to missing heritability. Based on the published results [207], most 
identified rare variants have larger effect size (OR>2) than those of common variants 
(OR: 1.1-1.3). More recently, four rare variants within the IFIH1 gene were identified to 
have a larger individual effect on the risk of type I diabetes than those of common 
variants [208]. For the BRCA1 and BRCA2 genes, many rare variants in these genes are 
associated with an increased risk of breast cancer by an average odds ratio of ~10 in 
randomly-ascertained cases aged 60-70 [209]. Rare variants are also likely to have more 
obvious functional consequences [203]. There is rapidly accumulating data showing that 
rare variants have a large cumulative effect on normal phenotypic variation and are 
extremely important in disease [204].  
 
Figure note 1.1. Distribution of single-nucleotide polymorphisms (SNPs) from the 
Encyclopedia of DNA Elements (ENCODE) (orange bars) and of all SNPs reported 
in the International HapMap Database (blue bars) by minor allele frequency (MAF). 
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Figure reproduced from Gorlov and colleagues [206] 
 
Note 1.2.1 Evidence of rare variants in disease aetiology 
 
Empirical evidence has already indicated that rare SNPs may be crucial in the genetic 
architecture of common diseases. Although scientists are convinced that mutation-
selection balance, genetic drift, and effective population size play an important role in 
shaping the frequency and distribution of genetic polymorphisms in the human genome 
[210-213], it is not feasible to estimate directly the effects of millions of SNPs. That the 
functional SNPs should somehow disturb a normal function is to be expected to be under 
the pressure of selection (mostly negative selection). A stronger effect of a SNP on gene 
function may be associated with stronger negative selection against it. Thus it is possible 
to estimate risk on the basis of quantitation of selection pressure. PolyPhen, a common 
server, can be used to study the selective pressure on the structural and functional 
properties of proteins [214], which uses empirically derived rules to predict whether a 
nonsynonymous SNPs (nsSNP) is damaging or benign [215]. Therefore, PolyPhen can 
also be used to evaluate whether the reported/identified association indeed has a 
functional meaning, as well as to distinguish causal from non- causal relationships 
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between a nonsynonymous SNPs and the phenotype of interest [214]. By applying 
PolyPhen, Gorlov and colleagues analysed the relationship between the MAF and the 
proportion of nsSNPs predicted to be protein changing. They found a statistically 
significant negative association between the MAF and the proportion of SNPs predicted 
to be functional (p<1E-06) (Figure note 1.2) [216]. A higher proportion of rare nsSNPs are 
predicted to be functional, and hence rare SNPs are more likely to change disease risk and 
confer a larger odds ratio. Gorlov and colleagues also evaluated the relatioship between 
MAF and the change in accessible surface propensity(dprop), one of the most important 
predictors of SNP functionality in PolyPhen [214], and found there was a negative 
association between the MAF and the degree of change to the protein structure: rarer 
SNPs more strongly impair protein structure than do the common variants, which 
indicates rare SNPs are more likely have a larger effect size than common SNPs [206]. 
 
Figure note 1.2. Proportion of nonsynonymous single-nucleotide polymorphisms 
(nsSNPs) predicted to be protein damaging by minor allele frequency (MAF). Each 
point represents the proportion of functional nsSNPs in a given MAF category. 
Error bars indicate standard error. Proportion predicted using the PolyPhen 
method. The black line is the unadjusted logarithmic regression curve, and the 
orange line is the curve adjusted for PolyPhen’s sensitivity and specificity.  
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Figure reproduced from Gorlov and colleagues [216]. 
  
Note 1.2.2 Strategy for detecting rare variants 
 
Since rare variants may play an important role in disease aetiology, this raises the 
question: how to detect rare variants? Three strategies have been described and 
implemented in recent research. One is to re-sequence loci containing common 
susceptibility variants identified from GWASs. The target genes, by using this strategy, 
usually contain common disease-associated polymorphisms or mutations with biological 
or aetiological evidence in prior studies or animal models. For example, four rare variants 
within the IFIH1 gene were identified to protect against type 1 diabetes (T1D) disease by 
re-sequenced exons and splice sites [208] of ten candidate genes which were detected as 
associated with T1D in a GWAS [217] or in functional [218] and rat model studies [219]. 
However, this strategy precludes the identification of new loci; and in many instances, the 
SNPs showing the most significant disease association map to genomic regions with no 
obvious function, thus re-sequencing would provide few clues as to how causal variants 
affect the disease gene. The second strategy is exome sequencing or whole-genome 
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sequencing. Exome sequencing is a robust approach to sequencing the complete coding 
region (exome) for identification of functional variants that are responsible for diseases 
onset without the high costs of whole-genome sequencing while maintaining high 
coverage in sequence depth [220]. Exome sequencing is a cheaper and effective 
alternative to whole genome sequencing but without the capability to identify the 
structural and non-coding variants associated with the disease. Eventually it will be 
possible to overcome this limitation by whole-genome sequencing, but it remains 
prohibitively expensive to perform adequately powered studies. The third way is to re-
analyse GWAS data using ‘population-based linkage analysis’ (PBLA). PBLA is a 
linkage analysis applied at the population level to detect megabase-scale regions where 
many pairs of cases have inherited long haplotypes from distant ancestors, perhaps ten to 
one hundred generations ago [184,221]. It tests for correlation between identical by 
descent (IBD) sharing and phenotypic sharing. If a linkage region with IBD was identified, 
the follow-up targeted re-sequencing allows recovery of a more complete inventory of 
sequence variation, and enables systematic fine-mapping efforts to identify those 
putatively causal variants with the strongest effects on disease susceptibility cost 
effectively. Even when whole-genome sequencing becomes cheap enough to pursue with 
substantial sample sizes, PBLA may still help reduce the massive multiple-testing 
problem by prioritising regions.  
 
More recently, a study using exome sequencing in a MS family identified one rare variant 
in TYK2 that had a modest effect on MS risk [222]. In a functional study, rs34536443 in 
TYK2 has been demonstrated to cause an amino acid substitution in the protein that 
enhanced activation of the kinase function upon stimulation with interferon-β, IL-6 and 
IL-10 [223]. This effect on MS susceptibility, as the author pointed out, might be 
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mediated by deviating T lymphocyte differentiation toward a Th2 phenotype, which is 
also important to other autoimmune diseases [222].  
 
1.7.4.2 Epigenetics and MS 
 ‘Epigenetic’ refers to the modification of gene expression or biological phenotypes 
resulting from changes to the genomic structure that do not alter the underlying genetic 
code [224]. The major epigenetic processes in mammalian cells are methylation and 
modification of histones. DNA methylation may be responsible for the stable maintenance 
of a particular gene expression pattern through mitotic cell division [225]. DNA 
methylation is generally associated with reduced or suppressed gene expression. Cells 
acquire epigenetic modifications over time and the methylation signatures persist through 
cell division. Histone modifications are the post-translational covalent addition of 
molecules to the histone subunits of the nucleosome [226]. Histone modification acts in 
diverse biological processes, such as gene regulation, DNA repair, chromosome 
condensation (mitosis) and spermatogenesis (meiosis). Histone modification may also 
interact with DNA methylation to regulate gene expression, since specific patterns of 
histone modifications associate with the pattern of DNA methylation [227]. 
 
The role of epigenetics in the aetiology of MS is still unclear. However, several studies 
have suggested that epigenetic modifications may be important in determining MS 
susceptibility. Moreover, older MZ twins with MS show significantly different patterns of 
genomic distribution of 5-methylcytosine DNA and histone acetylation [228], indicating 
the effect of the external environment on the epigenome [229]. Also, MS shows maternal 
parent-of-origin effects associated with DNA methylation [230] and these influence the 
age of MS onset [231]. HLA-DR15 status also influences the maternal parent-of-origin 
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effect: thus, MS patients who are HLA-DR15 positive have an increased female to male 
ratio and mothers who are HLA-DR15 positive are more likely to have affected female 
offspring than those who are HLA-DR15 negative [232]. However, this effect has not been 
seen in all studies [233]. Recently, a whole-genome sequencing study, assessing DNA 
methylation and gene expression in three MS-discordant MZ twin pairs, found no 
consistent differences in DNA sequence, DNA methylation or gene expression in CD4+ 
T-cells [234]. Researchers have subsequently argued that these data cannot conclusively 
rule out possible involvement of somatic changes in twins discordant for MS because of 
design limitations with the study, particularly the small sample size, the low average 
depth coverage of the genome sequencing and that the analysis limited to just CD4+ T-
cells [235]. 
 
1.7.4.3 Gene–gene interactions and MS 
 For common diseases driven by complex genetic susceptibility, gene–gene interactions 
appear to be a potential explanation for the missing heritability [203]. Gene–gene 
interaction refers to the situation where a single characteristic (phenotype) is governed by 
two or more genes and each gene affects the expression of the other genes involved. 
Several studies have examined the role of gene–gene interaction in MS, particularly HLA 
gene–gene interactions. For example, in a Swedish population, the combination of HLA-
DR15 carriage and absence of HLA-A*02 alleles increased the risk of MS by 23-fold 
[236]. However, the largest MS GWAS conducted to date found no definitive evidence 
for gene–gene interaction in MS susceptibility [188]. 
 
1.7.4.4 Pathway analysis and MS 
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In biological systems, genes and their products (usually proteins) operate within pathways 
that exert various functional outcomes within the body, such as cell signaling cascades or 
the metabolism of compounds such as vitamins or amino acids. Pathway analysis involves 
investigating genes only within a particular pathway and thereby provides specific 
information about the genetic pathway being affected in disease conditions—yielding 
biological insights into the disease process. However, most common diseases are 
influenced by the combined effects of many loci and/or a number of rare variants that 
interact with environmental factors in multiple complicated ways [207].  
 
Pathway-based analytical approaches allow the genetic variants associated with disease to 
be considered within the context of a known biological pathway. Evidence of enrichment 
of susceptibility variants within a pathway may offer more insight into the disease 
process. If disease-associated variants cluster within a known signaling pathway, then 
disruption or alteration of that pathway may be involved in the disease process. For 
example, we considered SNPs shown by GWASs to be associated with MS [191] and 
found evidence of enrichment of disease susceptibility SNPs within a module of the 
vitamin D metabolism and signaling pathway (Figure 1.5). This pathway includes known 
MS-associated genes CYP27B1 and IL12 [188]. While some of the remaining SNPs are 
only weakly associated with MS (we used the top 25% of the GWASs sample) the 
additional evidence from the pathway analysis, and the postulated involvement of vitamin 
D in the disease process, strengthens their appeal for further consideration. 
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Figure 1.5. One module of vitamin D pathway analysis including 13 genes, of which 8 
genes have been associated with MS (in red).  
 
 
 
To date, there have been few published pathway analyses in MS. One pathway-orientated 
MS study that took into account all SNPs with nominal evidence of association (p<0.05), 
rather than just those SNPs that exceed the genome-wide significance threshold [237], 
found three immunological pathways that were over-represented in MS. These included 
cell adhesion pathways, communication and signaling pathways, and one neural pathway, 
namely axon-guidance and synaptic potentiation. Recently, by analysing the T-helper cell 
differentiation pathway, the IMSGC/WTCCC2 GWAS found over-representation of 
genes involved in T-cell maturation, including 12 genes coding for the cytokine pathway, 
6 genes coding for co-stimulatory molecules and 7 genes coding for signal transduction 
molecules, all of which are immune relevant. These findings indicate that T-cell signaling 
pathways may be important in the pathogenesis of MS [188]. 
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1.7.4.5 Gene-environment interaction and MS 
The known environmental risk factors for MS include high Epstein–Barr virus IgG 
antibody titres, low vitamin D level and/or UVR exposure and cigarette smoking. 
Interactions between genes and environmental factors may explain at least part of the 
missing heritability: a particular genetic variable in the right environmental situation may 
exert a significantly greater effect on MS causation than if the environmental exposure 
were not present. So far, attention has largely focused on the major genetic risk factor 
HLA-DR15. Thus, the effect of an environmental exposure on MS might depend on 
whether a person is HLA-DR15 positive or HLA-DR15 negative; conversely, the effect of 
HLA-DR15 might depend on the level of the environmental factor.  
 
Since HLA-DR15 may be important in determining the CD4 Th1-mediated immune 
response to EBV infections [238], it is possible that EBV and HLA-DR15 interact with 
each other. Indeed, several HLA alleles recognize EBNA-1 epitopes [239]. Several 
epidemiological MS studies have looked at the interaction between HLA-DR15 and EBV 
(reviewed in [240]), but so far without any clear association [150].  
 
Several genetic vitamin D pathway variants (e.g. vitamin D receptor (VDR) [241], 
CYP24A1 [188] and CYP27B1 [191]) appear to increase MS risk, but few studies have 
examined interactions with 25(OH)D levels, or reported sun exposure or vitamin D intake. 
Regarding the vitamin D receptor (VDR) gene, the Tasmanian MS case-control study 
showed that only people with a copy of G at the Cdx-2 polymorphism (rs11574010) in the 
VDR gene showed increased MS risk from low winter childhood sun exposure [242], 
while in the US Nurses Cohorts study, only those with a ‘ff’ genotype of the FokI 
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polymorphism (rs10735810) within the VDR gene showed an effect on MS risk from low 
vitamin D intake. There was no significant interaction between latitude of residence and 
FokI genotype [243]. The SNPs for FokI and Cdx-2 are not in linkage disequilibrium with 
one another. There were also no interactions between low vitamin D intake and CYP27B1, 
CYP24A1, CYP2R1, GC or HLA-DR15 [243]. 
 
There is some interesting functional evidence of an interaction between HLA and vitamin 
D. Recently, a vitamin D response element (VDRE) was found in the HLA-DRB1 
promoter region[244]. The VDRE was highly conserved in the major MS-associated 
haplotype HLA-DR15, but not conserved among non-MS associated haplotypes [244]. 
This study also showed that the VDRE responded to 1,25(OH)2D3 and influenced gene 
expression in B-cells that were transiently transfected with the HLA-DR15 promoter [244]. 
These functional studies support the case that higher vitamin D levels at critical times—
specifically in HLA-DR15 positive individuals—might reduce the risk of MS onset. This 
concept may be in line with the finding that people with MS born in April were more 
often HLA-DR15 positive whereas those born in November were less often positive for 
this gene [245].  
 
Note 1.3 Additional studies on gene-vitamin D interaction influencing MS clinical 
course 
 
More recently, our prospective cohort study revealed that gene-vitamin D interactions 
influencing MS clinical course [246,247], including those genes involved in the vitamin D 
metabolism and VDR/RXR transcription formation complex pathway [246] and known 
MS risk-associated susceptibility [247] interact with 25(OH)D to influence MS clinical 
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course. We also demonstrated that those genes involved in the vitamin D pathway interact 
with IFN-β influencing the levels of 25(OH)D in people with MS [248]. These results are 
presented in Chapter 4, Chapter 5 and Chapter 6.  
 
 
As noted earlier, many studies have found a positive association between smoking and 
MS, including dose-response and duration of smoking. Meanwhile, the HLA-A*02 allele 
may have a protective role for MS [236,249]. A Swedish study found that among those 
people with HLA-DR15 and absence of HLA-A*02 alleles, smokers were at significantly 
increased risk of MS (OR 13.5) compared to non-smokers with neither of these genetic 
risk factors [250]. The odds ratio for smokers without genetic risk was 1.4 and compared 
to 4.9 for non-smokers with both genetic risk factors. They also observed a significant 
interaction between absence of HLA-A*02 and smoking among those carrying HLA-DR15 
alleles [250]. However, a pooled study including three MS case control studies showed no 
interaction between HLA-DR15 and smoking [150], suggesting the need for further 
investigations to understand whether there is a true interaction and what potential 
mechanisms might underlie it. 
 
Having younger siblings may be a marker of repeated exposure to common early life 
microbial infections. We found that low infant sibling exposure was associated with an 
increased risk of MS [251]. Moreover, we found an interaction between HLA-DR15 and 
low infant sibling exposure [252]: the combined effect of HLA-DR15 positivity and low 
infant sibling exposure on MS was nearly four-fold higher than expected, compared to the 
effects of HLA-DR15 positivity and low infant sibling exposure alone.  
Therefore there is now strong evidence to suggest that gene–environment interactions 
play a significant role in MS onset and may explain some of the missing heritability of 
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MS. Also, the investigations of gene–environment interactions have increased our 
understanding of how known environmental factors may influence gene expression and 
function and has linked known environmental and genetic factors together to provide 
biologically plausible mechanisms of how components of MS causation may occur.  
 
1.7.5 Implications for MS patients and their families 
For people with MS, progressive disability substantially affects life expectancy and 
impairs quality of life. The median life expectancy for MS patients is five to ten years 
shorter than for age-matched general populations [253]. People with MS and their 
families are therefore very interested in anything that potentially may improve outcomes, 
may allow better and more accurate diagnosis of MS and may provide accurate 
information about the risk of MS among relatives, especially to children and siblings. 
Many people with MS, on being diagnosed, are alarmed to hear that there is a familial 
risk; they are keen to know whether relatives can be tested for MS risk and what can be 
done to reduce that risk. The revolution in our understanding of MS genetics that has 
occurred over the last five years; that is detailed above, can help to answer some of these 
questions. However there are several important points that clinicians need to be aware of 
when counseling people with MS. 
• There is no genetic test that can absolutely define a person’s risk of developing 
MS. The most highly associated genetic risk loci in the HLA region increases the 
risk of MS three-fold and is present in around 70% of people with MS and around 
40% without MS. Therefore on an individual basis it provides little information. 
• The other 63 described MS loci all contribute only a fraction of the risk and are all 
common alleles with the frequency seen in MS cases only slightly different from 
the normal population. Consequently they are not useful markers at the individual 
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level. 
• The best test of increased risk is a family history of MS, with the risk increase for 
relatives now relatively well-understood (Figure 1.6). It is important to note that 
all relative risks are dependent on the background population risk. Therefore an 
accurate understanding of the population prevalence for the persons region of 
residence and ethnic group is essential. This can be estimated from the latitudinal 
data as described in the literature [75]. 
• The recent identification of the first MS rare variant in the CYP27B1 gene may 
represent the first instance where knowledge of a genotype may influence 
outcomes. In multiplex families it is possible that testing for the described SNPs in 
the CYP27B1 gene may be useful. However this has not been tested as yet and 
clearly more work is required before testing can be advocated. 
 
Figure 1.6. Age-adjusted recurrent risk of MS for all relative group 
according to a recent meta-analysis [170]. The risk rank from highest to 
lowest: monozygotic twin (18.44%), dizygotic twin (4.61%), sibling (2.68 %), 
offspring (2.07%), half-sib (1.89%), parent (1.45%), niece/nephew (1.02%), 
aunt/uncle (0.75%), cousin (0.73%), step-sib (0.20%), adoptee (0.13%) and 
general population (0.16%). 
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Despite the dramatic increase in our knowledge of MS genetics, we have a long way to go. 
What is exciting is the rate at which we are learning. As noted in figure 1.3, until 2007 
there was only one known MS genetic association and by 2012 we have information on 
over 60 loci. As genetic techniques become cheaper and more widely applicable, 
particularly whole-genome sequencing techniques, we will find more associations. These 
may well be rare variants with significant effects, such as the CYP27B1 variants; they 
may be only present in a small fraction of people with MS and they may even be personal 
family mutations. However, each new causative locus is another chink in the armour of a 
previously impenetrable disease. Finding genetic loci that are associated opens a whole 
field of human-based research that allows the development of new treatments, allows us 
to understand how the genes and the environment interact and provides information that 
facilitates epigenetic approaches understanding the cause and progression of MS.  
 
We cannot yet offer specific genetic testing to people with MS or their families. However, 
the finding of further rare variants may soon enable us to tailor treatments to families by 
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their genetic status. The genetic revolution has been a great step forward in MS research 
as it allows us to look at molecular mechanisms of this complicated disease in humans, 
rather than only in animals; this gives a far better chance of unraveling the cause of MS 
and developing preventative and treatment strategies.  
 
1.7.6 Conclusion  
Recent advances in genetic studies have confirmed that MS is a complex trait with genetic 
effects. Many environmental factors, and interactions between genes and environment, 
contribute to the development of MS. However, current knowledge of MS genetics is still 
insufficient and not yet clinically applicable. We cannot yet produce a predictive model of 
risk based on the genetic profile of an individual. However, gene identification efforts 
have considerably modified our understanding of the biological mechanisms underpinning 
the risk of and progression of MS. Promising approaches such as whole-exome and 
ultimately whole-genome sequencing have the potential to provide an exhaustive map of 
MS genes in the near future. We believe that the genetic information of MS can be 
meaningful, not only for scientists and clinicians, but also for MS patients and their 
families. In the long term, we are confident that progress in genetics research will lead to 
useful diagnostic and predictive tests and new treatments for MS. 
 
1.8 Summary  
 
MS is a chronic inflammatory degenerative disorder of the brain and spinal cord, leading 
to myelin and axonal damage caused by the individual’s inflammatory response. Three 
types of clinical course have been identified: relapsing remitting, secondary progressive 
and primary progressive. To date, there is no cure for the disease and in practice, 
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treatment varies with the stage reached in the course of the disease, but are mainly aimed 
at reducing the relapse rate and the accumulation of disability. The precise aetiology of 
MS is not known although research showed MS is driven by both environmental and 
genetic factors. So far, the best known and strongest environmental factors －lower 
ultraviolet radiation (UVR) exposure and/or lower vitamin D levels, Epstein Barr virus 
(EBV) infection and smoking have been well established. Additionally, 110 genetic 
variants have been identified conferring susceptibility to MS by GWAS, including the 
most significant HLA region and other about 100 non-HLA common variants. However, 
GWAS only explains a small fraction of the heritability of MS. Potential sources of the 
“missing heritability” include rare variants, many common variants with smaller effect, 
epigenetics, structure variants, gene-gene interactions, gene-environment interactions and 
pathway involvement. Using newer genetic technologies such as whole-exome 
sequencing, several rare functional variants have been identified as associated with MS. 
Promising approach such as whole-genome sequencing have the potential to provide an 
exhaustive map of MS genes in the near future. However, current knowledge of MS 
genetics is still insufficient and not yet clinically applicable. In the long term, we are 
confident that progress in genetics research will lead to useful diagnostic and predictive 
tests and new treatments for MS. 
 
1.9 Aims of my PhD research 
 
2. To detect rare genetic variants conferring susceptibility to MS using identity-by-
decent mapping, so-called “population-based linkage analysis”, utilising a large 
GWAS dataset comprising 3,543 cases and 5,898 controls. This will be presented in 
Chapter 2. 
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3. To assess the disease-causing variants to MS by family-based whole-genome 
sequencing analysis. This will be presented in Chapter 3. 
4. To detect whether those genes involved in vitamin D metabolism and the VDR/RXR 
transcription factor formation complex pathway modify the relationship between 25-
hydroxyvitamin D (25(OH)D) and relapse in people with MS, by using a well-
validated prospective cohort study followed from 2002 to 2005. This will be 
presented in Chapter 4. 
5. To detect whether known MS-associated susceptibility loci exert an effect on relapse 
and progression in clinical disability and whether these loci modify the association 
between 25(OH)D and relapse, by using a well-validated prospective cohort study 
followed from 2002 to 2005. This will be presented in Chapter 5. 
6. To detect whether those genes involved in the vitamin D pathway modify the 
relationship between interferon-β and 25(OH)D levels in patients with MS by using a 
well-validated prospective cohort study followed from 2002 to 2005. This will be 
presented in Chapter 6. 
 
Finally, Chapter 7 is presented a summary of main findings, an overarching 
discussion and future research.  
 
1.10 Postscript 
 
This chapter has provided some key information about MS, which will help to understand 
the rest of the thesis. The chapter has discussed the genetics of MS including rare variants. 
Rare functional variants are specifically important to the aetiology of MS, and different 
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methods have been developed to detect it. The next chapter will discuss how to detect rare 
variants by using identity-by-decent mapping with a large GWAS dataset. 
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Chapter 2. Identity-by-descent mapping to detect rare variants 
conferring susceptibility to multiple sclerosis 
 
2.1 Preface 
 
The previous chapter provided a general background of MS, including the environmental 
and genetic factors associated with the onset of the disease. Among the genetic factors, 
we particularly mentioned that there was ‘missing heritability” that is heritable risk 
factors not yet been identified, including rare variants. This chapter will particularly focus 
on detecting genetic rare variants which are recognised to potentially have larger effects 
on complex disease compared to genetic common variants. Most parts of this chapter 
have been published in PLOS ONE 2013; 8(3): e56379 (Appendix 2A), whereas text 
marked as grey boxes are added and were not part of the original publication. 
 
 
2.2 Introduction 
 
Multiple sclerosis is a complex neurological disease of the central nervous system (CNS) 
triggered by environmental and genetic factors. There is considerable evidence for a 
significant genetic component to MS susceptibility, such as a higher concordance rate in 
monozygotic twins (24%-30%) than dizygotic twins (3%-5%) [1,2]. As for other immune 
diseases, genome-wide association studies (GWASs) have been highly successful for MS: 
uncovering about 110 common genetic variants associated with disease [3-14]. The 
majority of these variants lie near genes with known functions in the immune system and 
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these variants have also been associated with other autoimmune diseases, often in the 
opposite direction [15]. Virtually all of the variants confer modest increases in disease 
risk, the outstanding exception being the strong association with the HLA-DRB1*15:01 
allele in the major histocompatibility complex (MHC), which was first detected in the 
1970’s [16,17]. 
 
Despite this success, the variants identified by GWASs to date only explain 18-24% of the 
heritability of MS [13,18]. While much of the missing heritability is probably explained 
by common variants of even smaller effect sizes, some heritability may be explained by 
rare variants of larger effect size. Standard analysis of GWAS data is not designed to 
detect associations with rare variants that many believe may play an important role in the 
aetiology of complex traits [19-21]. Interestingly, GWASs have had less success for 
putative neurodegenerative diseases, such as Parkinson’s disease, than for MS. For these 
diseases, family-based approaches detecting rare variants have been more successful 
[22,23]. This raises the possibility that rare variants under negative selection pressure are 
relatively more important in the genetic architecture of neurodegenerative processes, 
whereas common variants under balancing selection are more important in the genetic 
architecture of immunological processes. Discovery of rare MS susceptibility variants 
may alter perspectives on the relative importance of immunological & neurodegenerative 
processes in MS onset.  
 
Standard analyses of GWAS data are not designed to detect associations with low 
frequency variants (MAF≤ 5%), and other strategies are required. One approach is to re-
sequence loci containing common susceptibility variants identified from GWASs. This 
strategy was used to detect rare variants in IFIH1 conferring protection to type I diabetes 
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[19]. However this strategy precludes the identification of new loci. Eventually it will be 
possible to overcome this limitation by whole genome sequencing, but it remains 
prohibitively expensive to perform adequately-powered studies. An alternative is to re-
analyse GWAS data using identity-by-descent (IBD) mapping [24], also referred to as 
‘population-based linkage analysis’ (PBLA) [25]. PBLA describes linkage analysis 
applied at the population level to detect mega base-scale regions where cases have 
inherited long haplotypes from distant ancestors, 10–100 generations ago.  IBD mapping 
is performed on the unrelated individuals to determine whether these mega-base scale 
regions are identical and inherited from a common ancestor. If the common ancestor lived 
more than ten generations ago the individuals will share very short tracts of genetic 
material, and a shared haplotype that is very rare is also very likely to be IBD. HapMap 
Phase 3 identified that lower frequency variants should, on average, be younger than more 
common variants; and thus display a greater extent of haplotype sharing [26]. Therefore, 
if case pairs can be detected with long shared haplotypes (generally one to five megabases) 
inherited from distant common ancestors, then rare variants influencing disease risk can 
be localised. Even when whole genome sequencing becomes cheap enough to pursue with 
substantial sample sizes, IBD mapping may still help reduce the massive multiple testing 
problem by prioritizing regions. This is similar to the technique of prioritising association 
signals in regions of linkage [27]. 
 
Several methods of IBD mapping have been published: these include PLINK [25], 
GERMLINE [28], BEAGLE IBD [29] and BEAGLE fastIBD [30]. The models employed 
by PLINK and GERMLINE assume SNPs are in linkage equilibrium, and so ‘pruning’ of 
SNPs [25] is required to avoid false positives due to under-estimates of population 
haplotype frequencies. However pruning of SNPs in incomplete linkage disequilibrium 
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(LD) discards potentially useful information and reduces power. BEAGLE IBD and 
fastIBD implement a variable length Hidden Markov Model [31] to account for LD and 
model haplotype frequencies more accurately. BEAGLE fastIBD runs considerably faster 
than BEAGLE IBD (of the order of 1000 times faster with large GWAS datasets). This is 
mainly because 1) it does not formally model IBD status (‘IBD’/’not IBD’) between pairs 
of individuals using a Hidden Markov Model as in BEAGLE IBD; 2) it stores haplotype 
frequencies in a data dictionary (as in GERMLINE) which means computational time 
scales with sample size n like n log n instead of n2.   
 
To detect MS rare variants, we here use BEAGLE fastIBD to perform an IBD analysis on 
several large MS GWAS datasets comprised 3543 cases and 5898 controls. We identified 
a region of high significance on chromosome 19q13.43, with a genome-wide significant 
localisation signal (p= 1.9×10-6; LOD=4.65) using thresholds based on IBD segment 
length greater than 3cM and the probability p-value less than 10-9 (3cM_1e-9). This locus 
was deemed genome-wide significant according to the recently established genome-wide 
significance thresholds set for IBD mapping [32]. Analysis of expression data and 
investigation of genes in this area support the hypothesis for regulation of gene expression 
in this region to impact upon development or health of CNS tissue. Our analyses also 
illustrate some of the practical issues to deal with in IBD analyses, and demonstrate that 
IBD mapping can form a potentially powerful method for detecting rare variants in 
unrelated individuals at the population level.  
 
2.3 Methods 
  
2.3.1 Study subjects 
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All the MS cases and controls were recruited and genotyped from MS GWASs totaling 
3,543 cases and 5,898 controls. Of these, 1,618 cases and 3,413 controls were from an 
Australian and New Zealand MS GWAS conducted by the Australian and New Zealand 
Multiple Sclerosis Genetics Consortium (ANZgene) [3], and those DNA samples were 
genotyped on the Illumina Infinium Hap370CNV array [3]. An additional 861 Australian 
and New Zealand MS cases were genotyped with the Illumina Human660-Quad chip as 
part of a GWAS performed by the International MS Genetics Consortium (IMSGC) and 
the Wellcome Trust Case Control Consortium-2 (WTCCC2) [13]. Controls included 
1,531 unrelated Australian samples from a GWAS genotyped by Queensland Institute of 
Medical Research (QIMR) with the Illumina Human610-Quad chip [33], and 1064 MS 
cases and 954 controls genotyped with the Sentrix® HumanHap550 BeadChip from a 
GWAS conducted in the US (GeneMSA) [6] [accessed via dbGAP]. 
 
2.3.2 Quality control of data  
 
Conservative quality control measures were imposed both on the individual datasets 
before merging, and in the combined dataset after merging: SNPs with call rates less than 
0.95 or in Hardy-Weinberg disequilibrium (p<10-7) were discarded, as were samples with 
call rates less than 0.98.  Duplicates and close relatives were also removed. This data 
cleaning was performed using PLINK [25]. 
 
A principal components analysis (PCA) was conducted by EIGENSTRAT [34] to exclude 
ancestry outliers and examine population structure within the remaining samples. First, 
SNPs in strong LD were pruned (using the PLINK --indep command with options 50 5 
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1.5), and then we excluded previously identified regions of high LD [35]. Outliers in the 
PCA were excluded using standard settings in Eigenstrat (more than six standard 
deviations from the mean along the first 10 principal components). All chromosomal 
locations refer to Human genome version hg18. 
 
2.3.3 Running BEAGLE fastIBD and results processing 
 
The fastIBD analyses were conducted using BEAGLE 
(http://faculty.washington.edu/browning/beagle/). In brief, genotypes for the merged, 
cleaned dataset were converted to BEAGLE format by using the linkage2Beagle.jar utility 
program. We then used the BEAGLE method for phasing the data and identifying IBD 
segments simultaneously, using the ‘fastibdthreshold’ option. This procedure was run 10 
times for each chromosome starting with different seeds of the random number generator.  
 
The output of these calculations was a series of “putative” IBD segments shared between 
pairs of individuals. Each segment comes with the following information attached: ids for 
the pair of individuals, first and last SNPs in the IBD segment, length of the segment in 
centimorgans, and probability of the two individuals both carrying the segment if it was 
not IBD.  We filtered these segments using various maximum probabilities and minimum 
segment lengths, as recommended in the BEAGLE manual. Results from the 10 runs were 
combined by taking the union of IBD segments detected in each run.  From the final list 
of segments, we wrote a Perl script to count numbers of case-case pairs (yi), case-control 
pairs (ui) and control-control pairs (vi) estimated to share haplotypes IBD at each SNP i.  
 
2.3.4 Analysis of IBD 
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We focused on the detection of loci where groups of cases have inherited rare 
susceptibility alleles IBD.  To do this, we modelled IBD sharing yi in case-case pairs 
(“case pairs”) as a function of IBD sharing in xi = ui + vi in case-control pairs and control-
control pairs combined (“control pairs”).   
 
We tried various methods to model the yi as a function of the xi: linear regression, 
negative binomial regression and Poisson regression.  Models were fitted using R [36], 
and goodness of fit was assessed by examining diagnostic plots [Supplementary R 
commands].  
 
At SNPs i with more IBD sharing in cases than expected, residuals zi from the fitted 
models should be large and positive.  To present residuals on a scale more familiar to 
geneticists, we converted them to LOD scores using the formula LODi = zi2/(2*loge(10).  
 
At the SNPs with the highest LOD scores, we calculated the proportions of case pairs 
sharing IBD in various populations, and plotted networks of case and control pairs sharing 
IBD with each other using the R network package 
(http://cran.rproject.org/web/packages/network/index.html).  
 
2.4 Results 
 
2.4.1 Study samples from GWASs after cleaning 
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11 individuals were excluded because of call rates less than 0.98 and 202 were excluded 
because they were close relatives or duplicates. PCA was conducted on a subset of 77,856 
SNPs not in LD, which were common to all sample sets. Through successive iterations 
251 outliers (37 AUS cases; 9 AUS controls; 6 UK controls; 97 US cases; 102 US 
controls) were excluded. All datasets overlap well after removing outliers (Figure 2.1). In 
summary, there were 3,243 cases and 5,725 controls with 274,735 autosomal SNPs in the 
final analysis (Table 2.1).   
 
Table 2. 1. Sample numbers from GWASs  (after cleaning) 
GWAS 
Dataset 
     Country of origin No. Case No. Control Total No. SNPs 
Cases Controls 
ANZgene[3] AUS, 
NZ 
US, UK 1,608 3,404 5,012 300,900 
WTCCC2[13] AUS - 766 - 766 586,393  
QIMR[33] - AUS - 1,516 1,516 529,292 
GeneMSA [6] US US 878 805 1,683 550,677 
Total   3,252 5,725 8,977 274,735* 
* The number of SNPs that passed QC in all 4 GWAS datasets.  
AUS = Australia, NZ=New Zealand 
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Figure 2.1 Principal components analysis of the dataset. Most individuals in the 
dataset are of predominantly northern European ancestry (right hand side), but 
some have southern European ancestry (left hand side) (one dot for each individual). 
 
 
 
2.4.2 Results of IBD analysis 
We detected IBD with the threshold of IBD segment greater than 3cM and the haplotype 
probability p-value less than 10-9 (3cM_1e-9). A strong linkage signal was observed in the 
HLA region (LOD = 3.58), while the strongest signal in non-HLA region was on 
chromosome 19 (LOD =4.65), which reached genome-wide significance according to the 
recent established genome-wide significance threshold set for IBD mapping [32].  
 
Results note 2.1 Example of IBD processing results 
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The detail of IBD process was not provided in our original published paper. To well 
understand the whole process, we added the example here. Note 2.1. Table A presents the 
results of IBD detected on chromosome 1 with the threshold of 3cM_1e-9 as an example.  
This table presents the begin marker (SNP) and the end mark (SNP) for each case_case 
pairs (yi), case_control pairs (ui) and control_control pairs (vi) in each run. Then we 
united the IBD segments in the ten runs because the IBD segments detected in each run 
would overlap each other. Finally we noted how many case_case (yi), case_control (ui) 
and control_control (vi) pairs shared IBD segments in each SNP in whole genome (Note 
2.1. Table B).  
 
Results note 2.1.  Table A.  Results of IBD detected on chromosome 1 with 
the threshold of 3cM_1e-9 
ID1 ID2 Case/control 
(code)* 
Case/control 
(code)* 
Chr Begin 
marker 
End 
marker 
Case1 Case2   2   2  1 4802 5212 
Case1 Case3   2   2  1 4719 5212 
Case1 Control1   2   1  1 2573 2976 
Case1 Control2   2   1  1 2916 3132 
Control2 Conrol3   1   1  1 19714 19900 
Control2 Control4   1   1  1 19715 19905 
…       
* 2: case; 1: control.  
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Results note 2.1.  Table B.  IBD pairs at each SNP in whole genome with the threshold of 
3cM_1e-9 
Chr   SNP        cM   bp No.  
case_ case 
No.  
case_ control 
No.  
control_ control 
1 rs4650610 105.2237858 79054556 627 2089 1937 
1 rs1935562 81.0882568533 56976089 544 1933 1713 
1 rs2176690 232.6536960334 219883931 598 2107 1987 
…       
22 rs2285395  73.5750567738 49524956 104 355 306 
Total: 274,735 SNPs 
* Case_case pairs were set as case pairs (yi); both case_control pairs (ui) and control_control pairs (vi)  
were set as “control pairs” (= ui + vi).  
 
 
Figure 2.2  is a scatterplot of case-pair sharing yi versus control-pair sharing xi as each of 
the 274,735 SNPs i.  Using different colours to represent SNPs on different chromosomes, 
an outlier group of SNPs with relatively high case pair sharing on one chromosome stands 
out in green.   
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Figure 2.2.  Plots of raw data of IBD with one point for each SNP. The green region 
clearly deviates from the black line, which indicates the proportion of case pairs in 
this region is higher than that of control pairs. The black line represents where the 
proportion of case pairs is equal to control pairs. 
 
 
 
2.4.3.   Fitting, testing Poisson model and converted to LOD scores 
 
From examination of diagnostic plots (Figure 2.3-2.5), we found that the Poisson model 
provided the best fit to these data. Figure 2.6 shows a plot of residuals from the Poisson 
model converted to LOD scores. The highest linkage signal, corresponding to the green 
outlier region in Figure 2.2, was observed on chromosome 19 with LOD=4.65 and 
p=1.9×10-6. As expected, a strong signal also was observed in the HLA region 
(LOD=3.58; Figure 2.6). 
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Figure 2.3. Fitting Poisson model for the IBD data. All the four real lines in these 
four modules fit well with the default lines, suggesting Poisson model is appropriate 
for this data.  The residuals of the green region are higher than others.  
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Figure 2.4. Fitting negative binomial model for the IBD data. All the four real lines 
in these four modules do not fit well with the default lines, suggesting negative 
binomial models are not suitable for this IBD data. 
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Figure 2.5. Fitting linear model for the IBD data. All the four real lines in these four 
modules do not fit well with the default lines, suggesting that linear models are not 
suitable for this IBD data. 
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Figure 2.6.  Plot of linkage scores along the whole genome with the IBD threshold of 
3cM_1e-9 (shared haplotype segment >3cM and haplotype probability <10-9). 
Chromosome 19 has the strongest linkage signal (LOD=4.65).  
 
 
 
 
2.4.4   Analysis of linkage region on chromosome 19 
The linkage region on chromosome 19 with LOD score between 3.65 - LOD 4.65 is 
around 900kb in length (Hg18 chr19:62,529,738-63,437,743 bp) and corresponds to a 
cluster of zinc finger genes at 19q13.4, many of which have arisen by gene duplication. 
None of the genes in this region have been previously identified in published GWASs or 
associated with MS or autoimmune diseases.  
 
Results note 2.2 The interested linkage region on chromosome 19  
 
The interested linkage region generally refers to the region between the “highest LOD 
score” and “highest LOD score-1”. Results note 2.2. Figure A presents the interested 
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linkage region on chromosome 19, which is about 900 kb (between LOD 3.65 – LOD 
4.65). Results note 2.2. Figure B presents the reference genes of the linkage region in 
UCSC genome browser. Most of the reference genes are zinc finger proteins and many of 
which have arisen by gene duplication.  
 
Results note 2.2. Figure A. The interested linkage region on chromosome 19. 
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Results note 2.2. Figure B. RefSeq Genes in the interested linkage region on 
chromosome 19. 
 
 
The genes in this region were examined to identify candidate genes with putative roles, 
which could, impact on susceptibility to MS.  Published microarray expression data [37], 
profiling gene expression in the human hippocampus over a broad developmental range, 
were downloaded from Gene Expression Omnibus [38], series number GSE25219. Gene 
summary data was analysed in Partek Genomics Suite version 6.6 (Partek Inc., St. Louis, 
MO, USA) to generate expression profiles across all developmental periods for genes in 
the linkage region. Many of these genes exhibit similar expression profiles with high 
expression in early time points and low expression after birth. To categorize this observed 
trend, samples from a number of early foetal time periods (3, 4 and 5) (described in [37]) 
were grouped together and compared with expression of grouped samples from periods 9, 
10, 11, and 12. Differential expression of exon level probe sets between these two groups 
was then analysed. The data points corresponding to individual probe sets, and 
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representing expression changes between these two developmental stages, were then 
aligned against the linkage region in a UCSC genome browser view.  Differentially 
expressed probe sets were filtered using a false discovery rate adjusted p value cut off 
(1.53x10-3) equivalent to a p value threshold of 0.01 and a fold change minimum 1.5. 
Those probe sets that passed this threshold were plotted on the UCSC browser screen 
view [39]. Genomic locations for Affymetrix exon level probe sets within the linkage 
region were downloaded from the UCSC table browser [40] and used to construct a 
bedGraph file of expression changes. The green bars indicate a higher expression in foetal 
time points compared to later time points.  Some fold changes for genes in this region are 
very high (4-6 fold higher in foetal than post birth). 
 
Although little is known about the majority of genes in this region, ZNF274 is a DNA 
binding protein involved in regulation of H3K9me3 methylation at the 3’ end of some 
ZNF genes by recruitment of the histone methyltransferase SETDB1, and the corepressor 
TRIM28 (KAP1) [41].  To examine the pattern of H3K9me3 methylation in this region, 
genomic data on H3K9me3 methylation and KAP1, SETDB1 and ZNF274 binding in 
K562 cells [41] was used to make custom bedGraph files for visualization alongside the 
expression change with development (Figure 2.7).  From this data we observed that the 
vast majority of genes in this region with high foetal expression levels are marked by both 
H3K9me3 methylation and bound by KAP1 and SETDB1 at the 3’ end of the gene. A 
small number of genes are also bound at the 3’ end of the transcript by ZNF274. We also 
observed a pattern in the level of H3K9me3 methylation, with two maximum levels at 
about position 62,850,000 and 63,400,000 and trailing off at position 63,250,00. This 
bimodal pattern also occurs in the KAP1 and SETDB1 binding data and is even more 
apparent when viewing a wider view of the region. This position, marked in the figure by 
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vertical black line, also corresponds with the position of rs159870 (chr19:63239261) and 
there is break in synteny with rodent genomes in this zone. 
 
Figure 2.7.  Screen shot from the UCSC genome browser illustrating expression 
regulation within the identified linkage region on Chromosome 19 (hg18) 
(http://genome.ucsc.edu). Human Refseq gene models are shown at the bottom of the 
figure. Custom bedGraph tracks illustrating expression regulation, as described in 
the manuscript, are shown.  From top to bottom: (A) exon level expression fold 
change in hippocampus (FDR adjusted p value <0.01 and fold change >1.5) between 
early fetal (periods 3,4 and 5) and postnatal (periods 9,10,11 and 12) from Kang et al 
2011, green bars indicate increased expression in fetal compared with postnatal and 
red bars indicate decreased expression in fetal compared with postnatal. ChIP-chip 
binding patterns of (B) H3K9me3 (C) TRIM28/KAP1 (D) SETDB1 and (E) ChIP-
seq binding pattern of ZNF274 in K562 cells. For the ChIP-chip data log2 (ratio) 
values reflecting the ChIP enrichments are plotted on the Y axis. For the ChIP-seq 
data the number of tags reflecting the ChIP enrichments are plotted on the Y axis.  
ChIP-chip and ChIP-seq data are from Frietze et al 2010 supplementary data. 
Chromosomal coordinates and relative position on the chromosome is illustrated in 
the idogram at the top of the figure. The position of SNP rs159870 is shown by a 
vertical black line. 
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2.4.6 Comparison of IBD case pairs among different populations 
 
We next examined patterns of IBD sharing at the SNP with the highest LOD score on 
chromosome 19 (rs159872). We compared the proportion of IBD case pairs in different 
populations to examine if there are some particular populations that contribute to more 
IBD case pairs in this locus, and found the Tasmanian population has the highest 
proportion of IBD case pairs, but this did not reach statistical significance when compared 
to other populations except for the US population (p-value=0.033). When compared with 
all other combined Australian populations, the Tasmanian population significantly 
contributed more IBD case pairs at this locus(p=0.004); and was significant  when 
comparing with all other combined non-Tasmanian populations (p=5.44×10-5; Table 2.2).  
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Table 2.2: Comparison of IBD case pairs among different populations  
(rs159872 with the highest LOD score on chr19 (LOD=4.65)) 
Population No. case No. IBD case 
pairs 
% IBD case pairs P-value 
TAS 308 7 14.8×10-5  Ref. 
Mel 841 32 9.06×10-5  0.216 
Newc 111 0 0.00 1.00 
Syd 541 14 9.58×10-5  0.320 
Other 32 0 0.00 1.00 
AUS (non-TAS) 1525 46 3.96×10-5 0.004 
NZ 540 14 9.62×10-5  0.321 
US 879 22 5.70×10-5  0.033 
Non-TAS 2944 82 1.89×10-5 5.44×10-5 
*% IBD case pairs=IBD pairs/case×(case-1)/2; (Fisher’s Exact Test) 
 
2.4.7 Networks of cases and controls sharing haplotypes on chromosome 19 
 
Figure 2.8 shows networks of cases and controls sharing haplotypes IBD at the SNP with 
the highest LOD score on chromosome 19.  The biggest cluster comprises 10 cases 
sharing a haplotype in which 4 cases come from Melbourne, 4 come from New Zealand, 1 
come from Sydney and 1 come from USA. Another big cluster includes 2 cases from 
Melbourne, 3 cases from Tasmania and 4 cases from New Zealand (Figure 2.8 A) (red 
arrows). More generally, there are more big networks of cases sharing haplotypes than 
controls (Figure 2.8 B).  
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Figure 2.8.  Networks of cases and controls sharing haplotypes IBD at the SNP 
(rs159872) with the highest LOD score on chromosome 19. A. Diagram showing 
networks of cases sharing haplotypes in common at the linkage region on 
chromosome 19. B. Diagram showing networks of controls sharing haplotypes in 
common at the linkage region on chromosome 19.  Each dot represents an individual 
and each line connects pairs of individuals who share a haplotype. There are more 
big networks of cases sharing haplotypes than controls. 
 
 
 
2.5 Discussion  
 
We have applied BEAGLE fastIBD for the detection of rare MS variants utilising a large-
scale GWAS dataset. We identified a high linkage signal on chromosome 19 with a p-
value of 1.9×10-6 (LOD=4.65). In classical linkage analysis in small families, individuals 
are closely related and the segments of IBD tend to be fairly long (>10cM) which are 
easier to detect and less independent than IBD mapping, the generally-accepted threshold 
for genome-wide significance is p=2.0×10-5 [42]; while GWAS has more independent 
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tests than IBD mapping, the threshold of genome-wide significance is around p=5.0×10-8 
[43], so the threshold of p-value for IBD mapping genome-wide significant should be 
between 5.0×10-8 and 2.0×10-5. Recently, researchers demonstrated that the genome-wide 
significance thresholds for IBD mapping depend on the IBD segment size detected or IBD 
generations [32]. For example, an IBD segment size of 2 cM corresponds to 25 
generations and the genome-wide significance threshold is 2.0×10-6, while the segment 
size of 3.2 cM corresponds to 15 generations and the genome-wide significance threshold 
is 4.0×10-6 [32].  The strongest non-HLA linkage signal we detected in this study used a 3 
cM segment size; which corresponds to 17 generations, thus the genome-wide 
significance threshold is between 4.0×10-6  and 2.0×10-6. As such, the linkage signal on 
chromosome 19, with a  p-value of 1.9×10-6, was determined to be genome-wide 
significant. 
 
2.5.1  Causal relationship between genes in linkage region and MS 
 
Most genes in this linkage region are zinc finger (ZNF) proteins of which 32 genes have 
been suggested to be transcriptional regulators [44] (http://genome.ucsc.edu/). Seven 
genes (ZNF134, ZNF135, ZNF154, ZNF549, ZNF606, ZNF671 and ZSCAN1) in this 
region belong to the Krüppel family of ZNF genes. Only a few ZNF genes in this region 
have known vertebrate homologues and it includes a number of primate specific KRAB-
ZNF genes [45]. In humans KRAB-ZNF genes number about 400 and make up the largest 
group of C2H2 transcription factors [46] which are typically expressed at low levels and 
involved in cell specific silencing and driving different cell lineages.  
 
Detailed analysis of genes in this region did not reveal any direct links with MS. However 
examination of their expression profiles in published data revealed a shared early 
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developmental CNS specific expression profile with 22 genes in this region being 
members of the expression module M20 described in [37], characterised by higher 
expression in all brain regions in early foetal time points followed by decreased 
expression prior to birth and very low expression thereafter. The M20 network of genes 
has a strong correlation with both neuronal differentiation and neuronal migration and a 
strong negative correlation with myelination [37].   
 
Epigenetic mechanisms such as histone modification and DNA methylation are 
responsible for silencing many specific transcription factors including zinc finger genes, 
and the 3’ end of many ZNF genes are specifically covered by H3K9me3 [47]. The zinc 
finger gene ZNF274, located within the linkage region, is involved in gene silencing 
through recruitment of the histone methytransferase complex TRIM28 (KAP1)/ SETDB1 
to the 3’ end of specific ZNF genes [41]. Examination of H3K9me3, KAP1 and SETDB1 
binding data, confirms that many of the genes in the linkage region are covered by 
H3K9me3 at their 3’end (Figure 2.7). ZNF274 also interacts with p75NTR and is 
predicted to play a role in programmed cell death during development [48]. A number of 
the genes in this area are also highly expressed in differentiated human neural cells 
compared to earlier stems cells  (ZNF549, ZNF324, ZNF548, ZNF264, ZNF671, ZSCAN1 
and ZSCAN18 are members of cluster A [49]). There is very little available evidence for 
involvement in immune cell activity for genes in this region. ZNF304 is implicated in 
lymphocyte activation [50] and ZNF274 has very high expression in activated eosinophils 
compared with other immune cell types [51]. Other genes in this region have relatively 
low expression and are not differentially regulated between immune cell types [51], as 
viewed in the immunological genome [52]. 
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Together these findings suggest that many of the genes in this cluster may be involved in 
early differentiation of neuronal cells and potentially the silencing of genes required for 
myelination. Expression of ZNF genes is commonly detected in foetal brain and they are 
predicted to be involved in development of the nervous system, a KRAB zinc finger 
cluster on chromosome 8 has also been proposed to be involved in regulation of CNS 
development [53]. Although other clustered genes families have been shown to be co-
expressed in cell types or tissues, previous studies have failed to identify coordinated 
expression of KRAB-ZNF gene clusters [45]. However earlier experiments did not 
examine the very early timepoints in CNS tissues included in the Kang dataset [37]. These 
expression profiles described in the M20 module are supported by two independent data 
set of both exon array level and RNA-seq expression data in early human CNS 
development available at the Allan Brain Atlas (http://developinghumanbrain.org/). 
 
Thus this may be an example of a gene cluster of KRAB -ZNF genes exhibiting 
coordinated expression regulation, indicating the presence of a genomic regulatory block 
(GRB). Such regions are usually transcription factors controlled by highly conserved 
noncoding regions. Although the identification of GRBs remains difficult the evidence 
that we have collated is suggestive of two genomic regulatory blocks within the linkage 
region, interrupted at the position of SNP rs159870 where there is an absence of 
H3K9me3 methylation and a break in synteny (reviewed in [54]). 
 
The underlying cause for susceptibility in this region could therefore be due, not to 
differences in a specific gene expression or protein product, but to differences in the tight 
expression regulation of a GRB. As mentioned above, many of the C2H2 zinc finger 
genes in this region have an expression profile consistent with silencing of genes required 
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for myelination. Further analysis needs to be undertaken to examine if these genes are co-
regulated in demyelination and remyelination as well as CNS developmental states. 
Unfortunately, due to the species specificity of many of the KRAB-ZNF genes and the 
absence of rodent homologues of genes in this region, data from non-human models of 
demyelination and remyelination may not be useful. 
 
Ideally, re-sequencing is the next step to refine this potential signal further. Unfortunately, 
resequencing of the region would be complicated since there are many gene duplications 
in this linkage region. 
 
 For the SNP (rs159872) with the highest LOD score on chromosome 19, we hypothesise 
that there are some difference between cases and controls sharing haplotypes in the 
linkage region among different populations. We found the Tasmanian MS population has 
the highest proportion of case IBD sharing, significantly higher than non-Tasmanian 
combined populations as well as other non-Tasmanian combined Australian populations. 
While Tasmania has the highest prevalence of MS in Australia, it is generally agreed that 
this is primarily driven by environmental effects related to, sunlight and/ or vitamin D 
[55]. However there is also a modest founder effect in Tasmania [56], which might result 
in an increase in MS susceptibility driven by rare variants IBD. Interestingly, we found 
there are more big networks of cases sharing haplotypes than controls, and one big case 
network comprises 3 Tasmanian cases, 4 New Zealand cases and 2 cases from Melbourne, 
which may indicate the potential causal variants or gene mutations exist in those big case 
networks. However, this SNP falls in a region of low/none methylation and correlates 
with a break in syteny, the significance of which is unclear.   
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2.5.2  Technical considerations 
 
Even though Beagle fastIBD is several orders of magnitude faster than Beagle IBD, IBD 
analysis remains moderately computationally intensive on a dataset of this size (8,977 
individuals and 274,735 SNPs). For instance, on chromosome 2 with 22,607 SNPs, the 
computation time for each run was approximately 4.6 hours with memory requirement of 
3.3 GB on 2 cores of a SGI Altix ICE 8200 HPC cluster computer node. 
 
However, we also found IBD analysis limitations: it is only suited to discover rare 
variants if all variants act in the same direction in one gene. For example, the identified 
rare variants in BRCA1 and BRCA2 gene all increase risk of breast cancer [57], and the 
four rare variants identified in IFIH1 gene all protect against type I diabetes [19]. If some 
rare variants increase risk while others in the same gene decrease risk then the signal in 
the region will be attenuated. In addition, we found IBD analysis is very sensitive to 
genotyping error, resulting in reducing signal strength. The linkage signal detected 
depends on a lot of markers or long haplotypes, containing up to hundreds of SNPs, a 
single error occurring in reading a single marker significantly reduces the signal. In our 
data, samples came from different GWAS using different genotyping chips in different 
locations, which at least in part, may decrease the potential signal strength from our study. 
Furthermore, resequencing would be complicated by gene duplication and repeat regions, 
since the linkage region detected in this study had many gene duplicates, thus replication 
in other independent dataset is needed. 
 
The optimal method to detect rare disease-causing variants is whole genome sequencing 
of thousands of samples. When this becomes affordable, there will remain a role for IBD 
Chapter 2. Identity-by-descent mapping to detect rare variants conferring susceptibility to 
multiple sclerosis 
	   101	  
analysis to prioritize regions for follow-up analysis and minimize the massive multiple 
testing burden. Just as linkage analysis is now used to identify regions for follow-up in 
whole genome sequencing and exome sequencing of Mendelian disease families, and 
linkage analysis can be used to weight regions for GWA analysis [27].  
 
In summary, we have applied IBD analysis to a large complex disease GWA dataset and 
identified a linkage signal with genome-wide significance, although it. While our most 
significant result is of equivocal significance, and lies in a region that is hard to validate 
via sequencing, we believe IBD analysis has considerable potential, particularly to help 
interpret whole-genome sequencing data in complex trait studies. 
 
2.6 Summary 
Genome-wide association studies have identified about 110 common variants associated 
with MS, but these loci only explain a fraction of the heritability of MS. Some missing 
heritability may be caused by rare variants that have been suggested to play an important 
role in the aetiology of complex diseases such as MS. However current genetic and 
statistical methods for detecting rare variants are expensive and time consuming. 
‘Population-based linkage analysis’ (PBLA) or so called identity-by-descent (IBD) 
mapping is a novel way to detect rare variants in extant GWAS datasets.  
 
We employed BEAGLE fastIBD to search for rare MS variants utilising IBD mapping in 
a large GWAS dataset of 3,543 cases and 5,898 controls. We identified a genome-wide 
significant linkage signal on chromosome 19 (LOD=4.65; p=1.9×10-6). Network analysis 
of cases and controls sharing haplotypes on chromosome 19 further strengthened the 
association as there are more large networks of cases sharing haplotypes than controls. 
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This linkage region includes a cluster of zinc finger genes of unknown function. Analysis 
of genome wide transcriptome data suggests that genes in this zinc finger cluster may be 
involved in very early developmental regulation of the CNS. Our study also indicates that 
BEAGLE fastIBD allowed identification of rare variants in large unrelated population 
with moderate computationally intensity. Even with the development of whole-genome 
sequencing, IBD mapping still may be a promising way to narrow down the region of 
interest for sequencing priority.  
 
2.7 Postscript  
The chapter has described how to use IBD mapping to detect rare variants, and we have 
identified that a genome-wide significant linkage signal was on chromosome 19, which 
includes a cluster of zinc finger protein genes that may be involved in very early 
developmental regulation of the CNS. In the next chapter I will discuss how to detect rare 
variants/and or disease-causing variants of MS by using another powerful method -
family-based whole genome sequencing analysis. 
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Supplementary R commands 
 
1) Fitting and testing model for IBD data 
 
library(MASS) 
m1 <- glm.nb(case ~ control) 
#nb = negative binomial regression 
par(mfrow=c(2,2)) 
plot(m1,col=d$chr) 
 
m2 <- lm(case ~ control) 
#lm = linear regression 
par(mfrow=c(2,2)) 
plot(m2,col=d$chr) 
 
m3 <- glm(case ~ offset(log(control)),family=poisson) 
#glm = poisson regression 
par(mfrow=c(2,2)) 
plot(m3,col=d$chr) 
 
 
 
2) Plot of residuals from the Poisson model converted to LOD scores 
 
par(mfrow=c(2,1)) 
c <- 1 
shift <- -(min(d$bp[d$chr==c]))/1000000 
plot(d$bp[d$chr==c]/1000000+shift,LOD[d$chr==c],type="l",ylim=c(0,max(LOD)),xlim=c(0,14
00),xlab="position (megabases)",ylab="LOD score",col=d$chr[d$chr==c]) 
lines(c(-100,1500),c(2,2),lty=3) 
mid <- (min(d$bp[d$chr==c])+max(d$bp[d$chr==c]))/2000000+shift 
text(mid,3,c) 
for (c in 2:7) { 
    shift <- shift+(max(d$bp[d$chr==c-1])-min(d$bp[d$chr==c]))/1000000 
    lines(rep(shift+min(d$bp[d$chr==c])/1000000,2),c(-10,60),lty=2) 
    lines(d$bp[d$chr==c]/1000000+shift,LOD[d$chr==c],col=d$chr[d$chr==c]) 
    mid <- (min(d$bp[d$chr==c])+max(d$b[d$chr==c]))/2000000+shift 
    text(mid,3,c) 
} 
c <- 8 
shift <- shift+(max(d$bp[d$chr==c-1])-min(d$bp[d$chr==c]))/1000000 
plot(d$bp[d$chr==c]/1000000+shift,LOD[d$chr==c],type="l",ylim=c(0,max(LOD)),xlim=c(1400
,2800),xlab="position (megabases)",ylab="LOD score",col=d$chr[d$chr==c]) 
lines(c(1300,3000),c(2,2),lty=3) 
mid <- (min(d$bp[d$chr==c])+max(d$bp[d$chr==c]))/2000000+shift 
text(mid,3,c) 
for (c in 9:22) { 
    shift <- shift+(max(d$bp[d$chr==c-1])-min(d$bp[d$chr==c]))/1000000 
    lines(rep(shift+min(d$bp[d$chr==c])/1000000,2),c(-10,60),lty=2) 
    lines(d$bp[d$chr==c]/1000000+shift,LOD[d$chr==c],col=d$chr[d$chr==c]) 
    mid <- (min(d$bp[d$chr==c])+max(d$bp[d$chr==c]))/2000000+shift 
    text(mid,3,c) 
} 
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3) Network analysis 
 
library(network) 
n <- read.table("/Users/rlin2/Documents/BEAGLE/population_groups/3cM_1e-
9_chr19.network",header=FALSE) 
groups <- read.table("/Users/rlin2/Documents/BEAGLE/population_groups/3cM_1e-
9_chr19.grouplist",header=FALSE) 
m <- as.matrix(n) 
g <- network(m,directed=FALSE) 
a <- plot.network(g,vertex.col=groups[,2],vertex.cex=0.7) 
xmax <- max(a[,1]) 
ymax <- max(a[,2]) 
legend(xmax-
10,ymax+10,legend=c("Mel","Newc","NZ","Tas","Syd","US","SA"),pch=rep(16,7),col=1:7)  
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Genome-wide association studies (GWAS) have identified around 60 common variants associated with multiple sclerosis
(MS), but these loci only explain a fraction of the heritability of MS. Some missing heritability may be caused by rare variants
that have been suggested to play an important role in the aetiology of complex diseases such as MS. However current
genetic and statistical methods for detecting rare variants are expensive and time consuming. ‘Population-based linkage
analysis’ (PBLA) or so called identity-by-descent (IBD) mapping is a novel way to detect rare variants in extant GWAS
datasets. We employed BEAGLE fastIBD to search for rare MS variants utilising IBD mapping in a large GWAS dataset of 3,543
cases and 5,898 controls. We identified a genome-wide significant linkage signal on chromosome 19 (LOD=4.65;
p = 1.961026). Network analysis of cases and controls sharing haplotypes on chromosome 19 further strengthened the
association as there are more large networks of cases sharing haplotypes than controls. This linkage region includes a
cluster of zinc finger genes of unknown function. Analysis of genome wide transcriptome data suggests that genes in this
zinc finger cluster may be involved in very early developmental regulation of the CNS. Our study also indicates that BEAGLE
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Introduction
Multiple sclerosis (MS) is a complex neurological disease of the
central nervous system (CNS) triggered by environmental and
genetic factors. There is considerable evidence for a significant
genetic component to MS susceptibility, such as a higher
concordance rate in monozygotic twins (24%–30%) than dizygotic
twins (3%–5%) [1,2]. As for other immune diseases, genome-wide
association studies (GWAS) have been highly successful for MS:
uncovering around 60 common genetic variants associated with
disease [3–13]. The majority of these variants lie near genes with
known functions in the immune system and these variants have
also been associated with other autoimmune diseases, often in the
opposite direction [14]. Virtually all of the variants confer modest
increases in disease risk, the outstanding exception being the
strong association with the HLA-DRB1*15:01 allele in the major
histocompatibility complex (MHC), which was first detected in the
1970’s [15,16].
Despite this success, the variants identified by GWAS to date
only explain 18–24% of the heritability of MS [13,17]. While
much of the missing heritability is probably explained by common
variants of even smaller effect sizes, some heritability may be
explained by rare variants of larger effect size. Standard analysis of
GWAS data is not designed to detect associations with rare
variants that many believe may play an important role in the
aetiology of complex traits [18–20]. Interestingly, GWAS have
had less success for putative neurodegenerative diseases, such as
Parkinson’s disease, than for MS. For these diseases, family-based
approaches detecting rare variants have been more successful
[21,22]. This raises the possibility that rare variants under negative
selection pressure are relatively more important in the genetic
architecture of neurodegenerative processes, whereas common
variants under balancing selection are more important in the
genetic architecture of immunological processes. Discovery of rare
MS susceptibility variants may alter perspectives on the relative
importance of immunological & neurodegenerative processes in
MS onset.
Standard analyses of GWAS data are not designed to detect
associations with low frequency variants (MAF#5%), and other
strategies are required. One approach is to re-sequence loci
containing common susceptibility variants identified from GWAS
studies. This strategy was used to detect rare variants in IFIH1
conferring protection to type I diabetes [18]. However this strategy
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precludes the identification of new loci. Eventually it will be
possible to overcome this limitation by whole genome sequencing,
but it remains prohibitively expensive to perform adequately-
powered studies. An alternative is to re-analyse GWAS data using
identity-by-descent (IBD) mapping [23], also referred to as
‘population-based linkage analysis’ (PBLA) [24]. PBLA describes
linkage analysis applied at the population level to detect mega
base-scale regions where cases have inherited long haplotypes from
distant ancestors, 10–100 generations ago. IBD mapping is
performed on the unrelated individuals to determine whether
these mega-base scale regions are identical and inherited from a
common ancestor. If the common ancestor lived more than ten
generations ago the individuals will share very short tracts of
genetic material, and a shared haplotype that is very rare is also
very likely to be IBD. HapMap Phase 3 identified that lower
frequency variants should, on average, be younger than more
common variants; and thus display a greater extent of haplotype
sharing [25]. Therefore, if case pairs can be detected with long
shared haplotypes (generally one to five megabases) inherited from
distant common ancestors, then rare variants influencing disease
risk can be localised. Even when whole genome sequencing
becomes cheap enough to pursue with substantial sample sizes,
IBD mapping may still help reduce the massive multiple testing
problem by prioritizing regions. This is similar to the technique of
prioritising association signals in regions of linkage [26].
Several methods of IBD mapping have been published: these
include PLINK [24], GERMLINE [27], BEAGLE IBD [28] and
BEAGLE fastIBD [29]. The models employed by PLINK and
GERMLINE assume SNPs are in linkage equilibrium, and so
‘pruning’ of SNPs [24] is required to avoid false positives due to
under-estimates of population haplotype frequencies. However
pruning of SNPs in incomplete linkage disequilibrium (LD)
discards potentially useful information and reduces power.
BEAGLE IBD and fastIBD implement a variable length Hidden
Markov Model [30] to account for LD and model haplotype
frequencies more accurately. BEAGLE fastIBD runs considerably
faster than BEAGLE IBD (of the order of 1000 times faster with
large GWAS datasets). This is mainly because 1) it does not
formally model IBD status (‘IBD’/’not IBD’) between pairs of
individuals using a Hidden Markov Model as in BEAGLE IBD; 2)
it stores haplotype frequencies in a data dictionary (as in
GERMLINE) which means computational time scales with sample
size n like n log n instead of n2.
To detect MS rare variants, we here use BEAGLE fastIBD to
perform an IBD analysis on several large MS GWAS datasets
comprised 3543 cases and 5898 controls. We identified a region of
high significance on chromosome 19q13.43, with a genome-wide
significant localisation signal (p = 1.961026; LOD=4.65) using
thresholds based on IBD segment length greater than 3 cM and
the probability p-value less than 1029 (3cM_1e-9). This locus was
deemed genome-wide significant according to the recently
established genome-wide significance thresholds set for IBD
mapping [31]. Analysis of expression data and investigation of
genes in this area support the hypothesis for regulation of gene
expression in this region to impact upon development or health of
CNS tissue. Our analyses also illustrate some of the practical issues
to deal with in IBD analyses, and demonstrate that IBD mapping
can form a potentially powerful method for detecting rare variants
in unrelated individuals at the population level.
Methods
Study subjects
All the MS cases and controls were recruited and genotyped
from MS GWAS totaling 3,543 cases and 5,898 controls. Of these,
1,618 cases and 3,413 controls were from an Australian and New
Zealand MS GWAS conducted by the Australian and New
Zealand Multiple Sclerosis Genetics Consortium (ANZgene) [3],
and those DNA samples were genotyped on the Illumina Infinium
Hap370CNV array [3]. An additional 861 Australian and New
Zealand MS cases were genotyped with the Illumina Human660-
Quad chip as part of a GWAS performed by the International MS
Genetics Consortium (IMSGC) and the Wellcome Trust Case
Control Consortium-2 (WTCCC2) [13]. Controls included 1,531
unrelated Australian samples from a GWAS genotyped by
Queensland Institute of Medical Research (QIMR) with the
Illumina Human610-Quad chip [32], and 1064 MS cases and 954
controls genotyped with the SentrixH HumanHap550 BeadChip
from a GWAS conducted in the US (GeneMSA) [6] [accessed via
dbGAP].
Table 1. Sample numbers from GWAS (after cleaning).
GWAS dataset
Country of
origin
No.
Case
No.
Control Total No. SNPs
Cases Controls
ANZgene [3] AUS, NZ US, UK 1,608 3,404 5,012 300,900
WTCCC2 [13] AUS - 766 - 766 586,393
QIMR [32] - AUS - 1,516 1,516 529,292
GeneMSA [6] US US 878 805 1,683 550,677
Total 3,252 5,725 8,977 274,735*
*The number of SNPs that passed QC in all 4 GWAS datasets.
AUS = Australia, NZ =New Zealand.
doi:10.1371/journal.pone.0056379.t001
Figure 1. Plots of raw data of IBD with one point for each SNP.
The green region is obvious outstanding from the black line, which
indicates the proportion of case pairs in this region higher than that of
control pairs. The black line represents where the proportion of case
pairs equal to control pairs.
doi:10.1371/journal.pone.0056379.g001
IBD Mapping for Rare Variants in MS
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Quality control of data
Conservative quality control measures were imposed both on
the individual datasets before merging, and in the combined
dataset after merging: SNPs with call rates less than 0.95 or in
Hardy-Weinberg disequilibrium (p,1027) were discarded, as were
samples with call rates less than 0.98. Duplicates and close relatives
were also removed. This data cleaning was performed using
PLINK.
A principal components analysis (PCA) was conducted by
EIGENSTRAT [33] to exclude ancestry outliers and examine
population structure within the remaining samples. First, SNPs in
strong LD were pruned (using the PLINK – indep command with
options 50 5 1.5), and then we excluded previously identified
regions of high LD [34]. Outliers in the PCA were excluded using
standard settings in Eigenstrat (more than six standard deviations
from the mean along the first 10 principal components). All
chromosomal locations refer to Human genome version hg18.
Running BEAGLE fastIBD and results processing
The fastIBD analyses were conducted using BEAGLE (http://
faculty.washington.edu/browning/beagle/). In brief, genotypes
for the merged, cleaned dataset were converted to BEAGLE
format by using the linkage2Beagle.jar utility program. We then
used the BEAGLE method for phasing the data and identifying
IBD segments simultaneously, using the ‘fastibdthreshold’ option.
This procedure was run 10 times for each chromosome starting
with different seeds of the random number generator.
The output of these calculations was a series of ‘‘putative’’ IBD
segments shared between pairs of individuals. Each segment comes
with the following information attached: ids for the pair of
individuals, first and last SNPs in the IBD segment, length of the
segment in centimorgans, and probability of the two individuals
both carrying the segment if it was not IBD. We filtered these
segments using various maximum probabilities and minimum
segment lengths, as recommended in the BEAGLE manual.
Results from the 10 runs were combined by taking the union of
IBD segments detected in each run. From the final list of segments,
we wrote a Perl script to count numbers of case-case pairs (yi),
case-control pairs (ui) and control-control pairs (vi) estimated to
share haplotypes IBD at each SNP.
Analysis of IBD
We focused on the detection of loci where groups of cases have
inherited rare susceptibility alleles IBD. To do this, we modelled
IBD sharing yi in case-case pairs (‘‘case pairs’’) as a function of IBD
sharing in xi = ui + vi in case-control pairs and control-control
pairs combined (‘‘control pairs’’).
We tried various methods to model the yi as a function of the xi:
linear regression, negative binomial regression and Poisson
regression. Models were fitted using R [35] and goodness of fit
was assessed by examining diagnostic plots (SR_commands S1).
At SNPs i with more IBD sharing in cases than expected,
residuals zi from the fitted models should be large and positive. To
present residuals on a scale more familiar to geneticists, we
converted them to LOD scores using the formula LODi = zi2/
(2*loge(10).
At the SNPs with the highest LOD scores, we calculated the
proportions of case pairs sharing IBD in various populations, and
plotted networks of case and control pairs sharing IBD with each
other using the R network package (http://cran.rproject.org/
web/packages/network/index.html).
Results
Study samples from GWAS after cleaning
11 individuals were excluded due to call rates less than 0.98 and
an additional 202 individuals were excluded because they were
close relatives or duplicates. PCA was conducted on a subset of
77,856 SNPs not in LD, which were common to all sample sets.
Through successive iterations 251 outliers (37 AUS cases; 9 AUS
controls; 6 UK controls; 97 US cases; 102 US controls) were
excluded. All datasets overlapped well after the removal of outliers
(Figure S1). In summary, following cleaning there were 3,243
cases and 5,725 controls with 274,735 autosomal SNPs in the final
analysis (Table 1).
Results of IBD analysis
We detected IBD with the threshold of IBD segment greater
than 3 cM and the haplotype probability p-value less than 1029
(3cM_1e-9). A strong linkage signal was observed in the HLA
region (LOD=3.58), while the strongest signal in non-HLA region
was on chromosome 19 (LOD=4.65), which reached genome-
wide significance according to the recent established genome-wide
significance threshold set for IBD mapping [31].
Figure 1 is a scatterplot of case-pair sharing yi versus control-
pair sharing xi as each of the 274,735 SNPs i. Using different
colours to represent SNPs on different chromosomes, an outlier
group of SNPs with relatively high case pair sharing on one
chromosome stands out in green.
Fitting, testing Poisson model and converting to LOD
scores
From examination of diagnostic plots (Figure S2, S3, S4), we
found that the Poisson model provided the best fit for these data.
Figure 2 shows a plot of residuals from the Poisson model
converted to LOD scores. The highest linkage signal, correspond-
ing to the green outlier region in Figure 1, was observed on
chromosome 19 with LOD=4.65 and p=1.961026. As expected,
a strong signal also was observed in the HLA region (LOD=3.58;
Fig. 1).
Figure 2. Plot of linkage scores along the whole genome with
the IBD threshold of 3cM_1e-9 (shared haplotype segment
.3 cM and haplotype probability p,1029). Chromosome 19 has
the strongest linkage signal (LOD= 4.65).
doi:10.1371/journal.pone.0056379.g002
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Analysis of Linkage region on chromosome 19
The linkage region on chromosome 19 with LOD scores
between 3.65 and 4.65 is around 900kb in length (Hg18 chr19:
62,529,738–63,437,743 bp) and corresponds to a cluster of zinc
finger genes at 19q13.4, many of which have arisen by gene
duplication. None of the genes in this region have been previously
identified in published GWAS or associated with MS or
autoimmune diseases.
The genes in this region were examined to identify candidate
genes with putative roles, which could, impact on susceptibility to
MS. Published microarray expression data [36], profiling gene
expression in the human hippocampus over a broad developmen-
tal range, were downloaded from Gene Expression Omnibus [37],
series number GSE25219. Gene summary data was analysed in
Partek Genomics Suite version 6.6 (Partek Inc., St. Louis, MO,
USA) to generate expression profiles across all developmental
periods for genes in the linkage region. Many of these genes
exhibit similar expression profiles with high expression in early
time points and low expression after birth. To categorize this
observed trend, samples from a number of early foetal time
periods (3, 4 and 5) (described in [36]) were grouped together and
compared with expression of grouped samples from periods 9, 10,
11, and 12. Differential expression of exon level probe sets
between these two groups was then analysed. The data points
corresponding to individual probe sets, and representing expres-
sion changes between these two developmental stages, were then
aligned against the linkage region in a UCSC genome browser
view. Differentially expressed probe sets were filtered using a false
discovery rate adjusted p value cut off (1.5361023) equivalent to a
p value threshold of 0.01 and a fold change minimum 1.5. Those
probe sets that passed this threshold were plotted on the UCSC
browser screen view [38]. Genomic locations for Affymetrix exon
level probe sets within the linkage region were downloaded from
the UCSC table browser [39] and used to construct a bedGraph
file of expression changes. The green bars indicate a higher
expression in foetal time points compared to later time points.
Some fold changes for genes in this region are very high (4–6 fold
higher in foetal than post birth).
Although little is known about the majority of genes in this
region, ZNF274 is a DNA binding protein involved in regulation of
H3K9me3 methylation at the 39 end of some ZNF genes by
recruitment of the histone methyltransferase SETDB1, and the
corepressor TRIM28 (KAP1) [40]. To examine the pattern of
H3K9me3 methylation in this region, genomic data on H3K9me3
methylation and KAP1, SETDB1 and ZNF274 binding in K562
cells [40] was used to make custom bedGraph files for visualization
Figure 3. Screen shot from the UCSC genome browser illustrating expression regulation within the identified linkage region on
Chromosome 19 (hg18) (http://genome.ucsc.edu). Human Refseq gene models are shown at the bottom of the figure. Custom bedGraph tracks
illustrating expression regulation, as described in the manuscript, are shown. From top to bottom: (A) exon level expression fold change in
hippocampus (FDR adjusted p value,0.01 and fold change.1.5) between early fetal (periods 3,4 and 5) and postnatal (periods 9,10,11 and 12) from
Kang et al 2011, green bars indicate increased expression in fetal compared with postnatal and red bars indicate decreased expression in fetal
compared with postnatal. ChIP-chip binding patterns of (B) H3K9me3 (C) TRIM28/KAP1 (D) SETDB1 and (E) ChIP-seq binding pattern of ZNF274 in
K562 cells. For the ChIP-chip data log2 (ratio) values reflecting the ChIP enrichments are plotted on the Y axis. For the ChIP-seq data the number of
tags reflecting the ChIP enrichments are plotted on the Y axis. ChIP-chip and ChIP-seq data are from Frietze et al 2010 supplementary data.
Chromosomal coordinates and relative position on the chromosome is illustrated in the idogram at the top of the figure. The position of SNP
rs159870 is shown by a vertical black line.
doi:10.1371/journal.pone.0056379.g003
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alongside the expression change with development (Fig. 3). From
this data we observed that the vast majority of genes in this region
with high foetal expression levels are marked by both H3K9me3
methylation and bound by KAP1 and SETDB1 at the 39 end of the
gene. A small number of genes are also bound at the 39 end of the
transcript by ZNF274. We also observed a pattern in the level of
H3K9me3 methylation, with two maximum levels at about
position 62,850,000 and 63,400,000 and trailing off at position
63,250,00. This bimodal pattern also occurs in the KAP1 and
SETDB1 binding data and is even more apparent when viewing a
wider view of the region. This position, marked in the figure by
vertical black line, also corresponds with the position of rs159870
(chr19: 63239261) and there is break in synteny with rodent
genomes in this zone.
Comparison of IBD sharing among different populations
We next examined patterns of IBD sharing at the SNP with the
highest LOD score on chromosome 19 (rs159872). We compared
the proportion of IBD case pairs in different populations to
determine whether there are particular populations that contribute
to more IBD case pairs at this locus; and found the Tasmanian
population has the highest proportion of IBD case pairs. When
compared with all other combined Australian populations, the
Tasmanian population significantly contributed more IBD case
pairs at this locus (p = 0.004); and was significant when compared
with all other combined non-Tasmanian populations
(p = 5.4461025; Table 2).
Networks of cases and controls sharing haplotypes on
chromosome 19
Figure 4 shows networks of cases and controls sharing
haplotypes IBD at the SNP with the highest LOD score on
chromosome 19. The biggest cluster comprises 10 cases sharing a
haplotype in which 4 cases were from Melbourne, 4 from New
Zealand, 1 from Sydney and 1 from USA. Another big cluster
includes 2 cases from Melbourne, 3 cases from Tasmania and 4
cases from New Zealand (Fig. 4A). More generally, there are
more networks of cases sharing haplotypes than controls.
Discussion
We have applied BEAGLE fastIBD for the detection of rare MS
variants utilising a large-scale GWAS dataset. We identified a high
linkage signal on chromosome 19 with a p-value of 1.961026
(LOD=4.65). In classical linkage analysis in small families,
individuals are closely related and the segments of IBD tend to
be fairly long (.10 cM) which are easier to detect and less
independent than IBD mapping, the generally-accepted threshold
for genome-wide significance is p = 2.061025 [41]; while GWAS
has more independent tests than IBD mapping, the threshold of
genome-wide significance is around p= 5.061028 [42], so the
threshold of p-value for IBD mapping genome-wide significant
should be between 5.061028 and 2.061025. Recently, researchers
demonstrated that the genome-wide significance thresholds for
IBD mapping depend on the IBD segment size detected or IBD
generations [31]. For example, an IBD segment size of 2 cM
corresponds to 25 generations and the genome-wide significance
threshold is 2.061026, while the segment size of 3.2 cM
corresponds to 15 generations and the genome-wide significance
threshold is 4.061026 [31]. The strongest non-HLA linkage signal
we detected in this study used a 3 cM segment size; which
corresponds to 17 generations, thus the genome-wide significance
threshold is between 4.061026 and 2.061026. As such, the
linkage signal on chromosome 19, with a p-value of 1.961026, was
determined to be genome-wide significant.
Causal relationship between genes in linkage region and
MS
Most genes in this linkage region are zinc finger (ZNF) proteins
of which 32 genes have been suggested to be transcriptional
regulators [43] (http://genome.ucsc.edu/). Seven genes (ZNF134,
ZNF135, ZNF154, ZNF549, ZNF606, ZNF671 and ZSCAN1) in this
region belong to the Kru¨ppel family of ZNF genes. Only a few
ZNF genes in this region have known vertebrate homologues and
it includes a number of primate specific KRAB-ZNF genes [44].
In humans KRAB-ZNF genes number about 400 and make up the
largest group of C2H2 transcription factors [45] which are
typically expressed at low levels and involved in cell specific
silencing and driving different cell lineages.
Detailed analysis of genes in this region did not reveal any direct
links with MS. However examination of their expression profiles in
published data revealed a shared early developmental CNS
specific expression profile with 22 genes in this region being
members of the expression module M20 described in [36],
characterised by higher expression in all brain regions in early
foetal time points followed by decreased expression prior to birth
and very low expression thereafter. The M20 network of genes has
a strong correlation with both neuronal differentiation and
neuronal migration and a strong negative correlation with
myelination [36].
Epigenetic mechanisms such as histone modification and DNA
methylation are responsible for silencing many specific transcrip-
tion factors including zinc finger genes, and the 39 end of many
ZNF genes are specifically covered by H3K9me3 [46]. The zinc
finger gene ZNF274, located within the linkage region, is involved
in gene silencing through recruitment of the histone methytrans-
ferase complex TRIM28 (KAP1)/SETDB1 to the 39 end of
specific ZNF genes [40]. Examination of H3K9me3, KAP1 and
SETDB1 binding data, confirms that many of the genes in the
linkage region are covered by H3K9me3 at their 39end (Fig. 3).
ZNF274 also interacts with p75NTR and is predicted to play a role
in programmed cell death during development [47]. A number of
the genes in this area are also highly expressed in differentiated
Table 2. Comparison of IBD case pairs among different
populations (rs159872 with the highest LOD score on chr19;
LOD= 4.65).
Population No. case
No. IBD
case pairs
% IBD
case pairs p-value
TAS 308 7 14.8061025 Ref.
Mel 841 32 9.0661025 0.22
Newc 111 0 0.00 1.00
Syd 541 14 9.5861025 0.32
Other 32 0 0.00 1.00
AUS (non-TAS) 1525 46 3.9661025 0.004
NZ 540 14 9.6261025 0.32
US 879 22 5.7061025 0.033
Non-TAS 2944 82 1.8961025 5.4461025
*% IBD case pairs = IBD pairs/case6(case-1)/2; (Fisher’s Exact Test).
doi:10.1371/journal.pone.0056379.t002
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human neural cells compared to earlier stems cells (ZNF549,
ZNF324, ZNF548, ZNF264, ZNF671, ZSCAN1 and ZSCAN18 are
members of cluster A [48]). There is very little available evidence
for involvement in immune cell activity for genes in this region.
ZNF304 is implicated in lymphocyte activation [49] and ZNF274
has very high expression in activated eosinophils compared with
other immune cell types [50]. Other genes in this region have
relatively low expression and are not differentially regulated
between immune cell types [50], as viewed in the immunological
genome [51].
Together these findings suggest that many of the genes in this
cluster may be involved in early differentiation of neuronal cells
and potentially the silencing of genes required for myelination.
Expression of ZNF genes is commonly detected in foetal brain and
they are predicted to be involved in development of the nervous
system, a KRAB zinc finger cluster on chromosome 8 has also
been proposed to be involved in regulation of CNS development
[52]. Although other clustered genes families have been shown to
be co-expressed in cell types or tissues, previous studies have failed
to identify coordinated expression of KRAB-ZNF gene clusters
[44]. However earlier experiments did not examined the very early
timepoints in CNS tissues included in the Kang dataset [36].
These expression profiles described in the M20 module are
supported by two independent data set of both exon array level
and RNA-seq expression data in early human CNS development
available at the Allan Brain Atlas (http://developinghumanbrain.
org/).
Thus this may be an example of a gene cluster of KRAB -ZNF
genes exhibiting coordinated expression regulation, indicating the
presence of a genomic regulatory block (GRB). Such regions are
usually transcription factors controlled by highly conserved
noncoding regions. Although the identification of GRBs remains
difficult the evidence that we have collated is suggestive of two
genomic regulatory blocks within the linkage region, interrupted at
the position of SNP rs159870 where there is an absence of
H3K9me3 methylation and a break in synteny (reviewed in [53]).
The underlying cause for susceptibility in this region could
therefore be due, not to differences in a specific gene expression or
protein product, but to differences in the tight expression
regulation of a GRB. As mentioned above, many of the C2H2
zinc finger genes in this region have an expression profile
consistent with silencing of genes required for myelination.
Further analysis needs to be undertaken to examine if these genes
are co-regulated in demyelination and remyelination as well as
CNS developmental states. Unfortunately, due to the species
specificity of many of the KRAB-ZNF genes and the absence of
rodent homologues of genes in this region, data from non-human
models of demyelination and remyelination may not be useful.
Ideally, re-sequencing is the next step to refine this potential
signal further. Unfortunately, resequencing of the region would be
complicated since there are many gene duplications in this linkage
region.
For the SNP (rs159872) with the highest LOD score on
chromosome 19, we hypothesise that there are some difference
between cases and controls sharing haplotypes in the linkage
region among different populations. We found the Tasmanian MS
population has the highest proportion of case IBD sharing,
significantly higher than non-Tasmanian combined populations as
well as other non-Tasmanian combined Australian populations.
While Tasmania has the highest prevalence of MS in Australia, it
is generally agreed that this is primarily driven by environmental
effects related to, sunlight and/or vitamin D [54]. However there
is also a modest founder effect in Tasmania [55], which might
result in an increase in MS susceptibility driven by rare variants
IBD. Interestingly, we found there are more big networks of cases
sharing haplotypes than controls, and one big case network
comprises 3 Tasmanian cases, 4 New Zealand cases and 2 cases
from Melbourne, which may indicate the potential causal variants
or gene mutations exist in those big case networks. However, this
Figure 4. Networks of cases and controls sharing haplotypes IBD at the SNP with the highest LOD score on chromosome 19. (A)
Networks of cases sharing haplotypes in common at the linkage region on chromosome 19. (B) Networks of controls sharing haplotypes in common
at the linkage region on chromosome 19. Each dot represents an individual and each line connects pairs of individuals who share a haplotype. There
are more big networks of cases sharing haplotypes than controls.
doi:10.1371/journal.pone.0056379.g004
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SNP falls in a region of low/none methylation and correlates with
a break in syteny, the significance of which is unclear.
Technical considerations
Even though Beagle fastIBD is several orders of magnitude
faster than Beagle IBD, IBD analysis remains moderately
computationally intensive on a dataset of this size (8,977
individuals and 274,735 SNPs). For instance, on chromosome 2
with 22,607 SNPs, the computation time for each run was
approximately 4.6 hours with memory requirement of 3.3 GB on
2 cores of a SGI Altix ICE 8200 HPC cluster computer node.
However, we also found IBD analysis limitations: it is only
suited to discover rare variants if all variants act in the same
direction in one gene. For example, the identified rare variants in
BRCA1 and BRCA2 gene all increase risk of breast cancer [56], and
the four rare variants identified in IFIH1 gene all protect against
type I diabetes [18]. If some rare variants increase risk while others
in the same gene decrease risk then the signal in the region will be
attenuated. In addition, we found IBD analysis is very sensitive to
genotyping error, resulting in reducing signal strength. The linkage
signal detected depends on a lot of markers or long haplotypes,
containing up to hundreds of SNPs, a single error occurring in
reading a single marker significantly reduces the signal. In our
data, samples came from different GWAS using different
genotyping chips in different locations, which at least in part,
may decrease the potential signal strength from our study.
Furthermore, resequencing would be complicated by gene
duplication and repeat regions, since the linkage region detected
in this study had many gene duplicates, thus replication in other
independent dataset is needed.
The optimal method to detect rare disease-causing variants is
whole genome sequencing of thousands of samples. When this
becomes affordable, there will remain a role for IBD analysis to
prioritize regions for follow-up analysis and minimize the massive
multiple testing burden. Just as linkage analysis is now used to
identify regions for follow-up in whole genome sequencing and
exome sequencing of Mendelian disease families, and linkage
analysis can be used to weight regions for GWA analysis [26].
In summary, we have applied IBD analysis to a large complex
disease GWA dataset and identified a linkage signal with genome-
wide significance, although it. While our most significant result is
of equivocal significance, and lies in a region that is hard to
validate via sequencing, we believe IBD analysis has considerable
potential, particularly to help interpret whole-genome sequencing
data in complex trait studies.
Supporting Information
Figure S1 Principal components analysis for the data-
set.Most individuals in the dataset are of predominantly northern
European ancestry (right hand side), but some have southern
European ancestry (left hand side) (one dot for each individual).
(TIF)
Figure S2 Fitting Poisson model for the IBD data. All the
four real lines in these four modules fit well with the default lines,
suggesting Poisson model is appropriate for this data. The
residuals of the green region are higher than others.
(TIF)
Figure S3 Fitting negative binomial model for the IBD
data. All the four real lines in these four modules fit not well with
the default lines, suggesting negative binomial model is not suitable
for this IBD data.
(TIF)
Figure S4 Fitting linear model for the IBD data. All the
four real lines in these four modules fit not well with the default
lines, suggesting linear model is not suitable for this IBD data.
(TIF)
SR_commands S1 1) Fitting and testing model for IBD
data. 2) Plot of residuals from the Poisson model converted to
LOD scores. 3) Network analysis.
(PDF)
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Chapter 3.  Detecting disease-causing variants of MS by using family-
based whole genome sequencing analysis  
 
 
3.1 Preface 
 
 
IBD mapping, as described in Chapter 2, is one method of localising regions likely to 
harbor disease relevant rare variation. However the best method of identifying rare or 
private genetic variants is whole-genome sequencing (WGS) of disease enriched families. 
At present, WGS remains prohibitively expensive to perform adequately-powered case-
control studies, but family-based WGS is a powerful alternative. In this chapter I will 
describe the first stages of disease-causing variant detection using pedigree based WGS. 
This chapter is the first component of a much larger project, the bulk of which remains 
outside the scope of this dissertation. The analysis of pedigree based WGS for the 
identification of rare, disease-relevant variants can form the basis of a major research 
project in itself; however for the purposes of my dissertation I will focus on the initial 
variant filtering and confirmation of most likely risk variants within this chapter. Future 
analyses of these data are outside the limits of this thesis but I will retain a significant 
interest and input into the further analysis of this family.  
 
3.2 Introduction  
 
Multiple sclerosis is a complex disease driven by environmental and genetic factors. 
Studies have demonstrated a significant genetic component to MS susceptibility, such as a 
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higher concordance rate in monozygotic twins (24%-30%) than dizygotic twins (3%-5%) 
[1,2], and more than 100 common genetic variants outside the HLA region have been 
identified as associated with MS by GWASs [3-14]. However, rare, disease-causing 
variants of MS have been little identified [15]. Next-generation sequencing of whole-
genomes has proven to be a valuable method for the discovery of the genetic 
underpinnings of rare and complex diseases [16]. Although cheaper than Sanger 
sequencing (over the entire genome), whole-genome sequencing remains prohibitively 
expensive to perform adequately-powered population-based studies. Pedigree based 
studies allow the identification of “private” disease relevant variants and by their very 
structure and the number of transmission events in a large pedigree they are also enriched 
for rare-variant identification. In addition, identification of inheritance patterns in the 
pedigree permits the detection of ~70% of sequencing errors (resulting in >99.999% 
accuracy), and sharply reduces the search space for disease-causing variants [17]. 
However, previous family-based researches showed little success in the search for 
rare/disease-causing variants in MS [18-21], due to the limitations of classical genetic 
techniques such as microsatellite-based screens and low density marker sets, except 
exome sequencing [15]. We here analysed the whole genome sequence of eight samples 
from one extended MS-enriched family to asses for rare, disease-relevant variants.  
 
3.3 Methods 
3.3.1 Study subjects  
 
Eight samples from one extended pedigree (shown in Figure 3.1), with the proband 
sourced from Tasmania, Australia, were selected for sequencing, including three MS 
affected and four unaffected siblings and a daughter (26 years old) of a deceased sibling 
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with known MS. She however has an unknown disease status due to her age (Figure 3.1).  
Blood or saliva samples were collected from each of the eight subjects seen at the Royal 
Hobart Hospital or by their local neurologists in Ireland and Sydney, Australia were 
collected and stored at -80.C. MS cases were diagnosed and confirmed by the study 
neurologist based on the 2010 McDonald diagnosis criteria [22].  
 
Figure 3.1 Pedigree of the MS family.  
Individuals who provided sample for WGS are indicated by the star. Age at blood/saliva 
collection is shown. Three additional family members were diagnosed with MS but were 
deceased at the time of collection. 
 
 
3.3.2 Whole genome sequencing 
 
Whole genome sequencing was conducted at the University of Queensland Diamantina 
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Institute (UQDI). Genomic DNA was extracted from whole blood or saliva, such that 
gDNA was extracted from whole blood using a variety of standard laboratory approaches; 
or gDNA was isolated from saliva self-collected into Oragene DNA tubes according to 
the manufacturer’s instructions (DNAgenotek). DNA concentrations were assessed using 
pico green fluorescence, ultraviolet (OD260nm) spectrophotometry or on an ethidium 
bromide–stained low-percentage agarose gel compared to a high-molecular-weight 
standard. Because of possible bacterial gDNA contamination and difficulty in obtaining 
reliable pico green and spectrophotometry measurements, all saliva DNA samples were 
estimated and assessed for their integrity by agarose gel electrophoresis and using at least 
one other method. Wet-lab sequencing included preparation of eight Illumina 
TruSeqDNA libraries and sequencing run on an Illumina HiSeq system using 2x100bp 
paired-end reads at an average coverage (read depth) of 30x.  
 
Sequencing libraries were constructed using a modification of the Illumina TruSeqDNA 
sample preparation kit. Briefly, 1.6ug of genomic DNA was sheared to an average 
fragment size of 200bp using the Covaris E220. Fragments were purified using 
AmpPureXP beads (Beckman Coulter) to remove small products (<100bp), yielding 1ug 
of material which was end-polished, A-tailed and adapter ligated according to the 
manufacturer’s protocol. The libraries were subjected to minimal PCR cycling and 
quantified using the Agilent High Sensitivity DNA assay. Each library incorporated a 
unique barcode sequence allowing all eight to be multiplexed together at an equimolar 
ratio for subsequent sequencing. Libraries were assessed for both quality and yield using 
the Agilent High Sensitivity DNA assay and KAPA Library Quantification Kit.  
 
WGS was performed with eight multiplexed samples per flow cell lane using the Illumina 
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HiSeq2000 platform and TruSeqSBS version 3 reagents to generate 100bp paired-end 
reads (2x100bp). The pool was sequenced across 27 lanes generating greater than 30x 
coverage per sample (>100gigabases per sample). 
 
3.3.3 Analyses of whole genome sequencing data  
The Illumina Data Analysis Pipeline software (CASAVA 1.8.2) was used for initial base 
calling and multiplexing of data.  Sequence data were aligned to the current build of the 
human genome (hg19, released February 2009) using the Novoalign alignment tool 
(V2.08.02)[23], sequence alignment files were converted using SAMtools (v0.1.14)[24] 
and Picard tools (v1.42). SNPs and indels were called using the Genome Analysis Toolkit 
(GATK v5506)[25] and annotated using ANNOVAR[26]. 
 
Further analysis of sequence data was performed using custom scripts employing R and 
Bioconductor.  We retained good quality SNPs and indels (minimum depth of coverage 
for SNP calling: >10-fold for homozygous SNPs, >15-fold for heterozygous SNPs). 
Additionally, we used variants that passed GATK Variant Quality Score Recalibration 
that incorporates quality parameters, including sequencing depth and quality scores at the 
SNP position, maximal length of the homopolymer run and strand bias). Remaining SNPs 
and indels were assessed according to prediction of potentially damaging consequence 
("nonsynonymous SNV", "splicing", "frameshift substitution", "stopgain SNV", "stoploss 
SNV") using Ensemble, RefSeq and UCSC transcripts.  Further filtering excluded SNPs 
with a minor allele frequency (MAF)>0.001 observed in NCBI dbSNP (release 135), 
1000Genomes [27], 1000Genomes small indels (called using DINDEL [28]), SNPs from 
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the NHLBI-ESP (6,500 exome sequencing project)  and  956 control exomes generated 
internally by UQDI. Variants not present in any of these databases were considered novel.  
 
Non-coding elements were accessed by including those only with Genomic Evolutionary 
Rate Profiling (GERP [29]) score >= 2.0. GERP is a measure of conservation across 
species, such that neutral sites tend to score near zero, whereas constrained sites generally 
score positively. The maximum genome-wide score (~5.8) only applies to sites that are 
perfectly conserved across all sequenced mammals, whereas ‘no prediction’ applies to 
sites that are aligned to none or few species (mostly repetitive sequences) [30]. In the case 
of insertions and deletions the maximum GERP sort within the insertion or deletion 
location was recorded.  
 
3.3.4 Target variant filtration strategy 
 
Basic transmission analyses were performed using the assumption that the causative 
variant would be shared (heterozygous or homozygous/dominant or recessive) by the 
three affected siblings (1.3, 1.4, 1.5). A degree of low penetrance was included by 
allowing for one unaffected sibling to be heterozygous, which was the initial filtration 
step. Since we hypothesise that the MS susceptibility variant(s) segregating in this 
pedigree would be rare or private we filtered variants with minor allele frequency (MAF) 
≤0.001 and initially focused only on coding variants. Finally, variants were included if 
they were present in 10 or more reads, and had pass filter scores. 
 
Next we further filtered the candidate variants according to if the variants were predicted 
to significantly impact the protein product by at least one of the following in silico 
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prediction tools; Sorting Tolerant From Intolerant' (SIFT) [31] and Polymorphism 
Phenotying v2 (Polyphen2) [32]. SIFT uses a sequence homology based approach to 
classify amino acid substitutions [33,34], which is based on the evolutionary conservation 
of the amino acids within protein families. Briefly, highly conserved positions tend to be 
intolerant to substitution, whereas those with a low degree of conservation tolerate most 
substitutions. SIFT can predict correctly 69% of the substitutions associated with the 
disease to affect protein function [33]. Polyphen2 is a tool which predicts possible impact 
of an amino acid substitution on the structure and function of a human protein, such that 
whether a nonsynonymous SNPs (nsSNP) is damaging or benign [35]. Polyphen2 can 
achieve the rate of true positive predictions of 92% [32].  
 
Final candidates were filtered based on biological relevance and plausibility. Briefly, 
genes of interest were investigated using online databases NCBI “Gene” 
(http://www.ncbi.nlm.nih.gov/gene) and also commercial tools IPA (www.ingenuity.com) 
to determine their biological function, expression location (such as brain) and potential 
relevance to MS pathological processes including neurological or immune function.  
 
The WGS data for the final set of variants were manually visualised using Integrative 
Genomics Viewer (IGV) [36,37], to ensure that the surrounding data and read mapping 
looked clean prior to confirmation sequencing. Finally, 11 candidate variants of interest 
were identified after the preceding process of whole genome sequencing.  
 
3.3.5   Validation of candidate variants by Sanger sequencing 
  
Candidate variants identified by WGS analysis were confirmed by Sanger sequencing of 
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the original eight samples in-house. Primers were designed for PCR as shown in table 
3.1. PCR reactions were performed in 20ul volumes consisting of 10ul of GoTaq® Green 
(Promega Coproration, USA), 1.6ul of 10uM for both forward and reverse primers, 1.0ul 
of 20ng/ul DNA and 5.8ul water. Thermal cycling was performed on a Life Technologies 
Veriti™ thermal cycler. Conditions were as follows: One cycle of 95°C for 3 minutes, 40 
cycles of 95°C for 15 seconds, 60°C for 30 seconds  followed by 72°C for 30 seconds, 
with a final extension of one cycle of 72°C for 1 minute.  
 
Table 3.1. Primer design for the validation of eleven putative mutations 
identified by whole genome sequencing in MS family members 
Chr Position Forward Primer Reverse Primer 
Product 
Size (bp) 
2 54080702 tttcttctgtggctttggaga tgtgtgatcattgtgctgtca 354 
3 57850299 ggcaacaagagtgaaactcca gcctttcattggtgaaatcat 351 
6 31921581 aaccaaaaggaatggcctgt catcgcttctgctgttctca 381 
6 51930780 gatgagtcagaaggggcaaa aaaaattcaactgttgctgga 352 
7 122342308 ggtgtaagtctccagacgcaat atgcctgtcatcctttgacc 394 
7 140174293 caggtggatcatgaggtcag tggaaactacatagtggttgtgaga 387 
8 11723096 agctgagtgtggaggcacat ccaggctggttttcgaact 376 
8 144642151 ggcaggagcttccacttcta cagtggctcacccctgtaat 377 
8 408372 aggaacagcctggttctgtc cctgcttttcagcaaaatgg 411 
12 53170912 cccaccaaatacaccaggac cagacaagtttgcaagaaatcc 403 
12 57323282 ctgccccaggaacttacaga cagttttggaaagggctgag 361 
 
 
PCR amplicons were purified using Agencourt AMPure XP (Beckman-Coulter) following 
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the manufacturer’s directions. Sequencing reactions were performed in both directions 
using the BigDye® Terminator v3.1 Cycle Sequencing kit (Life Technologies). 
Sequencing reactions were subsequently purified using Agencourt CleanSEQ (Beckman-
Coulter) following the manufacturer’s directions, and sequenced on the ABI Prism® 310 
Genetic Analyzer (Applied Biosystems). 
 
Sequence analysis was performed using Sequencher V4.10.1 and variants were assessed 
by visual inspection. Variants that failed Sanger sequencing were considered artifacts of 
the next generation sequencing methodology.  
 
3.4 Results  
3.4.1 Candidate variants identified by the target variant filtration strategy 
The initial filtration step identified 237 variants, which were dominant in the three 
affected siblings (1.3, 1.4, 1.5) and only one of the unaffected sibling (allowing for 
incomplete penetrance). Of these, 130 variants had a MAF less than 0.001, and 20 of 
these variants were identified as coding. Finally, 15 variants passed the GATK quality 
scoring filters and were considered  candidate variants.  
 
When we further assessed whether these above candidate variants were predicted to alter 
the protein product by using both SIFT[31] and  Polyphen2 [32] in silico functional 
prediction algorithms, determined their potential biological plausibility or relevance to 
MS.  We refined our targets to 11 coding variants which were selected for confirmation 
by Sanger sequencing (Table 3.2).  
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Table 3.2.  11 coding variants were identified from whole genome sequencing analysis 
 
Chr Variation Intergenic RefGene Affected 
siblings hit 
Unaffected 
siblings hit 
PolyPhen2/ SIFT 
2 rs201490058 nonsynonymous 
SNV 
DTNB 3/3 1/4 Unknown/ deleterious 
2 rs145914833 nonsynonymous 
SNV 
GPR75 3/3 1/4 Benign/ 
deleterious 
3 rs199942083 nonsynonymous 
SNV 
SLMAP 3/3 1/4 probably_damaging/ 
tolerated 
6 6_31921581 nonsynonymous 
SNV 
RDBP 3/3 1/4 possibly_damaging/ 
tolerated 
6 6_51930780 nonsynonymous 
SNV 
PKHD1 3/3 1/4 Benign/ 
tolerated 
7 7_122342308 nonsynonymous 
SNV 
RNF148 3/3 1/4 Benign/ 
tolerated 
7 rs10709936 intronic MKRN1 3/3 1/4 *NA/NA 
8 8_408372 nonsynonymous 
SNV 
FBXO25 3/3 1/4 Unknown/ deleterious 
8 rs71316899 intronic - 
frameshift 
GSDMD 3/3 1/4 *NA/NA 
12 12_53170912 nonsynonymous 
SNV 
KRT76 3/3 1/4 Unknown/ deleterious 
12 12_57323282 nonsynonymous 
SNV 
SDR9C7 3/3 1/4 Unknown/ deleterious 
* Intronic SNPs cannot be predicted by PlolyPhen2 and SIFT software. 	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3.4.2 Validation of candidate variants confirmed by Sanger sequencing  
 
Eleven candidate variants identified by the WGS analysis were re-sequenced  using an 
alternate sequencing technology (Sanger) to ensure the variants were real and not artifacts of 
the WGS methodology. One variant (rs201490058 in chromosome 2, refGene: DTNB) was 
not sequenced successfully as this SNP is in a lengthy homopolymer region, another 
candidate (rs71316899 on chromosome 8, refGene GSDMD) failed to replicate in the 
resequencing as the genotype was not consistent with WGS, leaving nine candidate variants 
that were confirmed as real (Table 3.3).  
 
Amongst the nine validation candidate variants, six were novel variants and three were known 
variants. Of the novel variants, chr6_31921581 locates in the gene RD RNA-binding protein 
(RDBP), which has been demonstrated as associated with MS [8]. In addition, chr6_51930780 
locates within the gene of fibrocystin isoform 1 (PKHD1), which has been demonstrated as 
associated with amyotrophic lateral sclerosis (ALS) [38]. The other four novel variants have 
been shown to be potentially relevant to neurological disorders, with RNF148 
(chr7_122342308) shown to be involved in the prenatal and postnatal stage of brain 
development [39], and FBXO25 (chr8_408372) involved in the postnatal stage of brain 
development and expressed in the layer1 cortical glutamatergic neurons [39]; or the variants 
were as transcript factors and associated with tumor (chr12_53170912 in KRT76 and 
chr12_57323282 in SDR9C7). Of the known variants, two are rare variants (rs145914833 in 
GPR75 that express in brain; rs199942083 in SLMAP that was associated with type II 
diabetes) and one is a common variant (rs10709936 in MKRN1 that associates with two 
neurological disease: Depressive Disorder [40] and Schizophrenia) (Table 3.4). Of these 
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candidate variants, the two most interesting variants were chr6_31921581 that locates in 
RDBP and chr6_51930780 that locates in PKHD1. 
 
Interestingly, when we further tested whether the two interesting coding novel variants 
(chr6_31921581 and chr6_51930780) associated with MS in the combined MS GWAS 
dataset comprised 3,543 cases and 5,898 controls [41], we found that in the region of chr6: 
319195783- 31929014 that includes the novel variant of chr6_31921581 (RDBP), two 
genome-wide significant signals were identified with a p-value of 1.799e-37 (OR=1.49) and 
1.257e-52 (OR=1.63) for rs2072633 (chr6_31919578, upstream about 2kb to chr6_31921581) 
and for rs437179 (chr6_ 31929014, downstream about 7.4kb to chr6_31921581), respectively. 
When we further assessed the association in the Tasmanian group that comprised 308 cases 
and 617 controls, we found that the p-value for rs2072633 and rs437179 was 5.504e-07 
(OR=1.65) and 1.202e-06 (OR=1.63), respectively (Table 3.4). While no significant 
association (p>0.05) was found in the region near the novel variants of chr6_51930780 
(PKHD1) either in the combined GWAS dataset or in the Tasmanian group (Table 3.5).  
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Table 3.3.  Candidate genes confirmed by Sanger sequencing  
 
Ref gene   KRT76 SDR9C7 FBXO25 GSDMD RDBP PKHD1 RNF148 MKRN1 GPR75 SLMAP 
Chr 12 12 8 8 6 6 7 7 2 3 
Variant 12_53170912 12_57323282 8_408372 rs71316899 6_31921581 6_51930780 7_122342308 rs10709936 rs145914833 rs199942083 
Primer C/A G/A G/A 
-
/AGGGCA
GGGC G/T T/C G/A A/- A/C A/T 
*BTCK-1.3 C/A G/A G/A &I/D G/T T/C G/A A/- A/C A/T 
           
*BTCK-1.4 C/A G/A G/A I/I G/T T/C G/A A/- A/C A/T 
*BTCK-1.5 C/A G/A G/A I/D G/T T/C G/A A/- A/C A/T 
#BTCK-1.7 C/A G/A G/G I/D G/G T/T G/G A/A A/C T/T 
#BTCK-1.8 C/C G/G G/A I/D G/T T/C G/A A/- A/A A/T 
#BTCK-1.9 C/C G/G G/G  I/I G/G T/T G/G A/A A/A T/T 
#BTCK-1.10 C/C G/G G/G I/I G/G T/T G/G A/A A/A T/T 
@BTCK-1.612 C/C G/G G/G I/D  G/G T/T G/G A/A A/A T/T 
 Note  Real Real Real Fail Real Real Real Real Real Real 
& I/D refers to insertion/deletion; * affected siblings; # unaffected siblings; @ unknown niece of the seven siblings. 
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Table 3.4.  Description of candidate genes 
Chr Variant MAF 
(%)* 
RefGene Gene function& Associated with disease 
2 rs145914833 0.04 GPR75 Cell surface receptor; highly expressed in brain and spinal cord NA 
3 rs199942083 0.1 SLMAP Sarcolemma associated protein Type 2 diabetes [42,43] 
6 6_31921581 NA RDBP Represses RNA polymerase II transcript elongation MS [8] 
6 6_51930780 NA PKHD1 Correct bipolar cell division; a receptor protein ALS [38] 
7 7_122342308 NA RNF148 Calcium-binding protein; regulates neurotrophin; mediates Ca(2+)- 
dependent exocytosis 
NA 
7 rs10709936 50 MKRN1 Affect on RNA polymerase II-dependent transcription.   Depressive Disorder [40]; 
Schizophrenia 
8 8_408372 NA FBXO25 Destructing cardiac specific transcription factors. Encoding a brain-
expressed F-box protein. 
NA 
12 12_53170912 NA KRT76 Responsible for the structural integrity of epithelial cells Oral carcinogenesis [44] 
12 12_57323282 NA SDR9C7 Similar with the short-chain dehydrogenase/reductase (SDR) family Oesophageal carcinoma [45] 
* The MAF of those known SNPs obtained from UCSC; for the novel SNPs had no known MAF. 
& Gene function based on UCSC and the original papers. 
 
 
Table 3.5. The association with MS in the interesting regions near chr6_31921581 and chr6_51930780 
In the combine GWAS data  
Chr SNP bp A1 F_A F_U A2 P-value OR 
6 rs2072633 31919578 A 0.5566 0.4573     G 1.799e-37 1.49 
6 rs4151672 31919830 A 0.03967   0.04655     G 0.03078 0.846 
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6 rs438999 31928306 G 0.07782   0.09109     A 0.00234 0.842 
6 rs437179 31929014 A 0.4282    0.3147     C 1.257e-52 1.631 
6 rs2082105 51919253 A 0.1227    0.1238     G 0.8353        0.9902 
6 rs4715273 51929476 A 0.4837    0.4764     C 0.3478          1.03 
6 rs1896981 51936258 G 0.313    0.3072     A 0.4199         1.027 
6 rs10484883 51941936 A 0.2442    0.2368     G 0.2648  1.041 
In the Tasmanian GWAS data  
Chr SNP bp A1 F_A F_U A2 P-value OR 
6 rs2072633 31919578 A 0.5146  0.3912    G 5.504e-07        1.65 
6 rs4151672 31919830 A 0.0276   0.03809     G 0.2446        0.7168 
6 rs438999 31928306 G 0.09416   0.09319     A 0.9465         1.011 
6 rs437179 31929014 A 0.4643    0.3476     C 1.202e-06         1.626 
6 rs2082105 51919253 A 0.1169    0.1159     G 0.9496          1.01 
6 rs4715273 51929476 A 0.4886      0.47     C 0.4498         1.077 
6 rs1896981 51936258 G 0.3084    0.3015     A 0.7582         1.033 
6 rs10484883 51941936 A 0.2419    0.2253     G 0.4245         1.097 	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3.5 Discussion  
 
In this study, we conducted whole genome sequencing on a unique MS family, for its 
numbers of affected individuals in one generation. We particularly focused on the siblings 
(three affected and four unaffected), to find candidate variants that segregated with 
disease. The family appeared to be segregating MS in an autosomal dominant manner, 
which suggests that this family may harbor dominant mutations, and therefore re-
sequencing using a different platform is an appropriate strategy. Initially, we identified 11 
coding variants by whole genome sequencing, where all the affected siblings carried the 
disease-relevant variants and low penetrance where one unaffected sibling carried one of 
the disease-relevant variants. The filtering process was delicate: the challenge is to reduce 
the number of variants to a manageable number of candidates and yet not to lose a 
possible causative variant in the process. Next, the 11 candidate variants were further 
validated by Sanger sequencing, and nine candidate variants were identified to be 
potential disease-causing variants of MS, including six novel variants and three known 
variants.   
 
Of the nine candidate variants, we are particularly interested in two coding novel variants, 
chr6_31921581 and chr6_51930780. The variant of chr6_31921581 locates in the gene of 
RDBP, which is part of a complex termed negative elongation factor (NELF) that 
represses RNA polymerase II transcript elongation. RDBP localises to the major 
histocompatibility complex (MHC) class III region on chromosome 6, which has been 
shown to be implicated in MS as a risk allele (OR=1.54, p=1.51E-10 for rs2072633) in 
MS GWAS [8]. Furthermore, the observation of a GERP score of +5.20 for 
chr6_31921581 was also in keeping with a deleterious genetic change [30], and 
Polyphen2 and SIFT also showed evidence of an impact on protein function. 
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Interestingly, further analysis in our combined MS GWAS dataset (described in chapter 2) 
also supports that the variant locates to a region that is genome-wide significantly 
associated with MS, and significantly associated with MS in the Tasmanian group. 
Similar to the genes CYP27B1 [15] and TYK2 [46] where both  rare functional variants 
and common variants were identified as associated with MS [13],  we detected a novel 
functional variant in RDBP that also contributes to the disease independently of the  
common variants. As for PKHD1, which is predicted to have a single transmembrane 
(TM)-spanning domain and multiple copies of an immunoglobulin-like plexin 
transcription-factor domain. PKHD1 may be required for correct bipolar cell division 
through the regulation of centrosome duplication and mitotic spindle assembly, and may 
be a receptor protein that acts in collecting-duct and biliary differentiation. Although no 
previous evidence showed this gene was associated with MS, we found in this study that 
the variant of chr6_51930780 was dominant in the affected siblings, and Polyphen2 and 
SIFT also support chr6_51930780 as having a functional impact on protein structure. 
Previous, research has linked PKHD1 with ALS [38], a neurological disease with some 
similarities to progressive MS, suggesting that chr6_51930780 may be a disease-causing 
variant in MS.  Although no clear genetic overlap between MS and ALS has been 
detected [47].  
 
With the advent of next-generation sequencing (NGS) technologies, the discovery of 
novel disease genes is expected to accelerate [48]. Exome sequencing studies in MS 
families have successfully identified rare variants in the genes CYP27B1 [15] and TYK2 
[46]. These successful studies showed that small, pedigree based sequencing studies are 
much more powerful for rare disease gene identification than large scale population based 
GWASs.  Additionally, due to the high cost and the challenge of filtering and interpreting 
Chapter	  3.	  Detecting	  disease-­‐causing	  variants	  of	  MS	  by	  using	  family-­‐based	  whole	  genome	  sequencing	  analysis	  
	   133	  
the large number of identified variants, family-based whole-genome sequencing study is a 
powerful alternation to population-based whole genome sequencing, in spites of the fact 
that family-based whole genome analysis can be effective for finding candidate genes as 
sequence accuracy is enhanced. In our study, we filtered the candidate variants to coding 
ones, which is similar to exome sequencing, and our findings support that family-based 
whole genome sequencing –filtering to coding variants is an effective way to detect 
disease-causing variants.  
 
This chapter presents just our preliminary findings. Next we will genotype the two most 
interesting candidate variants in a wider cohort of MS cases and controls. In addition, we 
plan to re-analyse the raw WGS data using our collaborators’ pedigree-based variant 
detection pipeline at the Texas Biomedical Research Institute, San Antonio, USA. This 
pipeline utilises kinship information to increase the confidence of calls for rare and 
private variants. We will also extend our analyses to regulatory and non-coding variants 
following the pedigree-based variant re-call.  
 
Although we could not definitively demonstrate that the most promising disease-relevant 
variants represent a pathogenic mutation based on our preliminary findings, our findings 
have demonstrated several potential candidate disease-causing variants to MS, which will 
build up the foundation for further research, such as validation with our exome array data. 
Meanwhile, based on the current work, replication will be conducted in another 2 
multiplex MS families in Tasmania, with DNA collected from three affected siblings, the 
parents and on affected maternal aunt in one family and 3 affected siblings 3 unaffected 
siblings and an unaffected mother in the other.  Our preliminary findings, we believe as a 
useful clue, can open a new avenue for further genetic research on MS. 
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3.6 Conclusion  
 
We have applied whole genome sequencing on a MS family to detect rare/disease-causing 
variants, and nine candidate variants were identified with further validation by Sanger 
sequencing.  Two novel coding variants located in RDBP and PKHD1 are biologically 
plausible  promising potential disease-causing variants to MS, which will be validated in  
further research. Our study showed a reliable strategy for detecting rare/disease-causing 
variants and our preliminary findings suggest a foundation for  further MS genetic 
research and  replication. 
 
3.7 Postscript 
 
The chapter has described how to detect disease-causing variants of MS by using family-
based whole genome sequencing analysis, and we presents our preliminary findings: nine 
potential disease-relevant candidate variants were identified, where two most interesting 
candidate variants locate in RDBP and PKHD1 were further tested in a large cohort of MS 
cases and controls.  In the next chapter I will discuss how to detect another component of 
missing heritability of MS – gene-environment interactions. I will specifically focus on 
gene-vitamin D interaction, to assess whether gene-vitamin D interactions influencing MS 
clinical course via a well-validated prospective cohort study design. 
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Chapter 4. Novel modulating effects of PKC family genes on the 
relationship between serum vitamin D and relapse in multiple sclerosis 
 
4.1 Preface  
 
The previous two chapters (chapter 2 and chapter 3) described how to detect one 
component of missing heritability of MS- rare genetic variants and/or disease-causing 
variants, by using identity-by descent (IBD) mapping and family-based whole genome 
sequencing analysis. This chapter will describe how to detect another component of 
missing heritability of MS – gene-environment interactions. Among the well-estimated 
environmental factors that were associated with MS onset, low ultraviolet radiation 
(UVR) exposure and low vitamin D levels are among the strongest and most consistent. In 
this chapter, I will specifically focus on gene-vitamin D interaction, to assess whether 
gene-vitamin D interactions influencing MS clinical course via a well-validated 
prospective cohort study design. Most parts of this chapter have been published in 
Journal of Neurology, Neurosurgery & Psychiatry. 2014; 85(4): 399-404. (Appendix 4A). 
 
4.2 Introduction  
 
Multiple sclerosis is a complex disorder of the centre nervous system (CNS) where gene-
environment interactions are considered a key part of disease susceptibility [1]. Among 
the environmental factors thought to be associated with MS, low UVR exposure and low 
vitamin D levels are among the strongest and most consistent [2,3]. Studies investigating 
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vitamin D for its role in MS clinical course have found levels of the major circulating 
metabolite of vitamin D, 25-hydroxyvitamin D (25(OH)D), are lower during relapse 
relative to remission [4,5], and inversely associated with relapse risk [6-8]. The inverse 
relationship between vitamin D and relapse is likely mediated by the immunomodulatory 
effects of the active metabolite of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D), 
acting to up-regulate regulatory T-cell function and depress inflammatory immune 
activity [9]. 
 
Genome-wide association studies (GWAS) have successfully identified more than 100 
loci as associated with MS risk [10-12], and other studies have suggested a predictive 
gene-environment interactions between either childhood UVR exposure or vitamin D 
intake with MS risk and vitamin D receptor (VDR) polymorphisms [13,14]. Less success 
has been received in the search for genetic modulators of MS clinical course [15] and 
disease severity [11]. This may be due to the narrow time-frame during which relapses 
occur and during which genes may exert their effects on relapse risk, directly and via 
interaction with environmental factors. 
     
We were interested in whether the magnitude of the association between 25(OH)D and 
relapse was dependent on the genotype. Therefore, using a well-validated prospective 
cohort study design, we evaluated whether there was interaction between serum 
25(OH)D, a number of genetic predictors involved in the vitamin D metabolism and 
VDR/ retinoid X receptor (RXR) transcription factor formation pathway and subsequent 
hazard of relapse in MS. 
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4.3 Materials and methods  
4.3.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study was designed as a 
prospective cohort study to evaluate the role of UV exposure and 25(OH)D on the clinical 
course of MS [6,16]. Briefly, this study followed a cohort of 198 persons with clinically 
definite MS (2001 McDonald criteria [17]) living in southern Tasmania, Australia 
between 2002 and 2005. Of these, 145 participants of the relapsing-remitting MS (RRMS) 
phenotype were followed beyond one review and 141 participants had genotype data. 
When participants discontinued participation or were lost to follow-up (8/198; 4%), they 
were censored at the date of study exit or their last attended review. Ethics approval was 
obtained from the Southern Tasmania Human Research Ethics Committee. All 
participants provided informed consent. 
 
4.3.2 Measurement of relapses and 25(OH)D  
These measurements have been described in detail elsewhere [6].  Briefly, relapses were 
defined according to established criteria [17] and were reported by phone or at each 6-
monthly review. All relapse reports were validated by the study physician and study 
neurologist. 
 
At each summer and winter review  (January-April, and June-September), blood samples 
were taken. All samples were stored at -80◦C and shielded from light.  Since 25(OH)D is 
the major circulation form of vitamin D, provides the best estimate of a patient’s long-
term vitamin D status [18], and has been associated with MS onset and relapse, free and 
bound serum 25(OH)D concentrations were measured using a commercially available 
radioimmunoassay (Stillwater, Minnesota-DiaSorin Inc). Assays were performed 
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following the conclusion of the study. Consequently, neither participants nor study 
personnel were aware of participants’ 25(OH)D concentrations during the study.    
 
 4.3.3 Genotyping  
A total of 164 MS cases were genotyped on the Illumina Infinium Hap370CNV Array as 
a part of ANZgene MS GWAS [19]. An additional 29 MS cases were genotyped using the 
Illumina HumanOmniExpress-12v1_A array. All the samples were previously identified 
as being from persons of European descent [19], and a conservative quality control was 
conducted with PLINK [20]: individuals with call rates less than 0.90, single nucleotide 
polymorphisms (SNPs) with call rates less than 0.95 or in Hardy-Weinberg equilibrium 
(p<10-7), or duplicates were excluded, leaving 189 cases with 290,536 SNPs.  
  
4.3.4 Vitamin D pathway analysis and SNP selection 
It has long been recognised that genes do not work alone, but in an intricate network of 
interaction. As our a priori hypothesis was that there are gene-vitamin D interactions 
which modulate the clinical course of MS, we therefore generated a canonical vitamin D 
metabolism and VDR/RXR transcription factor formation pathway using Ingenuity 
Pathway Analysis (IPA) (www.ingenuity.com), which includes an extensive Knowledge 
Base derived from published interactions between gene products and the different forms 
of vitamin D. The pathway of vitamin D metabolic processes and formation of the 
VDR/RXR transcription factor complex is shown in Figure 4.1. In total, there were 21 
genes involved in this pathway. For each of these genes we selected all SNPs from the 
Hg19 genome and 1000 Genome data [21] with minor allele frequency (MAF) ≥1% 
located within the physical boundaries, including 1kb upstream or downstream, and the 
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genotyped SNPs for each of these genes were filtered further based on the genotype 
dataset. Finally, 276 genotyped SNPs from 21 genes were tested (Supplementary Table 
4.1), for those SNPs with high linkage disequilibrium (LD) in the same gene, TagSNPs 
were selected using the r2-based tagger tool SNAP [22].
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Figure 4.1.  The vitamin D metabolism and VDR/RXR transcription factor complex formation pathway. The vitamin D metabolism and 
VDR transcription factor complex formation pathway was generated using the canonical pathway information stored in IPA 
(Ingenuity® Systems, www.ingenuity.com). Genes or gene products are represented as nodes, and the biological relationship between 
two nodes is represented as an edge (line). All relationships are supported by multiple published references. The shape of each node 
represents the functional class of the gene product, as shown in the key.   
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Height (m) and weight (kg) were measured at study entry, and body mass index (BMI) 
was calculated as weight divided by height squared. Also at study entry, skin melanin 
density was measured on the upper inner arm using a spectrophotometer [23]. Clinical 
disability was measured every winter review by a single physician, including the 
Expanded Disability Status Scale (EDSS).   
 
4.3.5 Data analysis 
Predictors of 25(OH)D were evaluated by multilevel mixed-effects linear regression (SEs 
inflated to allow for unknown covariance structure), with SNPs as the predictors and 
25(OH)D as the outcome adjusted for season of measure (summer, winter), age, BMI, 
melanin density (%), current sun exposure (‘less than 0.5 h a day’; ‘1/2 to 1 h a day’; ‘1 to 
2 h a day’; ‘2 to 3 h a day’; ‘3 to 4 h a day’; ‘greater than 4 h a day’), vitamin D 
supplementation (‘never’ ; ‘less than 200 IU a day’; ‘200 to 400 IU a day’), fish intake 
(‘never’; ‘less than once a week’; ‘1 to 2 serves a week’; ‘2 to 4 serves a week’; ‘greater 
than 4 serves a week’) and smoking (No, Yes). Dependent variables were transformed as 
required to make the residuals less heteroskedastic; however all regression coefficients are 
reported on the scale of the original variable.    
 
The hazard of relapse was modelled as a function of 25(OH)D and other covariates on 
time-to-relapse and was calculated using Cox proportional hazards models for repeated 
events, using the gap-time model described by Prentice and colleagues [24]. Standard 
errors were adjusted to reflect multiple events per person. All covariates satisfied the 
proportional hazards assumption with the exception of the binary variable for sex and the 
categorical variable for baseline EDSS (0 – 2.5, 3.0 – 5.0, 5.5– 7.0, 7.5 – 9.0). For this 
reason, all models are stratified to allow the baseline hazards to differ by sex and baseline 
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EDSS category. 25(OH)D was estimated at monthly intervals between summer and winter 
measurements using methods described previously [6].  Briefly, a sinusoidal curve was 
fitted to the measured 25(OH)D to yield a sample-average value of 25(OH)D over the 
year, this used to predict values at monthly intervals between measures for each person. 
The sinusoidal regression model was:  
25(OH)D levels = 
365
2cos
365
2sin 210
tt π
β
π
ββ ++  
where t denotes the day of the year the sample was collected, and β j(j=0,1,2) are 
estimated regression coefficients. These modelled 25(OH)D values were then used as the 
primary predictor variable in survival analysis models. To examine whether there was an 
interaction between modelled 25(OH)D and a SNP on relapse, a product term was 
included in the model, and then the association between 25(OH)D and hazard of relapse 
can be estimated at each SNP allele level. 
 
To estimate cumulative effects of the significant and other top SNPs involved in the 
vitamin D pathway on relapse or on 25(OH)D levels, we created a variable that provided 
values for the number of risk genotypes to represent the “genetic risk score’’. Briefly, a 
person was designed as having a risk variant of a SNP if they carried a SNP that was 
independently associated with increased hazard of relapse. For instance, a person for 
whom the heterozygote and minor homozygote were each associated with an increased 
hazard of relapse, all persons heterozygous or homozygous for the minor allele would be 
considered carriers of the risk variant, whereas homozygotes for the major allele would be 
considered non-carriers of the risk variant. The total number of risk variants was summed 
and the risk score included as a covariate in the model.  
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Significance threshold was adjusted by Bonferroni correction for the number of genes 
evaluated. SNPs with a p-value < 0.00238 (0.05/21), or the adjusted p-value (Padj)< 0.05 
after adjustment for covariates and multiple comparisons for all 21 genes were considered 
to be significant. 
 
All data analyses were performed using STATA/IC V.12.1 (StataCorp LP, College 
Station, Texas, USA). 
 
4.4 Results  
 
The total of participants who were of relapsing-remitting MS (RRMS) course and 
followed beyond one review, and for whom SNP data were obtained, comprised the 
cohort for analysis. This group was followed up for an average of 2.3 years, included 
75.2% females, and had mean age 45.9 (SD, 10.2) years, and 82.3% (116/141) used 
immunomodulatory therapy during the study.  The mean EDSS at study entry was 2.8 
(SD, 1.5), and the mean MS duration from diagnosis was 6.95 year (SD, 7.08).  A total of 
122 confirmed relapses occurred in 70 participants. 
 
We found that the relationship between 25(OH)D and hazard of relapse was significantly 
different for different alleles of two genotyped SNPs (rs908742 in PRKCZ and rs3783785 
in PRKCH), even after adjustment for covariates (age, sex and baseline EDSS) and this 
interaction persisted after adjustment for multiple comparisons (pinteraction=0.001, 
padj=0.021, respectively; Table 4.1). For example, a significant protective association was 
found between 25(OH)D and relapse when subjects carried the major homozygous 
genotype of rs3783785 (HR=0.76, p=4.65x10-6) and rs908742 (HR=0.77, p=3.63x10-5). 
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However, it was not significant when subjects carried at least one copy of the rare allele 
of rs3783785, and an increased risk was observed when individuals carried the minor 
homozygous genotype of rs908742 (HR=1.18, p=0.017; Table 4.2). The modulating 
effect of the two SNPs also persisted after adjustment for immunomodulatory medication 
use (data not shown). The two SNPs were not associated with hazard of relapse or levels 
of 25(OH)D (Table 4.1). 
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Table 4.1. The significant genotyped SNPs and their associations with 25(OH)D levels and the 25(OH)D-relapse association 
2 genotyped SNPs modified the relationship between 25(OH)D and the hazard of relapse  
Chr SNP bp Allele MAF HR_25(OH)D 
(95%CI) 
P_interact P_adj_interact P_relap P_25(OH)D Nearest 
Gene 
1 rs908742 2033256 A/G 0.283 0.85 (0.77, 0.94) 0.001 0.021 0.39 0.35 PRKCZ 
14 rs3783785 61937292 G/A 0.270 0.83 (0.75, 0.92) 0.001 0.021 0.14 0.09 PRKCH 
2 genotyped SNPs associated with the levels of 25(OH)D (nmol/L) 
Chr SNP bp Allele MAF Coef_25(OH)D 
(95%CI) 
P_25(OH)D P_adj_25(OH)D P_interact P_relap Nearest 
Gene 
11 rs1993116 14910234 A/G 0.384 -5.14 (-8.27, -2.01) 0.001 0.021 0.58 0.06 CYP2R1 
16 rs7404928 23888840 G/A 0.249 -6.24 (-9.88, -2.59) 0.001 0.021 0.10 0.95 PRKCB 
P_relap: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons. 
P_interact: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons. 
P_25(OH)D: adjusted for sun exposure, season, age, BMI, vitamin D supplementation, melanin density, fish intake and smoking , before adjustment for multiple comparisons. 
Padj: adjusted for covariates, after adjustment for multiple comparisons for 21 genes involved in the vitamin D metabolism and information complex pathway. 
Bp =base pair (hg19); HR=hazard ratio; 25(OH)D= 25-hydroxyvitamin D; CI= confidence interval. 	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Table 4.2. The association between 25(OH)D and hazard of relapse stratified by allele 
for the significant genotyped SNPs that modified the 25(OH)D-relapse association 
Chr/gene SNP Genotype N HR_25(OH)D 
(95%CI) 
p 
1/PRKCZ rs908742 AA 14 1.18 (1.02, 1.35)  0.017 
  AG 52 0.91 (0.81, 0.999) 0.06 
  GG 75 0.77 (0.68, 0.87) 3.63x10-5 
     
pinteraction＝0.001 
14/PRKCH rs3783785 AA 78 0.76 (0.67, 0.85) 4.65x10-6 
  AG+GG 63 0.98 (0.89, 1.08) 0.732 
     
pinteraction＝0.001 
pinteraction was assessed with the SNP coded as 0,1,2 and the model was adjusted for age, sex and 
baseline EDSS, before adjustment for multiple comparisons. 
The GG genotype of rs3783785 (n=9) was combined with the AG genotype because of the low 
frequency. 
 
We also found two genotyped SNPs (rs1993116 in CYP2R1 and rs7404928 in PRKCB) 
that were significantly associated with lower levels of 25(OH)D; persisting after 
adjustment for sun exposure and other relevant confounders and after adjustment for 
multiple comparisons (ptrend =0.001, padj=0.021, respectively; Table 4.1). A clear dose-
response was observed with the CYP2R1 SNP rs1993116, compared to those homozygous 
for the minor allele heterozygotes had levels of 25(OH)D that were significantly lower by 
7.1 nmol/L (p=0.005) and major allele homozygotes were significantly lower by 12.4 
nmol/L (p=0.004). Dose-response could not be examined reliably for rs7404928 because 
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of the low numbers in the minor allele group (Table 4.3). These two SNPs were not 
associated with hazard of relapse, and did not modify the association between 25(OH)D 
and relapse (Table 4.1). 
 
We then examined the combined effect on 25(OH)D levels of the two genotyped SNPs 
associated with low 25(OH)D (rs1993116 in CYP2R1 and rs7404928 in PRKCB) by 
creating a ‘genetic risk score’. We found that 25(OH)D levels were significantly lower by 
13.58 nmol/L (p=0.00025) for those individuals carrying two ‘risk’ genotypes compared 
to those carrying less than one ‘risk’ genotype (Table 4.3). This cumulative effects of 
these two SNPs accounted for 3.5% of the variation in 25(OH)D levels with rs1993116 in 
CYP2R1 accounting for 2.6% of the variation. 
 
Table 4.3. The allele dosage response and the cumulative effect of the significant 
genotyped SNPs that were associated with low 25(OH)D 
Chr/gene SNP Genotype N 25(OH)D (95%CI) 
(nmol/L) 
p 
11/CYP2R1 rs1993116 AA 19  54.13 (50.98, 57.27) ref 
  
AG 68 -7.10 (-12.08, -2.12) 0.005 
  
GG 54 -12.41 (-20.89, -3.94) 0.004 
   p trend=0.001 
16/PRKCB rs7404928 GG+GA 68 54.67 (51.03, 58.31) ref 
  
AA 73 -7.19 (-11.98, -2.40) 0.003 
Cumulative effects of the 2 SNPs associated with lower 25(OH)D 
 ≤1 genotype * 23 62.31 (55.45, 69.17) ref 
 2 genotypes  118 -13.58 (-20.84, -6.31) 0.00025 
ptrend: adjusted for sun exposure, season, age, BMI, vitamin D supplementation, melanin 
density, fish intake and smoking, before adjustment for multiple comparisons. 
The GG genotype of rs7404928 (n=5) was combined with the GA genotype because of the low 
frequency. 
* Those carried 0 genotype (n=1) was combined with that carried 1 genotype.  
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We did not identify any SNPs that were significantly associated with hazard of relapse 
after adjusting for covariates and multiple comparisons. However, four genotyped SNPs 
(rs281508 and rs6740453 in PRKCE, rs3733359 in GC, and rs3818740 in RXRA; Table 
4.4) were significantly associated with the hazard of relapse after adjustment for 
covariates but not multiple comparisons. When we examined the combined effect on 
relapse of these SNPs creating a ‘genetic risk score’, we found a dose-response effect with 
increasing number of risk genotypes (ptrend =8.86x10-6). For example, compared to 
subjects carrying less than two risk genotypes, those with three and four risk genotypes 
had an increased relapse HR of 1.95 (95% CI 1.17 to 5.25) and 4.21 (95% CI  2.27 to 
7.81; Table 4.4), respectively. 
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Table 4.4. The allele dosage response and cumulative effect for the genotyped SNPs 
that were associated with the hazard of relapse 
Chr/gene SNP Genotype N HR_relap (95%CI) p 
2/PRKCE rs281508  AA 14 1.00 (ref) ref 
  AC 63 1.63 (0.78, 3.38) 0.193 
  CC 64 2.21 (1.14, 4.29) 0.02 
     
ptrend =0.019 
padj=0.40 
2/PRKCE rs6740453 GT 121 1.00 (ref) ref 
  
TT 20 1.71 (1.01, 2.89) 0.046 
     padj=0.97 
4/ GC rs3733359 AA+AG 22 1.00 (ref) ref 
  GG 119 1.97 (1.06, 3.66) 0.032 
     padj=0.67 
9/ RXRA rs3818740 CC 19 1.00 (ref) ref 
  CT 57 3.35 (1.13, 9.98) 0.03 
  TT 65 3.61 (1.22, 10.68) 0.02 
     
ptrend =0.031 
padj=0.65 
Cumulative risk of relapse for the 4 SNPs 
≤ 2 risk genotypes * 41 1.00 (ref) ref 
3 risk genotypes  87 1.95 (1.17, 3.25) 0.01 
4 risk genotypes  13 4.21 (2.27, 7.81) 5.17x10-6 
   ptrend=8.86x10-6 
ptrend: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons.  
None carried GG genotype of rs6740453, and the AA genotype of rs3733359 (n=1) was combined 
with the AG genotype because of the low frequency. 
* Those carried 0 risk genotype (n=1) and 1 risk genotype (n=5) was combined with that carried 2 
risk genotypes.  
 
 
4.5 Discussion  
 
In a prospective MS cohort designed to assess the effects of vitamin D and personal UVR 
exposure on MS clinical course, we have shown that two loci within the genes involved in 
the vitamin D pathway interact with an environmental factor, serum 25(OH)D, to 
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influence the clinical course of MS. Two SNPs (rs908742 in PRKCZ and rs3783785 in 
PRKCH) were found to significantly modify the association between serum 25(OH)D and 
hazard of relapse. In line with this finding, we identified a number of other genes involved 
in the vitamin D pathway that were associated with hazard of relapse, although these 
associations were not significant after adjustment for multiple comparisons. We also 
identified two SNPs (rs1993116 in CYP2R1 and rs7404928 in PRKCB) that were 
significantly associated with 25(OH)D levels. 
 
Previously, we found that higher 25(OH)D levels were associated with lower relapse risk 
in this same cohort [6]. Interestingly, the inverse association between 25(OH)D and 
relapse was observed among those with the major homozygous genotypes of rs3783785 
and rs908742, both located within introns of the protein kinase C (PKC) family genes 
PRKCH and PRKCZ. PKC family genes have been shown to be associated with other 
neurological disorders including Alzheimer’s disease, status epilepticus and cerebellar 
ataxia [25]. PKC family genes have been shown to be regulated by 1,25(OH)2D in 
chondrocytes [26] and mediated by VDR in downstream signalling pathways [27]. Our 
findings suggest that PRKCH and PRKCZ do not have strictly independent roles but work 
in conjunction with each other, as we found that other genes in the PKC family were 
associated with 25(OH)D levels (PRKCB), and hazard of relapse (PRKCE), although 
some of these associations were not significant after adjustment for multiple comparisons. 
For those associated with relapse, we demonstrated a cumulative effect with increasing 
number of risk genotypes, with those with three and four risk genotypes having hazard of 
relapse of 1.95 (95% CI 1.17 to 5.25) and 4.21 (95%CI 2.27 to 7.81; ptrend=8.86x10-6), 
respectively. 
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MS is believed to be the result of a misdirected immune response by autoreactive T-cells 
against as yet undetermined CNS antigens [28]. PRKCH, PRKCZ, PRKCB as well as 
other genes in the 11-member PKC family have been found to affect T-cell activation [29-
31]. It is possible therefore that abnormalities in PKC activity induced by one or more of 
these polymorphisms may lead to altered T-cell function. PRKCA has been reported to be 
associated with MS risk in UK, Finish and Canadian populations [32,33], and PRKCB and 
PRKCH had been associated with the risk of similar autoimmune diseases including 
systemic lupus erythematosus (SLE) [34] and rheumatoid arthritis [35,36]. In rheumatoid 
arthritis, PRKCH messenger RNA was expressed at high levels in T-cells and was 
significantly down-regulated during immune response [35]. 
 
We also identified two SNPs within the CYP2R1 and PRKCB genes that were inversely 
associated with levels of 25(OH)D. A CYP2R1 SNP (rs10741657) has previously been 
associated with vitamin D levels in a vitamin D GWAS [37]. Notably, the SNP 
(rs1993116) identified in this cohort is in complete LD with rs10741657 (LD=1), which 
supports the association identified in our cohort. Interestingly, the SNP (rs7404928) in 
PRKCB was suggested to be associated with risk of rheumatoid arthritis [35,36] and was 
identified in this cohort as a novel polymorphism associated with low 25(OH)D levels, 
but was not identified in the vitamin D GWAS. PRKCB is a member of the PKC gene 
family that has been demonstrated to be regulated by 1,25(OH)2D in chondrocytes [26] 
and mediated by VDR in downstream signalling pathways [27]. Studies have shown that 
PRKCB increases phosphorylation of VDR [38] and is a key element in normal T-cell 
migration [30], and 25(OH)D has been demonstrated to modulate TReg (regulatory T cell) 
and TH cell function in vivo [39], suggesting that  PRKCB may mediate some of the effect 
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of 25(OH)D on T cell function. Notably, the cumulative effects of these two SNPs 
accounted for 3.5% of the variation in 25(OH)D concentrations, in which rs1993116 in 
CYP2R1 accounted for 2.6%, which was similar to that identified from the vitamin D 
GWAS [37]. 
 
We now also consider most common diseases to be genetically influenced by the 
combined effects of many loci and/or a number of rare variants that interact with 
environmental factors in multiple ways [40]. In this study, we observed a cumulative 
effect of several SNPs on either the risk of relapse or 25(OH)D levels, supporting the 
theory that pathway analysis may increase the overall effect within known signalling 
pathways and enhance the genetic susceptibility to disease. Such an approach has proved 
useful in examining the contribution of T-cell function, cell adhesion, and cellular 
communication in the pathogenesis of MS [11,41]. In our study, using pathway analyses, 
we have been able to demonstrate that several genes potentially work together to 
influence 25(OH)D levels and/or the hazard of relapse. Consequently, modulation of these 
genes and/or pathways is an important potential avenue of investigation in the treatment 
of MS and other immunological disorders. 
 
A strength of our study was the availability of detailed environmental data, including 
potential confounders such as sun exposure and vitamin D supplementation. A weakness 
of our study is the sample size. Even though this is one of the largest and most well-
studied MS cohorts available, the difficulty of reaching statistical significance reflects the 
challenge of undertaking genetic studies of clinical course, in comparison with aetiology 
studies. These questions of gene-environment interactions on MS clinical course can only 
be answered in longitudinal studies of this nature. Therefore, as discussed above, we have 
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used other methodologies to overcome potential type 1 error, including allele dose 
responses and cumulative genotype risk scores. While some of the associations identified 
here are not significant after adjustment for multiple comparisons, we believe that these 
results still provide important evidence for real associations. Our results, demonstrate one 
methodology that can bridge the gap between the need for larger and larger genetic 
studies and the realities of undertaking MS longitudinal studies.  
 
4.6 Summary 
 
Background: The interplay between genes and environmental factors on MS clinical 
course has been little studied. 
Methods: We conducted a prospective cohort study of 141 participants with relapsing-
remitting MS and genotype data followed from 2002 to 2005, and examined genes in the 
vitamin D metabolism and VDR/RXR transcription factor formation pathway. Gene-
vitamin D interactions and the genetic predictors of relapse were assessed using survival 
analysis. Genetic predictors of 25(OH)D were evaluated by multilevel mixed-effects 
linear regression.  Significance threshold was adjusted by Bonferroni correction for the 
number of genes evaluated. 
Results: The relationship between 25(OH)D and hazard of relapse was significantly 
different for different alleles of two intronic SNPs (rs908742 in PRKCZ and rs3783785 in 
PRKCH) in the protein kinase C (PKC) family genes (pinteraction=0.001, Padj =0.021 for 
both). Two other intronic SNPs (rs1993116 in CYP2R1and rs7404928 in PRKCB) were 
significantly associated with lower levels of 25(OH)D (pinteraction=0.001, Padj=0.021 for 
both). A cumulative effect of multiple ‘risk’ genotypes on 25(OH)D levels and hazard of 
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relapse was observed for the significant SNPs (ptrend= 7.12x10-6 for 25(OH)D levels, 
ptrend=8.86x10-6 for hazard of relapse). 
Conclusion: Our data supports the hypothesis that gene-vitamin D interactions may 
influence MS clinical course, and that the PKC family genes may play a role in the 
pathogenesis of MS relapse through modulating the association between 25(OH)D and 
relapse.  
 
4.7 Postscript  
 
This chapter has discussed how to detect gene-vitamin D interactions in patients with MS 
in a prospective cohort study. We have demonstrated that PKC family genes modulated 
the relationship between serum vitamin D and relapse in patients with MS. These findings 
provided support for our hypothesis that gene-environment interactions influence clinical 
course of MS. These findings also lead a question to us: did known MS-associated 
susceptibility interact with serum vitamin D influencing clinical course of MS? Next 
chapter I will focus on known MS-associated susceptibility. I will examine whether they 
modulate the relationship between serum vitamin D and relapse by using the same 
prospective cohort design.   
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Supplementary table 4.1. Tested genotyped SNPs 
 
No SNP Genes nearby/within 
1 rs7935792 CYR2R1 
2 rs1993116 CYR2R1 
3 rs11023374 CYR2R1 
4 rs8176345 CYP27B1 
5 rs1555439 CYP24A1 
6 rs912505 CYP24A1 
7 rs927650 CYP24A1 
8 rs4809960 CYP24A1 
9 rs6097797 CYP24A1 
10 rs6097801 CYP24A1 
11 rs1352844 GC 
12 rs7041 GC 
13 rs222020 GC 
14 rs705117 GC 
15 rs1491709 GC 
16 rs3733359 GC 
17 rs2665833 PSMC5 
18 rs2239186 VDR 
19 rs886441 VDR 
20 rs2238136 VDR 
21 rs2189480 VDR 
22 rs1540339 VDR 
23 rs1544410 VDR 
24 rs4760648 VDR 
25 rs2239182 VDR 
26 rs2239179 VDR 
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27 rs4516035 VDR 
28 rs2254210 VDR 
29 rs2107301 VDR 
30 rs205908 CSNK2A1 
31 rs4815707 CSNK2A1 
32 rs461944 CSNK2A1 
33 rs6107514 CSNK2A1 
34 rs1010546 PRKCA 
35 rs4417581 PRKCA 
36 rs12232511 PRKCA 
37 rs4536508 PRKCA 
38 rs16960110 PRKCA 
39 rs759115 PRKCA 
40 rs1806448 PRKCA 
41 rs8078231 PRKCA 
42 rs3889392 PRKCA 
43 rs7342847 PRKCA 
44 rs6504441 PRKCA 
45 rs3889237 PRKCA 
46 rs2024321 PRKCA 
47 rs7220007 PRKCA 
48 rs4644888 PRKCA 
49 rs1006841 PRKCA 
50 rs877447 PRKCA 
51 rs8081512 PRKCA 
52 rs7218480 PRKCA 
53 rs7220127 PRKCA 
54 rs7219495 PRKCA 
55 rs8067877 PRKCA 
56 rs887797 PRKCA 
57 rs8069926 PRKCA 
58 rs7207345 PRKCA 
59 rs11656099 PRKCA 
60 rs9896134 PRKCA 
61 rs4790904 PRKCA 
62 rs16960114 PRKCA 
63 rs8069696 PRKCA 
64 rs10491204 PRKCA 
65 rs9303510 PRKCA 
66 rs16960070 PRKCA 
67 rs9908814 PRKCA 
68 rs8074995 PRKCA 
69 rs4411531 PRKCA 
70 rs8464 PRKCA 
71 rs956952 PRKCA 
72 rs7221968 PRKCA 
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73 rs9893560 PRKCA 
74 rs741141 PRKCA 
75 rs3848423 PRKCA 
76 rs17753569 PRKCB 
77 rs120909 PRKCB 
78 rs9922316 PRKCB 
79 rs4787676 PRKCB 
80 rs8063132 PRKCB 
81 rs9925126 PRKCB 
82 rs198207 PRKCB 
83 rs403018 PRKCB 
84 rs2283540 PRKCB 
85 rs4788426 PRKCB 
86 rs9302421 PRKCB 
87 rs2188355 PRKCB 
88 rs198145 PRKCB 
89 rs195990 PRKCB 
90 rs2340988 PRKCB 
91 rs2636957 PRKCB 
92 rs3785383 PRKCB 
93 rs1976194 PRKCB 
94 rs198178 PRKCB 
95 rs880824 PRKCB 
96 rs11074594 PRKCB 
97 rs392715 PRKCB 
98 rs8055243 PRKCB 
99 rs7404928 PRKCB 
100 rs381901 PRKCB 
101 rs10852259 PRKCB 
102 rs1548384 PRKCB 
103 rs12445719 PRKCB 
104 rs1873423 PRKCB 
105 rs9928102 PRKCB 
106 rs11645672 PRKCB 
107 rs10492795 PRKCB 
108 rs198143 PRKCB 
109 rs7195728 PRKCB 
110 rs1483185 PRKCD 
111 rs2306572 PRKCD 
112 rs3773732 PRKCD 
113 rs6740453 PRKCE 
114 rs4952774 PRKCE 
115 rs3924523 PRKCE 
116 rs281472 PRKCE 
117 rs13402503 PRKCE 
118 rs7604415 PRKCE 
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119 rs3820729 PRKCE 
120 rs10191412 PRKCE 
121 rs11125055 PRKCE 
122 rs1947195 PRKCE 
123 rs935653 PRKCE 
124 rs666214 PRKCE 
125 rs1375055 PRKCE 
126 rs1463162 PRKCE 
127 rs12185636 PRKCE 
128 rs642200 PRKCE 
129 rs4953274 PRKCE 
130 rs542413 PRKCE 
131 rs1375341 PRKCE 
132 rs10495927 PRKCE 
133 rs7594827 PRKCE 
134 rs7582320 PRKCE 
135 rs935672 PRKCE 
136 rs10495928 PRKCE 
137 rs1562653 PRKCE 
138 rs1124787 PRKCE 
139 rs4952775 PRKCE 
140 rs1470598 PRKCE 
141 rs6720975 PRKCE 
142 rs7581914 PRKCE 
143 rs629772 PRKCE 
144 rs4952779 PRKCE 
145 rs10175198 PRKCE 
146 rs952331 PRKCE 
147 rs6743144 PRKCE 
148 rs4953245 PRKCE 
149 rs6742737 PRKCE 
150 rs2176347 PRKCE 
151 rs4953262 PRKCE 
152 rs4953292 PRKCE 
153 rs506134 PRKCE 
154 rs940052 PRKCE 
155 rs483404 PRKCE 
156 rs4245804 PRKCE 
157 rs6719779 PRKCE 
158 rs585156 PRKCE 
159 rs4446102 PRKCE 
160 rs951012 PRKCE 
161 rs4264601 PRKCE 
162 rs3768757 PRKCE 
163 rs281508 PRKCE 
164 rs3886870 PRKCE 
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165 rs3768753 PRKCE 
166 rs4953251 PRKCE 
167 rs2595202 PRKCE 
168 rs6712557 PRKCE 
169 rs6716268 PRKCE 
170 rs2711292 PRKCE 
171 rs7577664 PRKCE 
172 rs4952787 PRKCE 
173 rs2204204 PRKCE 
174 rs13404973 PRKCE 
175 rs14138 PRKCE 
176 rs7601785 PRKCE 
177 rs6751349 PRKCE 
178 rs6724315 PRKCE 
179 rs3745405 PRKCG 
180 rs454006 PRKCG 
181 rs3783778 PRKCH 
182 rs14095 PRKCH 
183 rs17098304 PRKCH 
184 rs3742633 PRKCH 
185 rs1126133 PRKCH 
186 rs10141067 PRKCH 
187 rs11621346 PRKCH 
188 rs1033910 PRKCH 
189 rs767755 PRKCH 
190 rs767757 PRKCH 
191 rs3783814 PRKCH 
192 rs2181985 PRKCH 
193 rs3783785 PRKCH 
194 rs10483739 PRKCH 
195 rs1091679 PRKCH 
196 rs959728 PRKCH 
197 rs1088672 PRKCH 
198 rs1957895 PRKCH 
199 rs2140825 PRKCI 
200 rs1684885 PRKCI 
201 rs7914917 PRKCQ 
202 rs4748153 PRKCQ 
203 rs6602745 PRKCQ 
204 rs10508307 PRKCQ 
205 rs494800 PRKCQ 
206 rs596866 PRKCQ 
207 rs4750439 PRKCQ 
208 rs2453 PRKCQ 
209 rs677986 PRKCQ 
210 rs500766 PRKCQ 
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211 rs673964 PRKCQ 
212 rs521153 PRKCQ 
213 rs3793729 PRKCQ 
214 rs2026431 PRKCQ 
215 rs1409876 PRKCQ 
216 rs3793727 PRKCQ 
217 rs943452 PRKCQ 
218 rs3815975 PRKCQ 
219 rs6602820 PRKCQ 
220 rs472317 PRKCQ 
221 rs2026432 PRKCQ 
222 rs658230 PRKCQ 
223 rs4750531 PRKCQ 
224 rs587198 PRKCQ 
225 rs582052 PRKCQ 
226 rs604663 PRKCQ 
227 rs4357599 PRKCQ 
228 rs648778 PRKCQ 
229 rs501878 PRKCQ 
230 rs688391 PRKCQ 
231 rs11259403 PRKCQ 
232 rs2236380 PRKCQ 
233 rs586457 PRKCQ 
234 rs7082071 PRKCQ 
235 rs571715 PRKCQ 
236 rs591441 PRKCQ 
237 rs7072496 PRKCQ 
238 rs6602747 PRKCQ 
239 rs884080 PRKCZ 
240 rs3107151 PRKCZ 
241 rs908742 PRKCZ 
242 rs3128291 PRKCZ 
243 rs12755035 PRKCZ 
244 rs12589992 PRKD1 
245 rs7145714 PRKD1 
246 rs7148794 PRKD1 
247 rs875677 PRKD1 
248 rs1958990 PRKD1 
249 rs2273812 PRKD1 
250 rs4357843 PRKD1 
251 rs1953722 PRKD1 
252 rs2333660 PRKD1 
253 rs1958988 PRKD1 
254 rs2273814 PRKD1 
255 rs3783297 PRKD1 
256 rs1959431 PRKD1 
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257 rs11626603 PRKD1 
258 rs11851625 PRKD1 
259 rs2300892 PRKD3 
260 rs10178975 PRKD3 
261 rs3770764 PRKD3 
262 rs10460527 PRKD3 
263 rs11896614 PRKD3 
264 rs7039190 RXRA 
265 rs11185659 RXRA 
266 rs3132294 RXRA 
267 rs4917354 RXRA 
268 rs4240705 RXRA 
269 rs3118571 RXRA 
270 rs3818740 RXRA 
271 rs10881582 RXRA 
272 rs11102986 RXRA 
273 rs3118536 RXRA 
274 rs714112 RXRB 
275 rs100537 RXRG 
276 rs10800098 RXRG 
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Chapter 5. Association between Multiple Sclerosis risk-associated SNPs 
and relapse and disability - a prospective cohort study 
 
 
5.1 Preface 
 
The previous chapter has described how to detect gene-vitamin D interactions influencing 
MS clinical course and particularly focus on the genes involved in the vitamin D 
metabolism and VDR/RXR transcript factor formation complex pathway. We have 
demonstrated that PKC family genes significantly modified the relationship between 
serum 25(OH)D and relapse in patients with MS. In this chapter, I will discuss how to 
detect the interactions between known MS-associated susceptibility and serum 25(OH)D 
influencing MS clinical course, including relapse and disability via a well-validated 
prospective cohort study. Most parts of this chapter have been published in Multiple 
Sclerosis. 2013 Jul 25. [Epub ahead of print] (Appendix 5A), wheras text marked as grey 
boxes are added and were not part of the original publication. 
 
 
5.2 Introduction  
 
 
To date, the human leukocyte antigen (HLA) region and more than 60 non-HLA genetic 
loci have been identified as being associated with MS onset. However, there has been 
little success in the search for genetic susceptibility to MS clinical course and disease 
severity, with large GWAS identifying no significant associations [1-3] apart from an 
earlier age of onset effect with HLA-DRB1:15*01 positivity [2,4-7].  Two large 
Australian cohort studies found no evidence that genetic markers including seven known 
MS risk-associated SNPs that were significantly associated with a number of measures of 
Chapter 5. Association between MS risk-associated SNPs and relapse and disability – a 
prospective cohort study 
	   174	  
MS progression [8,9]. Relapse-associated genetic variations have been far more difficult 
to study, possibly due to the narrow time-frame during which relapses occur and during 
which the genes may exert their effects on relapse risk, as well as the relative difficulty in 
assessing relapse in longitudinal studies.  
 
There is also a possibility that many genes may realise much of their effects of disease 
course via gene-environment interaction. Of particular interest among the environmental 
factors associated with MS risk and clinical course, and therefore potentially interacting 
with genetic predictors of disease, are vitamin D and UV exposure. A number of studies 
have investigated the role of vitamin D in modulating MS clinical course, including more 
recent studies using longitudinal cohort designs, demonstrating an inverse association 
between serum 25-hydroxyvitamin D (25(OH)D) levels and monthly relapse rates [10], 
and an inverse association between 25(OH)D levels  and subsequent hazard of relapse 
[11-13]. Gene-environment interactions between polymorphisms in the vitamin D 
receptor (VDR) and either childhood UVR exposure or vitamin D intake and MS onset 
also have been demonstrated [14,15].  
 
Vitamin D has been shown to have significant effects on gene expression with over 2000 
genes demonstrating a change in expression in the presence of increased levels of 
1,25(OH)2D in-vitro [16] and 1,25(OH)2D has been shown to have multiple effects on the 
immune system largely through up-regulation of regulatory T-cells and a tendency to shift 
the immune system to a more tolerogenic state [17]. Recent GWAS have shown that 
genes that are associated with T-cell immunity are over-represented in the areas where 
SNPs are associated with MS onset, and have shown that these genes are significantly 
more likely to have vitamin D response elements and to have their expression altered by 
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increased 1,25(OH)2D [16,18].  
 
Given these facts, we therefore examined whether the known MS-associated genetic loci 
exert an effect on relapse and disability progression, and whether these loci modified the 
association between 25(OH)D and relapse. These associations cannot be assessed in a 
cross-sectional study such as a GWAS but requires longitudinal assessment of exposure 
and outcome to assess causality. Consequently, we have utilized the well-validated 
Tasmanian MS Longitudinal Study to assess the role of validated MS genetic variants on 
MS progression using a prospective cohort study design.   
5.3 Materials and methods  
5.3.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study was designed as a 
prospective cohort study to evaluate the role of UV exposure and 25(OH)D on the clinical 
course of MS [11,19].  Briefly, this study followed a cohort of 198 persons with clinically 
definite MS (2001 McDonald criteria [20]) living in southern Tasmania, Australia 
between 2002 and 2005.  Of these, 145 participants with the relapsing-remitting MS 
(RRMS) phenotype were followed beyond one review. Of the total cohort, 188 persons 
had genotype data. Of the subgroup of 145 persons included in the relapse analysis, 141 
had genotype data. 
 
Where participants discontinued participation or were lost to follow-up (8/198; 4%), they 
were censored at the date of study exit or their last attended review. Ethics approval was 
obtained from the Southern Tasmania Human Research Ethics Committee.  All 
participants provided informed consent. 
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5.3.2 Measurement of relapses, disability and 25(OH)D  
The measurements have been described in detail elsewhere [11,21].  Briefly, relapses 
were defined according to established criteria [20] and were reported by phone or at 
biannual review. All relapse reports were validated by the study physician and study 
neurologist. Clinical disability, including the Expanded Disability Status Scale (EDSS), 
the Multiple Sclerosis Severity Score (MSSS) and the Scripps Neurologic Rating Scale 
(NRS), was measured each winter by a single physician.  
At each biannual review, blood samples were taken. All samples were stored at -80◦C and 
shielded from light. Free and bound serum 25(OH)D concentrations were measured using 
commercially available radioimmunoassays (Stillwater, Minnesota-DiaSorin Inc). Assays 
were performed following the conclusion of the study.  Consequently, neither participants 
nor study personnel were aware of participants 25(OH)D concentrations during the study.  
 
5.3.3 Genotyping, imputation and SNP selection 
193 samples were genotyped including 164 MS cases as a part of the ANZgene MS 
GWAS using the Illumina Infinium Hap370CNV Array [22], and 29 cases were  
genotyped using the Illumina HumanOmniExpress-12v1_A array. All the samples were 
previously identified as European descent [22]. 61 known loci with genome-wide 
significant association with MS [1,3,14,15,22,23] were selected.  Since there was a small 
degree of disparity in the SNPs typed between the two genotyping arrays, missing 
genotypes were imputed to a common panel of SNPs using the BEAGLE package [24] 
with 1000 Genomes data of European ancestry [25] as the reference, after a conservative 
quality control conducted with PLINK [26]: individuals with call rates less than 0.90, 
SNPs with call rates less than 0.95 or in Hardy-Weinberg equilibrium (p<10-7), or 
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duplicates were excluded, leaving 189 cases with 290,536 SNPs. 
 
Methods note 5.1 Missing genotyped SNPs imputation  
 
As mentioned above, there was a small degree of disparity in the SNPs typed between the 
two genotyping arrays, missing genotypes need to impute into a common panel of SNPs 
using the BEAGLE package [24] with 1000 Genomes data of European ancestry [25] as 
the reference. To well understand the imputation, more details were added here. Firstly, 
the merged and cleaned genotypes dataset was converted to BEAGLE format by using the 
linkage2Beagle.jar utility program.  We then changed the genotype data as the same 
human genome version (e.g. hg 19), since 1000 Genomes data refer to hg19, and the 
position, alleles and order for each SNP may be different from two human genome 
versions (hg 18 vs. hg19). By editing Perl program, we changed the SNP position and 
flipped the alleles, and then we used Beagle “check-strand” utility program to get the 
chromosomal locations refer to hg19 version. Finally we used the BEAGLE method for 
phasing and imputing the data simultaneously by using the high performance computing 
facilities in University of Tasmania (The Tasmanian Partnership for Advanced 
Computing (TPAC). The output includes the allele dosage of each SNP for each 
individual, the imputation score (R2) for each marker and the phased files. Those 
genotyped or imputed SNPs can be assessed with imputation score  (R2). For example, the 
genotyped SNPs’ imputation scores should equal to 1, and among the imputed SNPs, 
those with imputation score closer to 1, the higher likelihood that it imputed from the 
nearby genotyped SNPs, and then more reliable to represent the missing genotyped SNP. 
When one SNP’s imputation score less than 0.5, generally it should be excluded for the 
analysis.  
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Finally, one non-HLA locus (rs17445836 near IRFB gene) was excluded due to a low 
imputation score (R2<0.5), leaving 60 known non-HLA MS-associated loci for the 
analysis. Additionally single SNP genotyping for HLA-DRB1*15:01 has been previously 
reported for this cohort with 133 of 141 cases having this genotyping data. 
 
5.3.4 Measurement of covariates 
Height and weight were measured at study entry, and body mass index (BMI) was 
calculated as weight divided by height squared. At entry and each biannual review, 
participants were asked about their lifestyle, including time in the sun during weekends 
and holidays in the current season and previous season, physical activity, smoking, fish 
intake, immunomodulatory therapy use, and vitamin D supplement use. Skin melanin 
density was measured on the upper inner arm using a spectrophotometer [27].  
 
5.3.5 Data analysis 
 
The hazard of relapse was modeled as a function of 25(OH)D and other covariates on 
time-to-relapse and was evaluated using Cox proportional hazards models for repeated 
events, using the gap-time model described by Prentice and colleagues [28]. Standard 
errors were adjusted to reflect multiple events per person.  All covariates satisfied the 
proportional hazards assumption with the exception of the binary variable for sex and the 
categorical variable for baseline EDSS (0 – 2.5, 3.0 – 5.0, 5.5– 7.0, 7.5 – 9.0).  For this 
reason, all models are stratified to allow the baseline hazards to differ by sex and baseline 
EDSS category (0 – 2.5, 3.0 – 5.0, 5.5– 7.0, 7.5 – 9.0). 25(OH)D was estimated at 
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monthly intervals between biannual measurements using methods described previously 
[11].  Briefly, a sinusoidal curve was fitted to the measured 25(OH)D and used to predict 
values at monthly intervals between measures.  To examine whether there was an 
interaction between 25(OH)D and a SNP on relapse, a product term was included in the 
model.  To examine whether there was an interaction between modeled 25(OH)D and a 
SNP on relapse, a product term was included in the model, and then the association 
between 25(OH)D and hazard of relapse can be estimated at each SNP allele level.   
 
Predictors of 25(OH)D were evaluated by multilevel mixed-effects linear regression, with 
SNPs as the predictors and 25(OH)D as the outcome adjusted for season of measure 
(summer, winter), age, BMI, melanin density (%), self-reported sun exposure (“less than 
0.5 hour a day; “1/2 to 1 hour a day”; “1 to 2 hours a day”; “2 to 3 hours a day”; “3 to 4 
hours a day”; greater than 4 hours a day”), vitamin D supplementation (“never” ; “less 
than 200 IU a day”; “200 to 400 IU a day”), fish intake (“never”; “less than once a week”; 
“1 to 2 serves a week”; “2 to 4 serves a week”; “greater than 4 serves a week”) and 
smoking (No, Yes). Dependent variables were transformed as required to make the 
residuals less heteroskedastic; however all regression coefficients are reported on the 
scale of the original variable.  
 
To estimate cumulative effects of the significant SNPs on relapse or on levels of 
25(OH)D, we created a variable that provided values for the number of risk genotypes 
affecting relapse or for the number of genotypes associated with low 25(OH)D  to 
represent the “genetic risk score”. For example, those subjects with 3, 4 or 5 genotypes 
that associated with lower 25(OH)D levels were each compared with the reference group - 
those carrying less than 3 genotypes associated with lower 25(OH)D levels.  
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All data analyses were performed using STATA/IC V.12.1 (StataCorp LP, College 
Station, Texas, USA). 
 
5.4 Results  
 
The cohort of 188 persons with genotype data was followed for an average of 2.3 years. 
The cohort was 68.6% female and of mean age 48.5 years (SD: 11.4). Of those with 
RRMS at study entry who were followed beyond one review and had genotype data 
(n=141), 75.2% were female and of mean age 45.8 years (SD: 10.4). A total of 122 
confirmed relapses occurred in 70 participants. 
 
We identified five SNPs (rs11810217, rs2760524, rs1790100, rs2300603, rs2283792) in 
the genes EVI5, RGS1, MPHOSPH9, BATF, MAPK1, respectively, which were associated 
with the hazard of relapse (Table 5.1), these associations persisted after mutual 
adjustment and after adjustment for immunomodulatory medication use (data not shown). 
In addition, we found five SNPs (rs11581062, rs7595037, rs17824933, rs180515, 
rs874628) in five genes (VCAM1, PLEK, CD6, RPS6KB1, MPV17L2, respectively) that 
were associated with the levels of 25(OH)D, even after adjustment for sun exposure and 
other confounders. We also identified three SNPs (rs354033, rs2119704, rs2248359 )in 
the genes ZNF767, GALC, CYP24A1 that modified the relationship between 25(OH)D 
and the hazard of relapse, even after mutual adjustment and after adjustment for 
immunomodulatory medication use (data not shown). None of these associations 
remained significant after adjustment for multiple comparisons for the 60 loci, however 
(Table 5.1). HLA-DRB1*15:01 was not associated with hazard of relapse (ptrend =0.64) 
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nor 25(OH)D levels (ptrend =0.55), and had no modulating effect on the relationship 
between 25(OH)D and relapse (pinteraction =0.33).  
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Table 5.1. Significant SNPs and their associations with hazard of relapse, levels of 25(OH)D and the 25(OH)D-relapse association 
5 SNPs associated with the hazard of relapse 
Chr SNP bp Allele MAF Genotyped 
/ imputed 
HR_relap (95%CI) P_relap Padj_rel
ap 
P_interact P_25(OH)
D 
Nearest Gene Gene function* 
1 rs11810217[20] 92920965 C/T 0.385 imputed 1.46(1.10, 1.93) 0.008 0.48 0.92 0.95 EVI5  A regulator of cell cycle 
progression 
1 rs2760524[21] 190797171 A/G 0.126 imputed 0.60(0.42, 0.86) 0.005 0.30 0.14 0.64 RGS1   Inhibits signal 
transduction; regulates 
B-cell activation and 
proliferation 
12 rs1790100[21] 122222678 T/G 0.218 imputed 1.38(1.02, 2.09) 0.039 1.00 0.68 0.80 MPHOSPH9  Unknown  
14   rs2300603[20] 75075310 C/T 0.233 genotyped 1.45(1.00, 2.09) 0.049 1.00 0.64 0.72 BATF A negative regulator of 
AP-1 
22 rs2283792[20] 20461125 T/G 0.477 imputed 1.44(1.12, 1.87) 0.005 0.30 0.08 0.79 MAPK1  A transcriptional 
repressor; involved in 
cellular processes. 
5 SNPs associated with the levels of 25(OH)D (nmol/L) 
Chr SNP bp Allele MAF Genotyped 
/ imputed 
Coef_25(OH)D 
(95%CI) 
P_25(O
H)D 
Padj_25
(OH)D 
P_interact P_relap Nearest Gene Gene function* 
1 rs11581062[20] 101180107 G/A 0.341 genotyped +4.33(0.44, 8.21) 0.029 1.00 0.35 0.30 VCAM1  Leukocyte-endothelial 
cell adhesion 
2 rs7595037[20] 68500599 C/T 0.439 genotyped -3.16(-5.99, -0.32) 0.029 1.00 0.43 0.87 PLEK  Major protein kinase C 
substrate of platelets 
17 rs180515[20] 55379057 G/A 0.392 imputed +3.79(0.09, 7.50) 0.045 1.00 0.42 0.17 RPS6KB1 Integrate nutrient and 
growth factor signals 
11 rs17824933[21] 60517188 G/C 0.272 imputed +5.68(1.40, 9.97) 0.009 0.54 0.18 0.74 CD6  Involved in cell 
adhesion 
19 rs874628[20] 18165700 G/A 0.273 genotyped -3.99(-7.27, -0.70) 0.028 1.00 0.35 0.14 MPV17L2  Unknown 
3 SNPs modified the relationship between 25(OH)D and the hazard of relapse 
Chr SNP bp Allele MAF Genotyped 
/ imputed 
HR_25(OH)D 
(95%CI) 
P_inter
act 
Padj_int
eract 
P_relap P_25(OH)
D 
Nearest Gene Gene function* 
7 rs354033[20] 148920397 A/G 0.262 imputed 0.88(0.78, 0.99) 0.029 1.00 0.28 0.41 ZNF767 Unknown 
14 rs2119704[20] 87557442 A/C 0.103 imputed 1.33(1.07, 1.65) 0.011 0.66 0.94 0.95 GALC Hydrolyzes galactose 
ester bonds  
20 rs2248359[20] 
 
52224925 
 
T/C 0.384 genotyped 1.14(1.03, 1.27) 0.015 0.90 0.35 0.84 CYP24A1 Maintain calcium 
homeostasis. Catalyzes 
25(OH)D and 
1,25(OH)2D 
P_relap: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons for 60 loci; Padj_relap: further adjusted for multiple comparisons for 60 loci. 
P_25(OH)D: adjusted for sun exposure, season, age, BMI, vitamin D supplementation, melanin density, fish intake and smoking, before adjustment for multiple comparisons for 60 loci. Padj_25(OH)D: 
further adjusted for multiple comparisons for 60 loci. 
P_interact: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons for 60 loci; Padj_interact:  further adjusted for multiple comparisons for 60 loci. 
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All the SNPs with imputation R2 >0.9; rs2300603, rs11581062, rs7595037, rs874628, rs2248359 are genotype SNPs  (R2 =1). 
*Gene function index from UCSC Browser: http://genome.ucsc.edu/ 
[20]= original from WTCCC2 MS GWAS; [21]= original from meta-analysis MS GWAS. 
Bp =base pair (hg18); HR=hazard ratio; 25(OH)D= 25-hydroxyvitamin D; 1,25(OH)2D= 1,25-dihydroxyvitamin D; CI= confidence interval.  	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Despite the absence of statistical significance after adjustment for multiple comparisons, a 
clear allele dose-response was observed for two SNPs (rs11810217 tagging EVI5, and 
rs2283792 tagging MAPK1) that were associated with the hazard of relapse (Table 5.2). 
When we examined the combined effect on relapse of these five relapse-associated SNPs, 
we found a clear dose-response effect with increasing number of risk genotypes 
(ptrend=0.00013).  For example, compared to subjects carrying less than 2 risk genotypes, 
those with 4 or 5 risk genotypes had hazard ratios of 2.22 (95% CI: 1.36-3.60) and 2.37 
(95% CI: 1.35-4.15), respectively (Table 5.2). 
 
Table 5.2. The allele dosage response and cumulative effect for the 5 SNPs that 
were associated with the hazard of relapse 
Chr/gene SNP Genotype N HR_relap (95%CI) p 
1/ EVI5 rs11810217 TT 19 1.00 [Reference]  
  TC 50 1.74(0.92, 3.29) 0.088 
  CC 72 2.44(1.33,4.47) 0.004 
     ptrend =0.008 
1/ RGS1 rs2760524  GG 100 1.00 [Reference]  
  AA+AG 41 1.82(1.21, 2.72) 0.004 
12/ MPHOSPH9 rs1790100 TT 80 1.00 [Reference]  
  GG+GT 61 1.50(1.01, 2.24) 0.044 
14/ BATF rs2300603 CC+CT 57 1.00 [Reference]  
  TT 84 1.54(1.02, 2.34) 0.041 
22/ MAPK1 rs2283792 GG 41 1.00 [Reference]  
  GT 69 1.93(1.09, 3.43) 0.024 
  TT 31 2.16(1.18, 3.95) 0.013 
     ptrend =0.005 
Cumulative risk of relapse for the 5 SNPs 
<=2 risk genotypes* 73 1.00 [Reference]  
3 risk genotypes 26 1.24(0.68, 2.26) 0.49 
4 risk genotypes 27 2.22(1.36, 3.60) 0.001 
5 risk genotypes 15 2.37(1.35, 4.15) 0.003 
     ptrend =0.00013 
* None carried 0 risk genotype, 1 person carried 1 risk genotype.  
p trend: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons. 
The homozygous genotypes were combined with the heterozygous ones because of small numbers (AA genotype 
of rs2760524 (n=2); GG genotype of rs1790100 (n=7); CC genotype of rs2300603 (n=4)), and were excluded for p trend test.  
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A clear allele dose-response was also observed for three of the five SNPs that associated 
with 25(OH)D serum levels (rs11581062, rs7595037, rs180515), such that with the 
subjects homozygous for the minor allele had significantly higher 25(OH)D levels relative 
to those homozygous for the common allele. When we examined the combined effect on 
25(OH)D levels of those five 25(OH)D-associated SNPs ((rs11581062, rs7595037, 
rs180515, rs17824933, rs874628), a clear dose-response was observed with increasing 
number of genotypes that were associated with lower 25(OH)D (ptrend= 1.03x10-5). For 
example, compared to those carrying 2 ‘risk’ genotypes, those with 4 or 5 genotypes had 
25(OH)D levels that were 7.96 nmol/L ((95% CI: (-14.89, -1.02); p=0.024)) and 13.54 
nmol/L lower ((95% CI: (-20.52, -6.56); p=0.00014)), respectively (Table 5.3).  
 
Table 5.3. The allele dosage response and the cumulative effect of the 5 SNPs 
that were associated with 25(OH)D 
Chr/gene SNP Genotype N 25(OH)D (95%CI) p 
1/ VCAM1 rs11581062 AA 62 48.55(45.13,51.97) ref 
  AG 63 +2.40(-2.56, 7.35)  0.343 
  GG 16 +10.46(1.63,19.29) 0.02 
     ptrend =0.029 
2/ PLEK rs7595037 TT 53 48.33(44.66, 52.01) ref 
  TC 52 +1.86(-3.48, 7.19) 0.495 
  CC 36 +6.87(0.56, 13.18) 0.033 
     ptrend =0.029 
7/ RPS6KB1 rs180515 AA 55 48.64(45.01, 52.26) ref 
  AG 65 +2.10(-2.92, 7.12) 0.412 
  GG 21 +8.56(0.73, 16.40) 0.032 
     ptrend =0.045 
11/ CD6 rs17824933 CC 76 47.66(44.71, 50.62) ref 
  CG+GG 65 +6.99(2.25, 11.73) 0.004 
     p trend =0.009 
19/ MPV17L2 rs874628 GG 14 46.07(39.22, 52.91) ref 
  GA 52 +2.22(-5.67, 10.10) 0.58 
  AA 75 +7.22(-0.41, 14.86) 0.06 
     ptrend =0.028 
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Cumulative effects of the 5 SNPs associated with lower 25(OH)D 
<=2 genotypes*   28 57.53(51.79, 63.27) ref 
3 genotypes 31 -2.55(-10.27, 5.17) 0.517 
4 genotypes 47 -7.96(-14.89, -1.02) 0.024 
5 genotypes 35 -13.54(-20.52, -6.56) 0.00014 
     ptrend =1.03 
x10-5 
*None carried 0 and 1 genotype.  
p trend: adjusted for sun exposure, season, age, BMI, vitamin D supplementation, melanin density, fish intake and 
smoking, before adjustment for multiple comparisons. 
The homozygous genotypes were combined with the heterozygous ones because of small numbers (GG genotype 
of rs17824933 (n=8)) 
 
 
Among the three SNPs that modified the relationship between 25(OH) and relapse, for 
rs354033 tagging ZNF767 and rs2248359 tagging CYP24A1, individuals carrying two 
copies of the common allele showed an inverse relationship between 25(OH)D and 
relapse, while those carrying at least one copy of the rare allele showed no significant 
25(OH)D-relapse association (Table 5.4).  
 
Table 5.4. The association between 25(OH)D and hazard of relapse stratified by allele 
for the 3 SNPs that modified the 25(OH)D-relapse association 
Chr/gene SNP Genotype N HR_25(OH)D (95%CI) p 
7/ ZNF767 rs354033 GG 79 0.81(0.73, 0.88) 7.46x10-6 
  AA+AG 62 0.95(0.85, 1.06) 0.372 
     pinteraction =0.029 
14/ GALC rs2119704 CC 116 0.90(0.83, 0.97) 0.006 
  AA+AC 25 0.68(0.55, 0.82) 0.0002 
     pinteraction =0.011 
20/ CYP24A1 rs2248359 CC 50 0.78(0.70, 0.86) 3.48x10-6 
  CT 71 0.91(0.80, 1.03) 0.146 
  TT 20 0.99(0.81, 1.17) 0.922 
     pinteraction =0.015 
p interaction: adjusted for age, sex and baseline EDSS, before adjustment for multiple comparisons. 
The homozygous genotypes were combined with the heterozygous ones because of small numbers (AA genotype 
of rs354033 (n=7); AA genotype of rs2119704 (n=1)). 
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We also evaluated the association between the 60 loci and cross-sectional measured 
disability or progression in disability, but found no consistent evidence for an association 
between any SNPs and progression in disability (Table 5.5)	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Table 5.5. Top SNPs and their associations with progression in clinical disability 
Chr/gene SNP Genotype N Baseline MSSS Annual change in EDSS Annual change in NRS 
MSSS (95% CI) p Coef. (95% CI) p Coef (95% CI) p 
1/CD58 rs1335532 AA 160 4.57(4.17,4.97)  ref 0.00(ref) ref 0.00(ref) ref 
  AG 25 +0.53(-0.57,1.62) 0.35 +0.12(-0.07,0.31) 0.22 -0.28(-2.31,1.74) 0.79 
  GG 4 +1.21(-1.49,3.90) 0.38 +0.34(-0.03,0.71) 0.07 +0.39(-2.25,3.04) 0.77 
 Trend    p=0.21  p=0.044  p=0.91 
          
5/PTGER4 rs4613763 CC 5 4.91(2.65,7.16) ref 0.00 (ref) ref 0.00(ref) ref 
  CT 41 -0.69(-3.05,1.67) 0.56 +0.14(-0.07,0.35) 0.19 +1.25(-1.59,4.08) 0.39 
  TT 140 -0.08(-2.38,2.22) 0.95 +0.10(-0.07,0.26) 0.25 -0.84(-3.50,1.83) 0.54 
 Trend    p=0.30  p=0.87  p=0.008 
          
5/IL12B rs2546890 AA 54 4.74(4.05,5.43) ref 0.00 (ref) ref 0.00(ref) ref 
  AG 92 +0.14(-0.73,1.02) 0.75 +0.06(-0.10,0.22) 0.49 +0.50(-0.89,1.88) 0.48 
  GG 43 -0.59(-1.61,0.43) 0.26 -0.08(-0.26,0.10) 0.36 +1.67(0.04,3.30) 0.045 
 Trend    p=0.30  p=0.44  p=0.049 
          
6/THEMIS rs802734 AA 91 4.43(3.90,4.95) ref 0.00 (ref) ref 0.00(ref) ref 
  AG 80 +0.40(-0.37,1.18) 0.31 +0.05(-0.08,0.18) 0.46 -1.36(-2.60,-0.12) 0.032 
  GG 18 +0.78(-0.58,2.13) 0.26 +0.28(0.01,0.55) 0.043 -1.44(-3.38,0.51) 0.147 
 Trend    p=0.18  p=0.06  p=0.029 
          
8/MYC rs4410871 CC 108 4.43(3.96,4.90) ref 0.00 (ref) ref 0.00(ref) ref 
  CT 70 +0.64(-0.15,1.43) 0.11 -0.01(-0.15,0.13) 0.85 +1.28(0.09,2.48) 0.035 
  TT 11 +0.10(-1.52,1.72) 0.91 -0.17(-0.42,0.07) 0.17 +1.22(-1.24,3.68) 0.33 
 Trend    p=0.26  p=0.36  p=0.048 
19/MPV17L2 rs874628 AA 103 4.63(4.13,5.12) ref 0.00 (ref) ref 0.00(ref) ref 
  AG 69 -0.002(-0.81,0.80) 1.00 +0.06(-0.08,0.21) 0.37 +0.42(-0.93,1.77) 0.54 
  GG 17 +0.46(-0.88,1.80) 0.50 +0.29(0.02,0.57) 0.033 -2.52(-4.61,-0.42) 0.019 
 Trend    p=0.62  p=0.032  p=0.18 
          
20/CYP24A1 rs2248359 CC 71 4.88(4.27,5.50) ref 0.00 (ref) ref 0.00(ref) ref 
  CT 91 -0.42(-1.23,0.39) 0.31 +0.04(-0.10,0.18) 0.56 -0.54(-1.78,0.71) 0.40 
  TT 27 -0.07(-1.23,1.09) 0.91 +0.27(0.08,0.45) 0.004 -0.05(-2.08,1.99) 0.96 
 Trend    p=0.64  p=0.018  p=0.74 
          
22/MAPK1 rs2283792 GG 41 4.31(3.60,5.01) ref 0.00 (ref) ref 0.00(ref) ref 
  GT 69 +0.51(-0.36,1.39) 0.25 +0.07(-0.07,0.21) 0.35 -0.61(-1.91,0.69) 0.36 
  TT 31 +0.47(-0.58,1.52) 0.38 +0.14(-0.07,0.36) 0.19 -1.80(-3.56, -0.04) 0.045 
 Trend    p=0.37  p=0.18  p=0.046 	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5.5 Discussion  
 
Using a well-validated prospective MS cohort designed to assess the effects of vitamin D 
and/or personal UVR exposure on MS clinical course, we investigated whether known 
MS risk-associated SNPs were associated with relapse, disability progression and 
25(OH)D levels, and whether these SNPs modified the relationship between 25(OH)D 
and relapse. We found five SNPs in or near genes EVI5, RGS1, MPHOSPH9, BATF, 
MAPK1 that were associated with relapse, where the risk alleles associated with MS onset 
also predicted increased relapse risk [23]. We also found three SNPs in or near genes 
ZNF767, GALC, CYP24A1 that modified the relationship between 25(OH)D and the 
hazard of relapse, and five SNPs in or near genes VCAM1, PLEK, CD6, RPS6KB1, 
MPV17L2 that were found associated with the levels of 25(OH)D. However, no SNP 
association remained significant after adjustment for multiple comparisons.  
 
 It is not surprising that our primary results were not significant after adjusting for 
multiple comparisons, given the number of participants required and/or the length of 
follow-up required to reach that level of significance is prohibitively difficult for studies 
of MS clinical course. Therefore we sought further evidence of association utilising allele 
dose-responses and cumulative genotype effects to provide support for our findings. 
These findings support the nominal SNP associations and provide evidence for 
associations, despite their not meeting the multiple testing correction thresholds, and thus 
may support an interpretation of a likely association. For example, two relapse-associated 
SNPs (rs11810217, rs2283792) and three 25(OH)D-associated SNPs (rs11581062, 
rs7595037, rs180515) showed a clear allele-response. Furthermore, when studying the 
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effects of risk SNPs on 25(OH)D levels, compared to those carrying 2 ‘risk’ genotypes, 
those with 4 or 5 ‘risk’ genotypes had 25(OH)D levels that were 7.96 nmol/L ((95% CI: (-
14.89, -1.02); p=0.024)) and 13.54 nmol/L lower ((95% CI: (-20.52, -6.56); p=0.00014)), 
respectively. Similarly, regarding the hazard of relapse, compared to subjects carrying 
less than 2 risk genotypes, those with 4 or 5 risk genotypes had hazard ratios of 2.22 (95% 
CI: 1.36-3.60) and 2.37 (95% CI: 1.35-4.15), respectively. Both of these findings are of 
clinical significance. Despite this, those SNPs associated with 25(OH)D levels were not 
associated with relapse or modified the 25(OH)D-relapse association, possibly because 
the magnitude of effect on 25(OH)D levels was too small in order to mediate an effect on 
relapse. 
 
Our findings do not support an association between the genetic loci studied and any of the 
measures of disability progression. We hypothesised that disability progression and 
relapse have differing genetic susceptibilities, with MS relapse driven by acute 
inflammation and disability more by neurodegeneration. As nearly all of the identified 
MS risk SNPs tagging genes involved in immunological/inflammatory pathways, their 
association with relapse but not disability progression is consistent with this construction.  
 
One theory of MS causation is that it is the result of a misdirected immune response by 
autoreactive T-cells against as yet undetermined CNS antigens [29,30] supported by the 
finding that MS genetic determinants are heavily biased towards variants in T-cell genes 
and the HLA region. One variant we found to be associated with relapse in our cohort was 
located in the RGS1 genes, which have been demonstrated to have important roles in the 
immune system [3], with RGS1 involved in T-cell signal transduction [31]. Furthermore, 
the associations between lower levels of 25(OH)D and relapse are likely mediated by the 
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immunomodulatory effects of microenvironmental 1,25(OH)2D, acting to up-regulate 
regulatory T-cell function and depress inflammatory immune activity [17]. In line with 
previous evidence that did not show HLA DRB1*15:01 to be associated with MS clinical 
course [3], in our cohort HLA DRB1*15:01 status was not associated with relapse nor did 
it modulate the association between 25(OH)D levels and relapse. This despite the fact that 
HLA DRB1*15:01 is known to be upregulated by 1,25(OH)2D through the well-described 
VDRE in its promoter region [32].  Interestingly, among those genes associated with 
25(OH)D levels or which modulated the relationship between relapse and 25(OH)D in our 
cohort, ZNF767 and VCAM bind VDR and CYP24A1 also demonstrates VDR binding and 
is a core component of 25(OH)D metabolism [18,33,34].  Thus these findings provide 
some support for our initial hypothesis that the effect of vitamin D on relapse may be 
partly modulated by genetic variants in established MS-associated genes.   
 
A core strength of our study is its prospective methodology and the availability of detailed 
environmental data, including potential confounders such as sun exposure and vitamin D 
supplementation. A weakness of our study is the sample size. Although this is one of the 
largest and most well-studied MS cohorts for the study of MS clinical course available, 
the limitation imposed by the sample size reflects the difficulty of undertaking studies of 
this nature. Genetic associations with clinical course can best be answered in longitudinal 
studies such as ours, but multiple testing penalties associated with studying large groups 
of genes and/or tagging SNPs requires very large sample size and/or follow-up. 
Therefore, we have used other methodologies to overcome potential type-1 error, 
including allele dose responses and accumulated genotype risk scores, as well as 
consistency between outcome measures (multiple measures of disability). Therefore we 
believe that in studies of this type where sample size effects significantly hinders the 
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ability to detect statistically significant genetic associations, the utilisation of this 
ancillary supporting evidence to provide additional support is a worthwhile analysis 
method. These associations can then be studied in other cohorts as a priori hypotheses 
without the need for multiple testing limitations. Our results, in combination with other 
studies, can bridge the gap between the need for larger and larger genetic studies and the 
realities of undertaking MS longitudinal studies with careful real-time verification of 
relapse history.  
 
In conclusion, our prospective cohort study provides evidence that MS risk-associated 
SNPs exert an effect on MS relapse but not progression in disability. In addition, some 
SNPs were associated with serum 25(OH)D levels and modified the relationship between 
vitamin D and relapse.  These findings support the hypothesis that gene-environment 
interactions may be an important mechanism by which MS clinical course is driven, and 
provide further support for the role of vitamin D in MS relapse. 
 
5.6 Summary 
 
Background: The modulating effects of the MS risk-associated SNPs on MS clinical 
course are not well established. 
Objectives: To investigate whether known MS risk-associated SNPs were associated with 
clinical course, and whether these SNPs modified the 25(OH)D-relapse association. 
Methods: Using a prospective cohort of 141 participants with relapsing-remitting MS and 
genotype data followed between 2002 and 2005, genotype-vitamin D interactions and the 
genetic predictors of relapse were assessed using survival analysis and genetic predictors 
of 25(OH)D and disability progression were evaluated by multilevel mixed-effects linear 
regression. 
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Results: While no SNP reached statistical significance after multiple testing, five SNPs 
were associated with relapse, with significant cumulative genotype risk effects and two 
demonstrated significant allele dose-response. Two SNPs altered the 25(OH)D-relapse 
association with significant allele dose-response. Five SNPs modified levels of 25(OH)D, 
with significant cumulative genotype ‘risk’ effect, and three demonstrated significant 
allele dose-response. We found no consistent evidence for an association between any 
SNPs and disability.  
Conclusions:  Our study provides evidence for an association between known MS risk-
associated SNPs and relapse. Our findings indicate gene-environment interactions may be 
an important mechanism on MS clinical course, and provide support for the role of 
vitamin D in MS relapse.   
 
5.7 Postscript  
 
This chapter has discussed how to detect the interactions between known MS-associated 
susceptibility and vitamin D influencing clinical course of MS. We provided evidence that 
known MS-associated susceptibility also modified the relationship between vitamin D and 
relapse in patients with MS. In addition, these findings provide further support for the role 
of vitamin D in MS relapse. Next chapter we will specifically focus on interferon-beta 
(IFN- β), the best therapeutic agent so far which can reduce relapse rate and accumulation 
disability of MS, to examine whether there are genetic effects modulate IFN- β effect on 
serum vitamin D levels by using the same prospective cohort as the previous two chapters 
described.  
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Chapter 6. Modulating effects of the gene WT1 on the interferon-β-
vitamin D association in MS 
 
6.1 Preface 
The previous two chapters demonstrated that gene-vitamin D interactions influenced 
clinical course, and provided further support for the role of vitamin D in MS relapse. 
Interferon-β (IFN-β) was the first therapeutic agent found that can significantly reduce 
relapse rate and probably prevent accumulation of disability in patients with MS. We have 
demonstrated previously that IFN-β treatment was associated with higher serum vitamin 
D levels among persons with MS. Therefore, we were interested in whether there are 
genetic effects modulating IFN-β effect on serum vitamin D levels. In this chapter, I will 
particularly discuss whether those genes involved in the vitamin D pathway modulate the 
demonstrated relationship between serum vitamin D and IFN-β, the relationship between 
IFN-β and sun in predicting serum vitamin D, and the interaction between IFN-β and 
serum vitamin D in modulating relapse risk in people with MS. This chapter is submitted.  
 
6.2 Introduction   
 
Interferon-β is an immunomodulatory agent that has been widely used in the treatment of 
relapsing-remitting MS (RRMS). Evidence has shown IFN-β treatment significantly 
reduces relapse rate and the occurrence of MRI-detected lesions [1]. Despite its ubiquity 
in treating MS, the therapeutic mechanism of IFN-β is unclear, but is thought to act via 
some immune-modulating mechanism, including inhibiting T-cell proliferation [2], 
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reduced antigen presentation [3], reduced T-cell migration into the CNS and altered 
cytokine production [4]. Recently, we demonstrated that IFN-β treatment was associated 
with higher 25-hydroxyvitamin D (25(OH)D) among persons with MS, this apparently 
mediated by a stronger association between personal sun exposure and subsequently 
measured 25(OH)D [5]. Additionally, a positive interaction was found between IFN-β 
treatment and sufficient 25(OH)D, such that each only exerted a therapeutic effect on 
relapse risk in the presence of the other, which indicated the therapeutic effects of IFN-β 
may involve vitamin D metabolism. Our goal here was to assess whether any genetic 
variants significantly modified this association, with a goal to identifying potential 
biological pathways underlying the effect of IFN-β on vitamin D and on relapse. 
 
Of the environmental factors identified as modulating MS risk and clinical course, 
vitamin D is among the strongest and most consistent [6-10]. In addition to the effects of 
environment and behavior, circulating vitamin D levels have been found to be influenced 
by genetic determinants, as some genes involved in vitamin D metabolism have been 
identified by GWAS [11] including 7-DHC reductase (DHCR7), 25-hydroxylase 
(CYP2R1) and vitamin D-binding protein (GC). Additionally, some genes involved in 
vitamin D metabolism or vitamin D-related signal transduction pathways, including 24-
hydroxylase (CYP24A1), 1,25-hydroxylase (CYP27B1) [12,13], vitamin D receptor (VDR) 
[14,15] and protein kinase C (PKC) family genes [16] have been identified as associated 
with MS risk or as modifying the vitamin D-MS relationship. Interestingly, most of the 
genes involved in vitamin D metabolism belong to the cytochrome p450 (CYP450) 
family, whose expression may be modulated by IFN-β [17,18]. Taken together, it is 
possible that some genes involved in vitamin D pathway may modulate the effects of 
IFN-β, by modulating the effect of IFN-β on 25(OH)D levels, or directly modulating its 
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effects on relapse risk. Identifying genetic factors which modulate IFN-β’s effects could 
have import not merely in clarifying its mode of action, but could potentially lead to 
pharmacogenomic applications in clinical practice, whereby particular genotypes might 
be more responsive to IFN-β therapy. 
 
To identify whether those genes involved in the vitamin D pathway modulate the effects 
of IFN-β on 25(OH)D and relapse, we utilised data from a prospective MS cohort study to 
evaluate whether differences exist in the IFN-β-25(OH)D relationship, the interaction 
between IFN-β and sun in predicting 25(OH)D, and the interaction between IFN-β and 
25(OH)D in modulating relapse risk, at different levels of single nucleotide 
polymorphisms (SNPs) in genes relevant to vitamin D. 
 
6.3 Methods 
6.3.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study was designed as a 
prospective cohort study to evaluate the role of UV exposure and 25(OH)D on the clinical 
course of MS [7,19]. Briefly, this study followed a cohort of 198 persons with clinically 
definite MS (2001 McDonald criteria [20]) living in southern Tasmania, Australia 
between 2002 and 2005. Where participants discontinued participation or were lost to 
follow-up (4%; 8/198), they were censored at the date of study exit or their last attended 
review. Of the main cohort, 145 RRMS participants were followed beyond one review 
and of these 141 had data on genetic parameters under study. Ethics approval was 
obtained from the Southern Tasmania Human Research Ethics Committee. All 
participants provided informed consent. 
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Height (m) and weight (kg) were measured at study entry, and body mass index (BMI) 
was calculated as weight divided by height squared. Twenty persons with high disability 
(median Expanded Disability Status Scale [EDSS] 8.5, interquartile range [IQR] 8–9) 
could not have their height and weight measured and thus, BMI could not be calculated 
for these persons. Because BMI is an important determinant of 25(OH)D serum levels 
[21], these 20 people were excluded, leaving 178 persons. Of these, 169 participants with 
MS had genotype data. 
 
At study entry and each biannual review, participants were asked about their lifestyle, 
including physical activity, smoking, fish intake, immunomodulatory therapy use, and 
vitamin D supplement use. Participants were queried for their average time in the sun on 
weekends/holidays in the two three-month periods prior to the date of review, with 
options including “never”, “less than half an hour a day”, “1/2 to 1 hour a day”, “1 to 2 
hours a day”, “2 to 3 hours a day”, and “more than 3 hours a day”. Fish intake was 
queried by the Cancer Council of Victoria Food Frequency Questionnaire [22].  
 
6.3.2 Measurement of 25(OH)D  
These measurements have been described in detail elsewhere [5,7]. Briefly, at each 
biannual review, blood samples were taken. All samples were stored at -80◦C and shielded 
from light. Serum 25(OH)D concentrations were measured using a commercially 
available radioimmunoassay (DiaSorin Inc., Stillwater, Minnesota). Assays were 
performed following the conclusion of the study, by a single operator in batches. 
Consequently, neither participants nor study personnel were aware of participants’ 
25(OH)D concentrations during the study.  
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6.3.3 Genotyping  
The methods have been described in detail in our previous study [16]. Briefly, 164 MS 
cases were genotyped as a part of ANZgene MS GWAS [12] and additionally 29 MS case 
were newly genotyped using the Illumina HumanOmniExpress-12v1_A array. All the 
samples were previously identified as being from individuals of European descent [12]. A 
conservative quality control was conducted with PLINK [23] before imputation: 
individuals with call rates less than 0.90, SNPs with call rates less than 0.95 or in Hardy-
Weinberg (p<10-7), or duplicates were excluded, leaving 189 cases with 290,536 SNPs.  
 
6.3.4 Vitamin D pathway analysis and SNPs selection 
As our a priori hypothesis was that genes involved in the vitamin D pathway may 
modulate the effects of IFN-β on serum vitamin D, we generated the canonical VDR/RXR 
pathway by Ingenuity Pathways Analysis (IPA; www.ingenuity.com), which is based on 
published interactions between gene products and the different forms of vitamin D. The 
vitamin D pathway is shown in Figure 6. 1. In total, there were 81 genes involved in the 
vitamin D pathway including six overlapping genes. For each of these genes we selected 
all SNPs from the Hg19 genome and 1000 Genome data [24] with minor allele frequency 
(MAF) ≥1% located within the physical boundaries, including 1kb upstream or 
downstream, and the genotyped SNPs for each of these genes were filtered further based 
on the genotype dataset. For those SNPs with high linkage disequilibrium (LD) in the 
same gene, TagSNPs were selected using the r2-based tagger tool SNAP [25].  
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Figure 6. 1  
The canonical VDR/RXR pathway. The module in the upside is the metabolic 
processes surrounding vitamin D and the formation of the transcription factor 
complex, and the downside is the various transcription factor complex pathways 
based on which co-factors bind the complex. This pathway was generated using the 
canonical pathway information stored in IPA (Ingenuity® Systems, 
www.ingenuity.com). Genes or gene products are represented as nodes, and the 
biological relationship between two nodes is represented as an edge (line). All 
relationships are supported by multiple published references. The shape of each 
node represents the functional class of the gene product, as shown in the key.  
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6.3.5 Data analysis 
Predictors of 25(OH)D were evaluated by multilevel mixed-effects linear regression, with 
SNPs as the predictors and as-measured 25(OH)D as the outcome, adjusted for sun 
exposure, season, age, BMI, vitamin D supplementation, unexposed skin melanin density, 
weekly fish intake and smoking. Dependent variables were transformed as required to 
make the residuals less heteroskedastic; however all regression coefficients are reported 
on the scale of the original variable.  
 
To assess the interaction between SNPs, sun exposure and IFN-β in predicting 25(OH)D, 
a double interaction model was employed. This model, using multilevel mixed-effects 
linear regression, made use of single interaction product terms between each of the pairs 
of the three primary covariates and a double interaction product term which included all 
three covariates. This double interaction term was evaluated to assess the significance of a 
difference in the IFN-β-sun interaction in predicting 25(OH)D by levels of the SNP under 
analysis.  
 
The hazard of relapse was modelled as a function of 25(OH)D and other covariates on 
time-to-relapse and was calculated using Cox proportional hazards models for repeated 
events, using the gap-time model described by Prentice and colleagues [26]. Standard 
errors were adjusted to reflect multiple events per person. All covariates satisfied the 
proportional hazards assumption with the exception of the binary variable for sex and the 
categorical variable for baseline EDSS (0 – 2.5, 3.0 – 5.0, 5.5– 7.0, 7.5 – 9.0). For this 
reason, all models are stratified to allow the baseline hazards to differ by sex and baseline 
EDSS category. 25(OH)D was estimated at monthly intervals between biannual 
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measurements using methods described previously [7]. Briefly, a sinusoidal curve was 
fitted to the measured 25(OH)D and used to predict values at monthly intervals between 
measures. To examine whether there was an interaction between 25(OH)D and a SNP on 
relapse, a product term was included in the model, and then the association between 
25(OH)D and hazard of relapse could be estimated for each SNP allele level, providing 
stratum-specific data. 
 
Experiment-wide significance threshold for each gene was assessed using the tool of 
Single Nucleotide Polymorphism Spectral Decomposition (SNPSpD) [27], the effective 
number of independent marker loci (MeffLi) for each gene were calculated by SNPSpD. 
SNPs with a p-value after adjustment for covariates reached the experiment-wide 
significance threshold, or with the p-value less than 0.05 after adjustment for covariates 
and the MeffLi were considered to be significant.  
 
All data analyses were performed using STATA/IC 12.1 (StataCorp LP, College Station, 
Texas, USA). 
 
6.4 Results 
 
The 169 participants who had BMI and genetic data comprised the analysis cohort. This 
group was followed for an average of 2.3 years, was 71.6% female and of mean age 47.8 
(SD: 11.2 years), and mean baseline EDSS of 3.5. Of this group, 55.6% used IFN-β 
medication and 29.9% used vitamin D supplement during the study. The 141 participants 
who were of relapsing-remitting course and followed beyond one review, and for whom 
genotype data was obtained, comprised the cohort for relapse analyses, and had 
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demographics similar to the parent cohort. A total of 122 confirmed relapses occurred in 
70 participants. Other characteristics of the cohort are shown in Table 6. 1. 
 
Table 6.1.  Demographic and clinical characteristics of study participants 
 All persons, n (%) RRMS, n (%) 
Total 169 141 
Sex 
Female 120 (71.6) 106 (75.1) 
Male 49 (28.4) 35 (24.9) 
Age at study entry, y 
21-39 41 (23.6) 38 (26.7) 
39-45 36 (21.6) 34 (24.0) 
45-52 39 (22.8) 33 (23.5) 
52-76 53 (32.0) 36 (25.8) 
BMI at study entry 
Normal 63 (37.5) 56 (40.5) 
Overweight 70 (41.8) 54 (37.4) 
Obese 36 (20.7) 31 (22.1) 
Relapse during study? 
No  126 (89.4) 
Yes  15 (10.6) 
Ever smoked? 
No 64 (37.4) 59 (41.3) 
Yes 105 (62.6) 82 (58.7) 
Any vitamin D supplements during study? 
No 118 (70.1) 99 (70.2) 
Yes 51 (29.9) 42 (29.8) 
Any immunomodulatory therapy during study? 
No 47 (26.2) 25 (16.7) 
Yes 122 (73.8) 116 (83.3) 
Any interferon-β medications used during study? 
No 75 (44.4) 51 (36.2) 
Yes 94 (55.6) 90 (63.8) 
Age at study entry, y, mean (SD; range) 47.8 (11.2; 21-77) 45.9 (10.1; 21-76) 
MS duration from diagnosis, y, median (IQR) 6 (2-12) 4 (2-10) 
MS duration from 1st symptoms, y, median (IQR) 11.5 (6-19) 10 (5-17) 
EDSS at study entry, median (IQR) 3 (2-4.5) 2.5(2-3.5) 
Abbreviations: BMI= body mass index; EDSS= Expanded Disability Status Scale; IQR= interquartile 
range. 
 
We found that two genotyped SNPs (rs10767935 and rs5030244) in the gene WT1 
significantly modified the relationship between IFN-β and 25(OH)D, such that IFN-β only 
increased 25(OH)D levels among those carrying the rare allele of rs10767935 and the 
major allele of rs5030244, these effects persisting even after adjustment for covariates and 
multiple comparisons for MeffLi (pinteraction=0.001, 0.0002; padj=0.003, 0.006, 
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respectively). WT1 is a component of transcription factors complex 1 in the downstream 
of vitamin D pathway (Figure 1), and encodes a zinc finger DNA-binding protein that 
acts as a transcriptional activator or repressor. The experiment-wide significance 
threshold for WT1 was 0.017, with the effective number of independent marker loci 
(MeffLi) of 3. Additionally, a clear allele dose-response was observed for these two 
SNPs, such that among subjects carrying at least one copy of the rare allele of rs10767935 
(CT and TT genotype), those using IFN-β had significantly higher 25(OH)D by 13.32 
nmol/L (p=4.19x10-7), relative to those not using IFN-β medication. For rs5030244, 
subjects carrying major homozygous allele (TT genotype) with IFN-β use had 
significantly higher 25(OH)D by 9.05 nmol/L (p=8.32x10-8) compared to those not using 
IFN-β medication. Among those carrying the homozygous major allele of rs10767935 
(CC genotype) or at least one copy of minor allele of rs5030244, the levels of 25(OH)D 
did not differ by IFN-β use (Table 6. 2).  
 
Table 6.2. Relationship of IFN-β and 25(OH)D by level of the significant SNPs in WT1 in 
MS patients  
Chr/gene SNP Genotype IFN-β N 25(OH)D (95% CI) p 
11/WT1 rs10767935 CC none 48 46.38 (43.40, 49.35) ref 
      used 58 +2.54 (-1.09, 6.17) p=0.17 
    CT+TT none 27 42.46 (38.79, 46.13) ref 
      used 36 +13.32 (8.16, 18.49) p=4.19x10-7 
           pinteraction=0.001 
padj=0.003 
11/WT1 rs5030244 CC+CT none 12 52.52 (46.09, 58.95) ref 
   used 14 -5.18 (-12.02, 1.67) p=0.14 
  TT none 63 43.34 (40.87, 45.80) ref 
   used 80 +9.05 (5.74, 12.36) p=8.32x10-8 
       pinteraction =0.0002 
padj=0.0006 
pinteraction: adjusted for age, sex, sun exposure, BMI, smoking, baseline EDSS, season and vitamin D 
supplement use, before adjustment for multiple comparisons; Padj: further adjusted for multiple 
comparisons.  
The TT genotype of rs10767935 (n=7) and CC genotype of rs5030244 (n=2) were combined with the 
heterozygous genotype because of the low frequency. 
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We then estimated whether these two genotyped SNPs modified the relationship between 
IFN-β and 25(OH)D in the RRMS group. We found similar findings, these two SNPs 
significantly modifying the relationship between IFN-β and 25(OH)D, persisting after 
adjustment for covariates and multiple comparisons of MeffLi (pinteraction =0.0003, 0.0004; 
padj =0.0009, 0.0012, respectively) (Table 6. 3). In addition, similar allele dose-responses 
were found for these two SNPs in the RRMS subgroup, with those individuals with IFN-β 
use and carrying at least one copy of the rare allele of rs10767935 or the major 
homozygous allele of rs5030244 had 25(OH)D levels significantly higher than those that 
didn’t use IFN-β medication (Table 6. 3).  
 
Table 6.3. Relationship of IFN-β and 25(OH)D by level of the significant SNPs in WT1 in 
RRMS patients 
Chr/gene SNP Genotype IFN-β  N  25(OH)D (95% CI) p 
11/WT1 rs10767935 CC none 31 48.57 (44.90, 52.24)  ref 
      used 55 +2.00 (-2.06, 6.06) p=0.33 
    CT+TT none 21 43.21 (38.99, 47.43) ref 
      used 34 +15.10 (9.58, 20.61) p=7.87x10-8 
      pinteraction=0.0003 
padj=0.0009 
11/WT1 rs5030244 CC+CT none 11 52.61 (45.74, 59.47) ref 
   used 22 -5.08 (-12.32, 2.16) p=0.17 
  TT none 41 44.75 (41.71, 47.79) ref 
   used 77 +9.63 (6.00, 13.26) p=1.89x10-7 
      pinteraction =0.0004 
padj=0.0012 
pinteraction: adjusted for age, sex, sun exposure, BMI, smoking, baseline EDSS, season and vitamin D 
supplement use, before adjustment for multiple comparisons; Padj: further adjusted for multiple comparisons.  
The TT genotype of rs10767935 (n=6) and CC genotype of rs5030244 (n=2) were combined with the heterozygous 
genotype because of the low frequency. 
 
 
Previously, we found that IFN-β therapy significantly potentiated the production of 
25(OH)D from sun exposure, such that those on therapy realised nearly three-times 
greater 25(OH)D from equivalent sun exposure [5]. We next examined whether these two 
SNPs in WT1 modulated the association between sun exposure and IFN-β in predicting 
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25(OH)D levels. A notable trend was evident, showing the interactive relationship 
between IFN-β and sun exposure in predicting 25(OH)D differed appreciably by level of 
the two SNPs, such that those carrying at least one copy of the T allele (CT and TT) of 
rs10767935 or those homozygous for the T allele of rs5030244 demonstrated a marked 
difference in the sun-25(OH)D association by IFN-β therapy, whereas those homozygous 
for the C allele of rs10767935 or carrying any C allele (CC and CT) of rs5030244 showed 
no difference. These differences did not reach statistical significance, however (Table 6.4 
-6.5; Figure 6.2 -6.3). Analogous interactions were seen for the associations of fish intake 
and vitamin D supplement dose in predicting 25(OH)D, but these too did not reach 
statistical significance (Table 6.6-6.7). No interactions with sun were found for the other 
WT1 SNP, rs5030244, however (Table 6.8), and trends for fish intake and vitamin D 
supplement use were less clear than those seen for rs10767934 (Tables 6.9-6.10). 
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Table 6.4. Interactive relationship between sun and IFN-β in predicting 25(OH)D, by 
level of SNP rs10767935 in WT1  
 Mean 25(OH)D (95% CI)  
 Not using IFN-β Using IFN-β Sun-IFN-β 
interaction 
All persons  
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
 Trend: 
 
44.86 (41.47, 48.26) 
-3.20 (-6.84, 0.44) 
-1.80 (-6.12, 2.51) 
+6.01 (1.06, 10.96) 
+3.90 (-1.38, 9.19) 
p=1.12x10-6 
 
45.84 (42.50, 49.19) 
+2.49 (-1.35, 6.33) 
+4.70 (0.73, 8.67) 
+ 12.05 (6.87, 17.22) 
+ 19.26 (12.69, 25.83) 
p=1.13x10-22 
 
 
 
 
 
 
p=0.01 
rs10767935=CC 
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
 Trend: 
 
42.56 (38.59, 46.54) 
+2.05 (0.18, 3.92) 
+4.20 (0.26, 8.14) 
+6.46 (0.25, 12.66) 
+8.82 (0.13, 17.52) 
p=0.026  
 
43.31 (39.81, 46.81) 
+3.45 (2.10, 4.80) 
+7.18 (4.24, 10.11) 
+ 11.21 (6.42, 15.99) 
+ 15.56 (8.64, 22.48) 
p= 1.30x10-4 
 
 
 
 
 
 
p=0.20 
rs10767935=CT 
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
Trend: 
 
42.20 (37.22, 47.17) 
+0.85 (-1.28, 2.98) 
+1.72 (-2.62, 6.06) 
+2.60 (-4.05, 9.25) 
+3.50 (-5.54, 12.55) 
p=0.40 
 
47.20 (41.88, 52.53) 
+4.61 (3.40, 5.81) 
+ 9.67 (6.99, 12.34) 
+ 15.23 (10.78, 19.68) 
+ 21.34 (14.76, 27.92) 
p= 3.60x10-5 
 
 
 
 
 
 
p=0.11 
rs10767935=TT 
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
Trend: 
 
41.83 (31.53, 52.14) 
-0.30 (-4.81, 4.21) 
-0.60 (-9.54, 8.35) 
-0.89 (-14.22, 12.43) 
-1.18 (-18.82, 16.45) 
p=0.72 
 
51.45 (39.57, 63.33) 
+5.96 (3.39, 8.53) 
+ 12.62 (6.80, 18.44) 
+ 20.06 (10.19, 29.94) 
+ 28.38 (13.50, 43.27) 
p=0.23 
 
 
 
 
 
 
p=0.12 
    
Sun-IFN-β-SNP 
interaction 
p=0.23 
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun exposure 
and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and vitamin D 
supplement use. 
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Table 6.5. Interactive relationship between sun and IFN-β in predicting 25(OH)D, 
overall and by level of SNP rs5030244 in WT1 
 Mean 25(OH)D (95% CI)  
 Not using IFN-β Using IFN-β Sun-IFN-β 
interaction 
All persons  
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
Trend: 
 
44.78 (41.39, 48.18) 
-3.18(-6.81, 0.46) 
-1.70 (-6.02, 2.61) 
+5.99 (1.05, 10.93) 
+4.00 (-1.28, 9.29) 
p=1.12x10-6  
 
45.80 (42.46, 49.14) 
+2.52 (-1.32, 6.36) 
+4.75 (0.78, 8.72) 
+12.12 (6.94, 17.31) 
 +19.40 (12.82, 25.98) 
p=1.13x10-22  
 
 
 
 
 
 
p=0.01 
rs5030244 = CC+CT 
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
Trend: 
 
46.15 (40.26, 52.04) 
+3.81 (0.35, 7.27) 
+7.94 (0.43, 15.46) 
+12.43 (0.18, 24.68) 
+17.29 (-0.46, 35.05) 
p=0.01 
 
39.40 (34.01, 44.79) 
+4.87 (2.17, 7.57) 
+10.35 (4.23, 16.48) 
+16.54 (6.13, 26.94) 
 +23.51 (7.78, 39.23) 
p=0.004 
 
 
 
 
 
 
p=0.51 
rs5030244 =TT 
  <1/2 
  1/2 – <1 
  1 – <2 
  2 - <3 
  3 +  
Trend: 
 
41.40 (37.75, 45.05) 
+1.19 (-0.44, 2.82) 
+2.42 (-0.95, 5.78) 
+ 3.68 (-1.52, 8.87) 
+ 4.98 (-2.16, 12.11) 
p=0.09 
 
46.06 (42.48, 49.64) 
+3.80 (2.66, 4.94) 
+7.92 (5.43, 10.40) 
+12.38 (8.32, 16.45) 
 +17.23 (11.32, 23.14) 
p=5.60x10-7 
 
 
 
 
 
 
p=0.033 
Sun-IFN-β-SNP 
interaction 
p=0.81  
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun 
exposure and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and 
vitamin D supplement use. 
The CC genotype was combined with CT genotype because of the low frequency 
(n=2). 
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Table 6.6. Interactive relationship between average weekly fish intake and IFN-β in 
predicting 25(OH)D, overall and by level of SNP rs10767935 in WT1  
 Mean 25(OH)D (95% CI) Sun-IFN-β 
interaction  Not using IFN-β Using IFN-β 
All persons  
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend: 
 
44.30 (40.19, 48.41) 
+0.98 (-3.91, 5.87) 
-1.29 (-6.52, 3.95) 
+0.54 (-5.12, 6.20) 
p=0.86 
 
51.23 (47.48, 54.98) 
+0.72 (-3.20, 4.64) 
+3.09 (-1.46, 7.63) 
+4.02 (-1.45, 9.48) 
p=0.12 
 
 
 
 
 
p=0.16 
rs10767935=CC 
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend:  
 
54.78 (49.72, 59.85) 
-0.84 (-3.60, 1.92) 
-1.67 (-7.10, 3.77) 
-2.48 (-10.51, 5.55) 
p=0.47 
 
58.36 (53.08, 63.65) 
+2.00 (-0.57, 4.57) 
+4.07 (-1.25, 9.39) 
+6.21 (-2.05, 14.47) 
p=0.22 
 
 
 
 
 
p=0.13 
rs10767935=CT 
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend:  
 
52.03 (46.79, 57.26) 
+0.84 (-1.75, 3.42) 
+1.69 (-3.57, 6.94) 
+2.55 (-5.46, 10.56) 
p=0.47 
 
65.31 (58.70, 71.91) 
+1.19 (-2.60, 4.97) 
+2.39 (-5.32, 10.11) 
+3.63 (-8.16, 15.41) 
p=0.16 
 
 
 
 
 
p=0.78 
rs10767935=TT 
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend:  
 
49.42 (41.00, 57.84) 
+2.39 (-2.95, 7.73) 
+4.91 (-6.31, 16.12) 
+7.54 (-10.12, 25.20) 
p=0.44 
 
73.09 (59.78, 86.41) 
+0.17 (-8.44, 8.77) 
+0.33 (-16.91, 17.57) 
+0.50 (-25.43, 26.42) 
p=0.64 
 
 
 
 
 
p=0.38 
Sun-IFN-β-SNP 
interaction 
p=0.30 
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun exposure 
and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and vitamin D 
supplement use. 
 
 
 
 
 
 
 
 
Chapter 6. Modulating effects of WT1 on the relationship between interferon-β and vitamin D 
levels in the patients with MS 
	   222	  
 
Table 6.7. Interactive relationship between vitamin D supplement use and IFN-β 
in predicting 25(OH)D, overall and by level of SNP rs10767935 in WT1 
 Mean 25(OH)D (95% CI) Sun-IFN-β 
interaction  Not using IFN-β Using IFN-β 
All persons  
   No 
   Yes  
Trend: 
 
43.16 (40.76, 45.55) 
+2.55 (-1.03, 6.12) 
p=0.16 
 
51.39 (48.36, 54.43) 
+2.31 (-1.20, 5.82) 
p=0.20 
 
 
 
p=0.87 
rs10767935 = CC 
   No 
   Yes 
   Trend: 
 
48.56 (43.70, 53.42) 
+4.14 (-2.33, 10.60) 
p=0.21 
 
51.02, 45.96, 56.07) 
+2.89 (-2.36, 8.13) 
p=0.28 
 
 
 
p=0.42 
rs10767935 = CT 
   No 
   Yes 
   Trend: 
 
44.18 (37.31, 51.06) 
+0.81 (-6.07, 7.69) 
p=0.82 
 
56.49 (48.63, 64.34) 
+2.17 (-6.14, 10.48) 
p=0.61 
 
 
 
p=0.006 
rs10767935 = TT 
   No 
   Yes 
   Trend: 
 
40.20 (26.99, 53.42) 
-1.77 (-13.51, 9.97) 
p=0.77 
 
62.56 (44.24, 80.87) 
+1.29 (-17.23, 19.80) 
p=0.89 
 
 
 
p<0.001 
Sun-IFN-β-SNP 
interaction 
 
p=0.74 
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun 
exposure and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and 
vitamin D supplement use. 
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Table 6.8. Interactive relationship between average weekly fish intake and IFN-β in 
predicting 25(OH)D, overall and by level of SNP rs5030244 in WT1 
 Mean 25(OH)D (95% CI) Sun-IFN-β 
interaction  Not using IFN-β Using IFN-β 
All persons  
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend: 
 
44.30 (40.19, 48.41) 
+0.98 (-3.91, 5.87) 
-1.29 (-6.52, 3.95) 
+0.54 (-5.12, 6.20) 
p=0.86 
 
51.23 (47.48, 54.98) 
+0.72 (-3.20, 4.64) 
+3.09 (-1.46, 7.63) 
+4.02 (-1.45, 9.48) 
p=0.12 
 
 
 
 
 
p=0.16 
rs5030244=CC+CT 
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend:  
 
63.90 (53.88, 73.91) 
-0.91 (-7.24, 5.43) 
-1.80 (-14.27, 10.68) 
-2.68 (-21.12, 15.77) 
p=0.52 
 
57.78 (48.90, 66.67) 
-3.26 (-8.08, 1.57) 
-6.33 (-15.43, 2.78) 
-9.22 (-22.10, 3.67) 
p=0.86 
 
 
 
 
 
p=0.60 
rs5030244=TT 
  <1 servings/wk 
  1 – 2 servings/wk 
  2 – 4 servings/wk 
   >4 servings/wk 
Trend:  
 
51.75 (47.52, 55.98) 
+0.29 (-2.00, 2.58) 
+0.58 (-4.03, 5.20) 
+0.88 (-6.08, 7.84) 
p=0.66 
 
62.09 (56.76, 67.42) 
+2.63 (0.16, 5.10) 
+5.38 (0.22, 10.54) 
+8.25 (0.17, 16.33) 
p=0.044 
 
 
 
 
 
p=0.21 
Sun-IFN-β-SNP 
interaction 
p=0.27 
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun exposure 
and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and vitamin D 
supplement use. 
The CC genotype was combined with CT genotype because of the low frequency (n=2). 
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Table 6.9. Interactive relationship between vitamin D supplement use and IFN-β in 
predicting 25(OH)D, overall and by level of SNP rs5030244 in WT1 
 Mean 25(OH)D (95% CI) Sun-IFN-β 
interaction  Not using IFN-β Using IFN-β 
All persons  
   No 
   Yes  
Trend: 
 
43.16 (40.76, 45.55) 
+2.55 (-1.03, 6.12) 
p=0.16 
 
51.39 (48.36, 54.43) 
+2.31 (-1.20, 5.82) 
p=0.20 
 
 
 
p=0.87 
rs5030244=CC+CT 
   No 
   Yes 
   Trend: 
 
60.30 (43.19, 77.41) 
+12.26 (-11.97, 36.48) 
p=0.32 
 
42.68 (32.39, 52.97) 
-4.45 (-12.29, 3.39) 
p=0.27 
 
 
 
p=0.13 
rs5030244=TT 
   No 
   Yes 
   Trend: 
 
45.02 (41.28, 48.76) 
+2.44 (-2.34, 7.21) 
p=0.32 
 
55.22 (50.44, 60.01) 
+4.34 (-0.97, 9.65) 
p=0.11 
 
 
 
p=0.77 
Sun-IFN-β-SNP 
interaction 
 
p=0.11 
Geometric mean 25(OH)D and coefficients relative to reference mean by level of sun 
exposure and IFN-β adjusted for age, sex, smoking, BMI, season, baseline EDSS and 
vitamin D supplement use. 
The CC genotype was combined with CT genotype because of the low frequency (n=2). 
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Figure 6.2 
Interactive relationship between sun and IFN-β in predicting 25(OH)D, overall and by level of SNP rs10767935 in WT1. 
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Figure 6.3 
Interactive relationship between sun and IFN-β in predicting 25(OH)D, overall and by level of SNP rs5030244 in WT1. 
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We next evaluated whether these two SNPs in WT1 significantly impacted the interaction 
between IFN-β and 25(OH)D in predicting relapse. We previously demonstrated that the 
association of 25(OH)D with relapse significantly differed by IFN-β therapy, such that 
25(OH)D was only inversely associated with relapse among persons on therapy [5]. When 
we evaluated whether this interaction differed by level of the two SNPs, we found no 
evidence of a difference in this interaction by level of either rs10767935 or rs5030244 
(Table 6.10) 
 
Table 6.10. Interactive relationship between IFN-β & 25(OH)D in predicting relapse risk, 
overall and by level of SNP 
Chr/gene SNP Genotype IFN-
β 
N HR of 25(OH)D 
(95% CI) 
p IFN-β & 
25(OH)D 
interaction 
11/WT1 rs10767935 All persons  none 48 0.97 (0.86, 1.09) p=0.57 ref 
   used 93 0.80 (0.71, 0.89) p<0.001 p=0.001 
  CC none 31 1.15 (0.60, 2.22) p=0.67 ref 
      used 55 0.59 (0.33, 1.06) p=0.078 p=0.018 
  CT+TT none 21 2.42 (0.97, 6.05) p=0.058 ref 
   used 34 0.25 (0.11, 0.55) p=0.001 p=0.009 
       pinteraction =0.58 
11/WT1 rs5030244 All persons none 48 0.97 (0.86, 1.09) p=0.57 ref 
   used 93 0.80 (0.71, 0.89) p<0.001 p=0.001 
  CC+CT none 11 1.98 (0.30, 13.22) p=0.48 ref 
   used 12 0.30 (0.09, 1.06) p=0.062 p=0.091 
  TT none 41 1.64 (0.89, 3.02) p=0.11 ref 
   used 77 0.48 (0.29, 0.80)  p=0.005 p=0.004 
      pinteraction =0.57 
pinteraction: adjusted for age, sex, and baseline EDSS.  
The TT genotype of rs10767935 and CC genotype of rs5030244 were combined with the heterozygous genotype 
because of the low frequency (n=6 and n=2, respectively). 
 
 
6.5 Discussion  
 
In this prospective cohort study, we found that two genotype SNPs (rs10767935 and 
rs5030244) in WT1 significantly modified the previously demonstrated association 
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between IFN-β and 25(OH)D in patients with MS and RRMS, persisting even after 
adjustment for relevant covariates and for multiple comparisons. 
 
These two SNPs locate in the introns of the Wilms tumor 1 gene, which encodes a zinc 
finger DNA-binding protein that acts as a transcriptional activator or repressor, which has 
been demonstrated to modulate the response to active form of vitamin D (1,25-
dihydroxyvitamin D3) by induction of VDR [28]. In addition, the human VDR gene has 
been confirmed as a downstream target of WT1, with three WT1-responsive sites 
identified in the VDR promoter [29]. Interestingly, WT1 is involved in cell proliferation as 
a co-factor with PDGFA gene and also binds to VDR in the downstream of vitamin D 
pathway (Figure 6.1). These findings suggested the effect of WT1 variants may be 
mediated by VDR activation in downstream signalling pathways which consequently 
influence 25(OH)D levels. However, the mechanism how 25(OH)D level is impacted by 
the transcriptional activation by WT1 on VDR is unclear. 
 
These two SNPs in WT1 significantly modulated the relationship between IFN-β and 
25(OH)D, with those individuals on IFN-β therapy and carrying at least one copy of the 
rare allele of rs10767935 or the major homozygous allele of rs5030244 having 
significantly higher 25(OH)D levels than those not using IFN-β medication. Notably, we 
reported previously that IFN-β treatment was associated with higher 25(OH)D among 
persons with MS apparently mediated by a stronger association between personal sun 
exposure and subsequently measured 25(OH)D5. In the present analysis, we showed a 
marked difference in the interaction between IFN-β use and sun in predicting 25(OH)D 
by level of the rs10767935 SNP, such that carriers of the major allele of rs10767935 (CC) 
showed no significant difference in the sun-25(OH)D relationship between those on or off 
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IFN-β treatment, while those carrying the minor allele (CC/TT) showed a five-fold 
greater sun-25(OH)D link among those on IFN-β therapy compared to those not on 
therapy. Despite the marked differences in the interaction between IFN-β and sun 
predicting by level of rs10767935, this interaction did not reach statistical significance, 
likely due in part to the small numbers in our sample and the double interaction method 
employed which reduced statistical power. Despite the significant interaction with IFN-β 
in predicting 25(OH)D, no interaction with IFN-β and sun in predicting 25(OH)D was 
evident for the rs5030244 SNP. That we did not see a similar interaction with sun for the 
rs5030244 SNP despite the significant difference in the IFN-β effect by level of the SNP 
reflect sample size and methodological limitations, or it may indicate this SNP acts on 
vitamin D by a different pathway than sun exposure. 
  
A core strength of our study was the availability of detailed environmental data, including 
potential confounders such as vitamin D supplementation and fish intake. A weakness of 
our study is the sample size. Although this is one of the largest and most well-studied MS 
cohorts available, the limitation imposed by the sample size reflects the difficulty of 
undertaking studies of this nature. However, we have used other methodologies to 
overcome potential type 1 error, including allele dose responses and the consistency of 
associations between multiple measures of association, namely direct prediction of 
25(OH)D and interaction with sun in predicting 25(OH)D. These findings provide further 
support for a real association for the significant SNPs. 
 
In conclusion, this is the first prospective study to demonstrate two SNPs (rs10767935 
and rs5030244) in WT1 significantly modified the previously demonstrated association 
between IFN-β and 25(OH)D in the patients with MS. While replication studies and 
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investigations into the molecular mechanism by how WT1 alter therapeutic effects of IFN-
β are required, these findings indicate that WT1 variants may play an important role in the 
altering therapeutic effects of IFN-β. These results may suggest WT1 variants may play 
some role in the function of IFN-β and may potentially have application in 
pharmacogenomic-informed allocation of IFN-β in clinical practice.   
 
6.6 Summary 
 
Objective: To investigate whether those genes involved in the vitamin D pathway 
modulate the demonstrated relationship between 25(OH)D and IFN-β, the relationship 
between IFN-β and sun in predicting 25(OH)D, and the interaction between IFN-β and 
25(OH)D in modulating relapse risk in people with MS. 
 
Methods: We conducted a prospective cohort study of 169 participants with MS and 
genotype data followed from 2002 to 2005. Gene-IFN-β and gene-IFN-β-sun interactions 
predicting 25(OH)D were evaluated by multilevel mixed-effects linear regression. Gene-
IFN-β interactions with 25(OH)D in modulating relapse risk were assessed using survival 
analysis. Experiment-wide significance threshold was adjusted by the effective number of 
independent marker loci (MeffLi) for each gene.  
 
Results: Two intronic genotyped SNPs (rs10767935 and rs5030244) in the gene WT1 
significantly modified the relationship between IFN-β and 25(OH)D even after 
adjustment for covariates and multiple comparisons for MeffLi in MS patients 
(pinteraction=0.001, 0.0002; padj=0.003, 0.006, respectively) and in RRMS subgroup 
(pinteraction =0.0003, 0.0004; padj =0.0009, 0.0012, respectively). There was a marked 
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difference in the interaction between sun and IFN-β in predicting 25(OH)D by level of the 
rs10767935 WT1SNP, though this did not reach statistical significance. There were no 
differences in the interaction between 25(OH)D and IFN-β in predicting relapse by level 
of either WT1 SNP. 
 
Conclusions: We have demonstrated for the first time that two SNPs (rs10767935 and 
rs5030244) in WT1 significantly modified the previously demonstrated association 
between IFN-β and 25(OH)D in the patients with MS. Some evidence was shown for a 
difference in the sun-IFN-β-25(OH)D association by level of rs10767935, but no 
difference by SNP was found for the 25(OH)D-IFN-β-relapse association. These findings 
indicate that WT1 variants may play a role in altering the therapeutic effects of IFN-β in 
MS.  
 
6.7 Postscript  
 
This chapter has discussed how to detect the interactions between IFN-β and the genes 
involved in the vitamin D pathway influencing the levels of serum vitamin D. We 
demonstrated that the WT1 gene significantly modified the association between IFN-β and 
25(OH)D in patients with MS and RRMS, and showed evidence for modulating the sun-
IFN-β-25(OH)D association and the 25(OH)D-IFN-β-relapse association. These findings 
indicate that WT1 may play an important role in altering the therapeutic effects of IFN-β 
in MS. In the next chapter I will make my final conclusions from my PhD research and 
discuss the potential impact of my PhD research output, and will present my own views 
on the future direction of MS research.   
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Chapter 7. Conclusion 
 
 
7.1 Rare variants/disease-causing variants and MS  
 
 
The first two chapters (Chapter 2 and Chapter 3) focused on detecting rare disease-
causing genetic variants that confer susceptibility to MS by using two approaches: 
identity-by-decent (IBD) mapping and family-based whole genome sequencing analysis. 
By utilising IBD mapping in a large GWAS dataset of 3,543 cases and 5,898 controls, we 
identified a genome-wide significant linkage signal on chromosome 19 (LOD=4.65; 
p=1.9×10-6). This linkage region includes a cluster of zinc finger protein genes of 
unknown function. Research into zinc finger genes demonstrated that some of them acting 
as transcript factors are involved in signaling pathways [1], regulation of cell proliferation 
and migration [2-7], cell survival [8] and DNA methylation [5,9,10], consequently 
influencing the development of a variety of types of cancer, including gallbladder cancer 
[2], gastric cancer [5,11-13], breast cancer [9], prostate cancer [9,14], colorectal cancer 
[15,16], oropharyngeal cancer [17], hepatocellular carcinoma [18] and type 1 diabetes 
(T1D) [3].  
 
Little is known about zinc finger genes that are associated with MS, however, and none of 
the identified clusters of zinc finger genes have been previously identified in published 
GWAS or associated with MS or autoimmune diseases. When we examined the putative 
roles in CNS function for the genes in the linkage region in public human expression 
datasets, particularly the expression in foetal cells, we found most of the genes in this 
region exhibited high hippocampal expression in the foetus with low postnatal and adult 
expression, which suggested most genes in this linkage region are involved in early 
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developmental regulation of the CNS. Hence our hypothesis that a defect in CNS function 
is laid down early in development, which leads to MS susceptibility. 
 
Unfortunately, the identified genome-wide significant linkage signal lies in a region that 
had many gene duplications and is hard to validate via sequencing, thus replication in 
other independent datasets is needed. Firstly using family-based sequencing data is an 
option. In family data, the common ancestor is fairly recent with long IBD segments, 
which is easier to detect even with low density genotype data, and with lower false 
discovery rates [19]. Alternatively, using population-based next-generation sequencing 
data is another powerful way. Since the IBD segments between two putatively unrelated 
subjects in a large population is fairly small, deeper coverage of genetic variants obtained 
through sequencing can increase the power to detect small IBD segments [20]. Exome 
sequencing, an assay of choice to efficiently sequence the coding regions of the genome, 
has enabled efficient discovery of highly penetrant variants that are too rare to be detected 
by SNP-array studies [21]. Early findings from family-based exome studies have 
demonstrated the power of using IBD segments to localize potential causal coding 
variants [22]. However, exome sequencing contains highly irregular density of read 
targets, and thus poses problems of accuracy [23]. Ideally, whole-genome sequencing is a 
means of providing higher quality data with less variation in site density. Recent studies 
have applied IBD detection algorithms to whole-genome sequences and yielded very high 
detection accuracy [20]. Taken together, it may be promising to perform IBD on merged 
exome sequencing and genotype data in conjunction, or using whole-genome sequencing 
data alone. To date the number of MS whole-genome sequences available is very small. 
 
 
In Chapter 3 we conducted whole-genome sequencing analysis to assess disease-causing 
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variants to MS in a family that comprised three affected and four unaffected siblings and a 
daughter of a deceased sibling with known MS. We identified nine candidate variants by 
whole genome sequencing with further validation by Sanger sequencing. Amongst the 
nine candidate genes, two novel coding variants (chr6_31921581 and chr6_51930780) 
located in RDBP and PKHD1 suggested to be promising potential disease-causing 
variants to MS.  
 
RDBP is part of a complex termed negative elongation factor (NELF) that represses RNA 
polymerase II transcript elongation. RDBP localises to the major histocompatibility 
complex (MHC) class III region on chromosome 6, which has been demonstrated to be 
associated with MS in a GWAS [24]. Furthermore, the GERP score, Polyphen2 and SIFT 
showed evidence that the variant of chr6_31921581 has an impact on protein function. 
Interestingly, further test in our combined MS GWAS dataset also support that 
chr6_31921581 locates in a region that genome-wide significantly associated with MS, 
and significantly associated with MS in the Tasmanian group. As for PKHD1, which has 
been demonstrated as associated with ALS [25], is predicted to have a single 
transmembrane (TM)-spanning domain and multiple copies of an immunoglobulin-like 
plexin transcription-factor domain. We found that the variant of chr6_51930780 was 
dominant in the affected siblings, and Polyphen2 and SIFT also support its function to 
impact protein damage, suggesting chr6_51930780 is likely to be a disease-causing 
variant to MS.  
 
This chapter presents our preliminary findings, and future analyses of the data are outside 
the limits of this thesis. Our findings have demonstrated the candidate disease-causing 
variants to MS, which have build up the foundation for the further research, such as 
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validation with our exome array data and replication in another MS family in Tasmania.  
 
 
7.2 Gene-vitamin D interactions and MS  
 
 
Chapter 4 and Chapter 5 focused on detecting gene-environment interactions that were 
associated with MS clinical course using a prospective cohort design, particularly 
focusing on the interactions between serum vitamin D metabolites and known MS-risk 
susceptibility variants or those in genes involved in the vitamin D pathway. Although we 
didn’t identify any known MS susceptibility variants associated with relapse after 
adjustment for multiple testing, we did find that five SNPs were associated with relapse 
(ptrend <0.05), with significant cumulative genotype risk effects, and two demonstrated 
significant allele dose-response. We also found two SNPs that altered the 25(OH)D-
relapse association with significant allele dose-response (pinteraction <0.05), and five SNPs 
that modified levels of 25(OH)D (ptrend <0.05), with significant cumulative genotype ‘risk’ 
effect, and three demonstrated significant allele dose-response.  
 
Given the nature of prospective cohort design, the genetic associations with clinical 
course can best be evaluated in longitudinal studies. However, the associations with 
genome-wide significance or significance after multiple testing requires a very large 
sample size and/or follow-up, which is prohibitively difficult for studies of MS clinical 
course. Therefore, using other methodologies to overcome potential type-1 error is 
necessary. In these studies, we conducted allele dose-responses and cumulative genotype 
effects analysis, and our findings support the nominal SNP associations and provide 
evidence for an association between known MS risk-associated SNPs and relapse. 
Therefore we believe that in studies of this type where sample size effects significantly 
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hinder the ability to detect statistically significant genetic associations, the utilisation of 
this ancillary supporting evidence to provide additional support is a worthwhile analysis 
method. These associations can then be studied in other cohorts as a priori hypotheses 
without the need for multiple testing limitations.  
 
Using the same prospective MS cohort design, we also studied whether interactions 
between serum vitamin D and genes involved in the vitamin D pathway influence MS 
clinical course. We found two novel intronic SNPs in PRKCZ and PRKCH that 
significantly modify the association between serum 25(OH)D and hazard of relapse even 
after adjustment for multiple testing (pinteraction=0.001, Padj =0.021 for both). We also 
identified one intronic SNP in CYP2R1 and one novel intronic SNP in PRKCB that were 
significantly associated with 25(OH)D levels (pinteraction=0.001, Padj=0.021 for both) after 
adjustment for multiple testing, and further with a cumulative effect of multiple ‘risk’ 
genotypes (ptrend= 7.12x10-6). Among the identified SNPs, three locate in the protein 
kinase C (PKC) family genes, which have been shown to play critical roles in motor 
activity, development of the nervous system, and in learning and memory [26]. It has been 
demonstrated that PKC family genes are associated with other neurological disorders 
including Alzheimer’s disease, status epilepticus and cerebellar ataxia [26]. The 
underlying mechanisms of PKC are not well understood. Research showed PKC plays a 
vital role in the regulation of signal transduction, cell proliferation and differentiation 
through positive and negative regulation of the cell cycle [27]. The eleven-member PKC 
family has been demonstrated to affect T-cell activation, such that PRKCA plays a crucial 
role in determining the magnitude of the T-cell proliferative response upon T-cell 
activation [28], and PRKCB has been suggested to be a key element in proper T cell 
migration [29]. Additionally both PKCZ and PRKCE have been implicated as having a 
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role in IL-2 signaling in a murine T-cell line [30], and PRKCQ was involved in 
controlling the proliferation and differentiation of T-cells [31]. Interestingly, MS is 
believed to be the result of a misdirected immune response by autoreactive T-cells against 
as yet undetermined CNS antigens [32]. Therefore, modulation of these genes may be an 
important potential avenue of investigation in the treatment of MS and other 
immunological disorders. 
 
Recently, PKCs have been suggested as potential therapeutic targets for treating diabetic 
complications, and oncological, inflammatory, immunological and dermatological 
disorders [27]. For example, biological agents that affect the activity of PRKCQ are being 
developed and tested for their potential as novel therapy for several T-cell-mediated 
disease conditions such as MS, rheumatoid arthritis, asthma, and inflammatory bowel 
disease, and to assist in organ transplantation [31], via targeting effector T-cells (Teffs) 
and regulatory T-cells (Tregs) to reduce and conversely increase their in vivo survival and 
function [33]. Interestingly, several PKC family genes have been demonstrated to be 
associated with infectious and autoimmune disease, such that PRKCA was associated with 
MS risk in UK, Finish and Canadian populations [34,35], and PRKCB and PRKCH had 
been associated with the risk of similar autoimmune diseases including systemic lupus 
erythematosus (SLE) [36] and rheumatoid arthritis [37,38]. Although the exact underlying 
mechanisms of these PKC isoforms are not well understood, these findings indicated that 
they might be potential therapies to MS and other autoimmune disease, as with PRKCQ. 
However, different PKC isoforms have high sequence identity but they are involved in 
different diseases [39]. Each PKC isoform performs unique function due to its isoform-
specific patterns of subcellular compartmentalization, protein-protein interactions and 
post-translational modifications [39]. In addition, the clinical trial candidates of PKCs 
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mainly target the catalytic domain, which is highly conserved throughout the PKC family 
and which make it difficult to target a particular isoform selectively [27]. Thus, 
identification of the crystal structures and thorough analysis of available structures and 
information on the PKC ligands will be helpful in drug design and development processes 
[39]. At present, few crystal structures of PKC isoforms are known [39] and further 
research into the crystal structure of PKC family genes is required. In the current study, 
we found that the identified PKC family genes do not have strictly independent roles but 
work in conjunction with each other, suggesting cooperative mechanisms among PKC 
family genes. This potential for cooperative effects requires further investigation.  
 
Overall, our findings in Chapter 4 and Chapter 5 have indicated for the first time that 
gene-vitamin D interactions may be an important mechanism in MS clinical course, and 
that the PKC family genes may play a role in the pathogenesis of MS relapse through 
modulating the association between 25(OH)D and relapse. First, replication in other 
independent dataset is yet required, ideally via high-quality prospective cohort designs. 
Secondly, understanding the mechanism of action of PKCs in disease conditions will be 
helpful in finding new and potential PKC modulators. The underlying mechanisms of 
which PKC family genes and how they interact with serum vitamin D, and how they work 
in conjunction require further investigation. Third, the crystal structures of the PKC 
family genes need to be dissected, and consequently develop and test PKC as therapeutic 
agents of MS or other immunological disorders in the long run. 
 
 
7.3 Gene-IFN-β interactions and serum vitamin D  
 
 
Chapter 6 described how to identify the interactions between IFN-β and those genes 
involved in the vitamin D pathway influence serum vitamin D levels. We found that two 
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novel intronic SNPs in Wilms’ Tumor 1 (WT1) gene significantly modified the previously 
demonstrated association between IFN-β and 25(OH)D in people with MS and RRMS, 
and showed evidence of modulating the sun-IFN-β-25(OH)D association and the 
25(OH)D-IFN-β-relapse association. These findings indicate that WT1 may play an 
important role in altering the therapeutic effects of IFN-β in MS. Subject to validation, 
these results potentially implicate WT1 as a pharmacogenomic target in MS, though 
clearly more work is needed to delineate the mechanism at the cellular level. 
 
WT1 gene encodes a zinc finger DNA-binding protein that acts as a transcriptional 
activator or repressor, and plays an essential role in the normal development of the 
urogenital system. It is well known that WT1 gene is associated with Wilms’ tumor [40-
42] onset and a variety of urinary system-related disease [43-47]. WT1 has also been 
associated with Alzheimer's disease [48], as elevations of WT1 correlate with increased 
levels of apoptosis, which has been suggested to play a role in neurodegeneration in 
Alzheimer's disease.  
 
Little is known about WT1 on MS and on the therapeutic effect of IFN-β, however. It is 
known that IFN-β is one of the first-line treatments for RRMS. The therapeutic 
mechanism of IFN-β is still not fully understood, but it is now thought that it binds to 
receptors on immune cells and initiates a complex transcriptional response, and it inhibits 
antigen presentation and T-cell proliferation with reduced cytokine and matrix 
metalloproteinase expression [49]. Notably, one study demonstrated that co-
administration of WT1 peptide and IFN-β enhanced tumor immunity, mainly through the 
induction of WT1-specific cytotoxic T-lymphocytes (CTLs), enhancement of natural killer 
cell activity, and promotion of MHC class I expression on tumor cells [50]. This study 
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suggested that WT1 was involved in immune activity, mediated by CTLs and 
consequently may also alter the therapeutic effect of IFN-β. WT1 has also been 
demonstrated to modulate the response to active form of vitamin D (1,25-
dihydroxyvitamin D3) by induction of VDR [51]. In addition, the human VDR gene has 
been confirmed as a downstream target of WT1, with three WT1-responsive sites 
identified in the VDR promoter [52]. Interestingly, WT1 is involved in cell proliferation as 
one cofactor with the PDGFA gene and also binds to VDR in the downstream section of 
the vitamin D pathway (Figure 6.1 in this thesis). These findings suggest WT1 expression 
may be mediated by VDR in downstream signaling pathways, consequently influencing 
the level of serum 25(OH)D. However, the mechanism by which serum 25(OH)D levels 
are impacted by transcriptional activation of VDR by WT1 is unclear. Taken together 
these results are enticing; however more investigation into the mechanisms of how WT1 is 
involved in immune activation and altering IFN-β’s effect in MS is still needed.  
 
In summary, we demonstrated first time in Chapter 6 that the WT1 gene modified the 
relationship between IFN-β and 25(OH)D in people with MS and RRMS. These findings 
firstly need to be ereplicate in other independent studies, ideally via prospective cohort 
design. Furthermore, the modulating effects of WT1 may be mediated by immune system 
or by VDR in signaling pathways. The underlying mechanisms of how WT1 involved in 
immune activation with IFN-β and how WT1 involved in transcriptional activation on 
VDR need further investigation. In addition, we have demonstrated previously that IFN-β 
treatment was associated with higher 25(OH)D levels among persons with MS, this 
apparently mediated by a stronger association between personal sun exposure and 
subsequently measured 25(OH)D [53]. The observed modulating effect of WT1 on the 
relationship between IFN-β and 25(OH)D maybe also mediated by sun exposure, since 
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evidence provided from the study that WT1 modified the relationship between sun 
exposure and IFN-β in predicting 25(OH)D. Therefore, more research into WT1 on the 
relationship among sun exposure, IFN-β and 25(OH)D is needed. 
 
 
7.4 Final conclusions of PhD 
 
Briefly, my PhD research focuses on how to dissect the genetic architecture of MS in two 
ways. One way is to discover genetic variants associated with MS, including detecting 
rare disease-causing variants that confer susceptibility on MS. Another way is to discover 
gene-environment interactions associated with MS, including detecting gene-vitamin D 
interactions and gene- IFN-β interactions in patients with MS. 
 
By utilising IBD mapping - BEAGLE fastIBD with a big GWAS dataset, we identified a 
genome-wide significant linkage signal on chromosome 19. The genes in the linkage 
region may be involved in early developmental regulation of the CNS. Our findings 
suggested BEAGLE fastIBD is a good way to detect rare variants in large unrelated 
population.  
 
By utilising family-based whole genome sequencing analysis, we identified nine 
candidate genes may be disease-causing variants of MS. Where two novel coding variants 
located in RDBP and PKHD1 suggest to be promising potential disease-causing variants 
to MS, which will be validated in the further research. Although analysis is ongoing, the 
initial findings indicated that family-based whole genome sequencing analysis is a 
promising alternative to detect disease-causing variants.  
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By utilising a prospective cohort design in the Southern Tasmanian Multiple Sclerosis 
Longitudinal Study, we demonstrated that gene-vitamin D interactions influence MS 
clinical course, such that a number of known MS risk-associated genetic variants and a 
number of novel PKC family genes significantly modified the relationship between 
25(OH)D and relapse. In addition, we also demonstrated that a number of known MS 
risk-associated genetic variants and PKC family genes were also associated with MS 
relapse and 25(OH)D levels. These findings indicated for the first time that PKC family 
genes may play an important role in the pathogenesis of MS relapse and their effects on 
relapse may be modulated by vitamin D levels. By using the same longitudinal study, we 
also demonstrated for the first time that gene- IFN-β interactions influence serum vitamin 
D levels, such that WT1 gene significantly modified the relationship between IFN-β and 
25(OH)D. These findings may suggest a genetic basis for the significant pharmacological 
differences seen between cases treated with IFN-β. If supported by replication studies, 
these findings may provide the basis for determining potential responders or non-
responders to IFN-β therapy, thereby allowing clinicians to select the appropriate 
treatment, that is, those who are more likely to respond to therapy and not exposing those 
who may be better suited to other medications. 
 
 
7.5 Future research 
 
 
Future research should initially focus on replications of our findings. In the case of IBD 
mapping to detect rare variants, this will preferably use family-base sequencing data or 
population-based next-generation sequencing data or ideally whole-genome sequencing 
data to replicate it. We are considering to use the pedigree-based sequencing data 
comprised a large Mexican family from Biomedical Research Institute, Texas, USA in the 
future. As for assessing disease-causing variants of MS by using family-based whole 
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genome sequencing analysis, further research will involve testing the two most interesting 
candidate variants in as many MS cases and controls as can be recruited. This work has 
already commenced and I will provide significant input into future work based on my 
PhD thesis. Furthermore, raw whole-genome sequencing data will be reanalysed using 
pedigree-based pipeline to detect missing vital rare variants in the coming days.  
 
 
The results of gene-vitamin D interactions influencing MS clinical course need to be 
replicated in other high-quality longitudinal MS studies, preferably with lager sample 
sizes and longer follow-up. These types of studies are very hard to conduct, expensive and 
highly demanding on the participants. I am unaware of any similar longitudinal study to 
the MSL Study anywhere in the world, making these findings difficult to replicate by 
such means. On the other hand, the mechanisms of how PKC family genes interact with 
serum vitamin D require further investigation, particularly from the cellular level. Since 
researchers have identified PKC family genes products as potential therapeutic targets for 
treating inflammatory and immunological disorders, the crystal structures of PKC family 
genes need to be dissected further, and the identification of novel PKC inhibitors have 
been conducted by several pharmaceutical companies and institutes [54-59]. These 
proteins or agonists/antagonists studied in vitro need to develop and test PKC as a 
therapeutic agent in MS or other immunological disorders, and evenly apply in the 
clinical realm. 
 
Similarly, the results of gene-IFN-β interactions influencing serum vitamin D levels need 
to be replicated in other independent datasets, preferably via longitudinal studies, with 
large sample size and long follow-up. In addition, the mechanisms of how WT1 alter the 
therapeutic effect of IFN-β need further investigation, including the mechanisms of how 
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WT1 is involved in immune activation and how WT1 is involved in transcriptional 
activation of VDR in the vitamin D signaling pathway in patients of MS, preferably via 
cellular level investigations.  
 
If validated in other studies the next step would be to study these genes using functional 
genomics either in silica or in vitro. These findings open up a significant new frontier for 
MS research and demonstrate that the hunt for genetic factors that influence MS clinical 
course can be conducted in well thought out studies of MS clinical course without 
requiring vast numbers of cases. Utilising the methods as we have that were described by 
Bradford-Hill (the Hill criteria [60] ) we have been able to ascribe causality within the 
framework of our research studies despite the limitations of sample size and multiple 
testing burden. I believe that these findings, if replicated, can be rapidly introduced into 
the basic science sphere of research to elucidate the cellular mechanism by which these 
gene-environment interactions affect MS clinical course. 
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